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068-P12 
LUNG ADENOCARCINOMA BIOMARKER SCREENING 
IN AN AUSTR`ALIAN POPULATION
Ainge Allen H1, Stone E1, Plit Ml1, Havryk A1, Goldrick A1, Field A2, Mead 
S2, Qiu M2, Chou A2, Morey A2 1Department of Respiratory Medicine, St 
Vincent’s Hospital, Sydney, New South Wales/AUSTRALIA; 2Department of 
Anatomical Pathology, Sydpath, St Vincent’s Hospital, Sydney, New South 
Wales/AUSTRALIA
Aims: The emergence of new targeted therapies and clinical trials in lung ade-
nocarcinoma suggest that routine molecular biomarker testing is warranted 
to detected subtypes of adenocarcinoma which will beneﬁt from new thera-
pies. Australian data is still emerging. We aim to detect the incidence of treat-
ment speciﬁc molecular subtypes of lung adenocarcinoma in the Australian 
population.
Methods: This is a single centre prospective pilot study of patients with a 
histopathological diagnosis of adenocarcinoma who have been presented at 
a Lung Cancer multidisciplinary meeting. Formalin ﬁxed parafﬁn embedded 
tissue of 22 tumour samples were submitted for targeted PCR-based EGFR 
and KRAS mutation analysis; and EGFR ampliﬁcation, MET ampliﬁcation 
and EML4-ALK rearrangement testing by in-situ hybridization. one sample 
had insufﬁcient tissue for analysis.
Results: So far 22 patients received a deﬁnite tissue diagnosis of lung adeno-
carcinoma, 8/22 with Stage III and 10/22 with Stage IV disease. 4/22 (19%) 
are positive for an EGFR mutation, with activating EGFR mutations in 3/22 
(14%) and an EGFR mutation of uncertain clinical signiﬁcance in one patient 
(5%). EGFR ampliﬁcation was detected in 2/22 patients (9%), KRAS muta-
tions were detected in 5/22 patients (23%) patients, of which none carried 
EGFR mutations. EML4-ALK translocation was seen in 2/22 patients (9%) 
and MET ampliﬁcation in 1/22 (5%) patients.
Conclusions: Preliminary results indicate that treatment speciﬁc molecular 
subtypes of lung adenocarcinoma occur more commonly in the Australia 
population than other Western populations. Though further investigation is 
required, routine molecular biomarker testing is warranted.
Disclosure: This study was funded by an unrestricted grant from Roche.
094-P12 
MACROPHAGE POLARISATION IN PRIMARY LUNG 
CANCER
Al Matroodi SA1,2, Collins A2, Darby IA1, McDonald C2, Pouniotis DS1,2 
1School of Medical Sciences, RMIT University, Bundoora West, Victoria/
AUSTRALIA; 2Institute for Breathing and Sleep, Austin Health, Bowen 
Centre, Heidelberg, Victoria/AUSTRALIA
Macrophages are part of the tumour microenvironment and have been 
shown to play a major part in promoting and/or suppressing tumour 
growth and metastasis. Here, we aim to identify how macrophage pheno-
types are affected by the local and systemic microenvironment of patients 
with primary lung cancer. Alveolar macrophages (AMs) were isolated 
from patients with primary lung cancer (n=8) and non-cancer control 
patients (n=9) and analysed for phenotypic differences by flow cytom-
etry. Preliminary results showed that surface expression of M2 markers 
(CD163, CD36, CD150 CD195) were more highly expressed (p < 0.05) 
compared to M1 marker (CD253, HLA-DR, IP-10) expression was sig-
nificantly decreased (p < 0.05) in patients with primary lung cancer com-
pared to non-cancer controls. In addition, surface expression of myeloid 
markers CD11b and CD71 was shown to be increased in patients with 
primary lung cancer suggesting that lung tumours have the ability to alter 
AM functions and may also play a role in changing the polarising condi-
tions of AM phenotypes. Although these results are preliminary findings, 
this study aims to clarify how macrophages in primary lung cancer are 
affected by the tumour microenvironment and how the local and systemic 
microenvironment influence macrophage phenotypes and functions and 
further investigations will also investigate how blood monocyte pheno-
types are affected in patients with primary lung cancer This study will 
potentially contribute to the identification of new biomarkers for primary 
lung cancer and help in the development of more effective anti-tumour 
treatments in the future.
020-O12 
CELLS OF ORIGIN OF THE DIFFERENT SUBTYPES OF 
LUNG CANCER
Asselin-Labat ML1, Weeden C1, Viitaniemi K1, McQualter J2, Antippa P3, 
Irving L3, Bertoncello I2 1 The Walter and Eliza Hall Institute of Medical 
Research, Parkville, Victoria/ AUSTRALIA; 2 The University of Melbourne, 
Victoria/ AUSTRALIA; 3 The Royal Melbourne Hospital, Parkville, Victoria/ 
AUSTRALIA
Lung cancers are divided into distinct histopathological subclasses. Squamous 
cell carcinomas are suspected to originate from the proximal airways, small 
cell lung cancer are predominantly located in the bronchioles while adenocar-
cinomas, the most common type of lung cancer, are more frequently detected 
in the distal part of the lung. It is speculated that these different subclasses 
arise from distinct cells of origin localised within a deﬁned regional compart-
ment. Prospective isolation of progenitor cells in the lung will enable further 
evaluation of their roles in tumour initiation.
To isolate lung epithelial subpopulations, fresh human lung samples 
obtained from surgery (Victorian Cancer Biobank) are dissociated into a 
single cell suspension. Cells are stained and sorted by flow cytometry based 
on their differential expression of speciﬁc cell surface markers including 
EpCAM (Epithelial Cell Adhesion Molecule) and CD49f (Integrin a6). 
These markers have previously been used to isolate mouse lung stem/pro-
genitor cells. Characterisation of the sorted subpopulations demonstrated 
that distinct populations of progenitor cells were isolated from the proxi-
mal and distal lung. To address potential cells of origin for the different 
lung tumour subtypes, gene signatures of the normal epithelial subpopula-
tions will be compared to the gene expression proﬁles of lung carcinomas. 
Known lung cancer oncogenes (K-Ras, EML4-Alk, KIF5-Ret…) will be 
introduced into the different progenitor cells to evaluate their capacity to 
preferentially transform a speciﬁc cell type.
Establishing a link between the ﬁrst cell in which a speciﬁc mutation occurs 
and the molecular subtypes of lung cancer will enable better stratiﬁcation of 
patients for improved therapeutic strategies.
Funding source: Victoria Cancer Agency
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034-O12 
THE COMPLEX RELATIONSHIP BETWEEN LUNG TUMOR 
VOLUME AND SURVIVAL IN PATIENTS WITH NON-
SMALL CELL LUNG CANCER TREATED BY DEFINITIVE 
RADIOTHERAPY: A PROSPECTIVE, OBSERVATIONAL 
PROGNOSTIC FACTOR STUDY OF THE TRANS-TASMAN 
RADIATION ONCOLOGY GROUP (TROG 99.05).
Ball D1, Fisher R1, Burmeister B2, Poulsen M3, Graham P4, Penniment M5, 
Vinod S6, Krawitz H7, Joseph D8, Wheeler G1, McClure B1 1Peter MacCallum 
Cancer Centre, Melbourne, Victoria/AUSTRALIA; 2Princess Alexandra 
Hospital, Brisbane, Queensland/AUSTRALIA; 3Radiation Oncology Mater 
Centre, Brisbane, Queensland/AUSTRALIA; 4St George Hospital, Sydney, 
New South Wales/AUSTRALIA; 5Royal Adelaide Hospital, Adelaide, South 
Australia/AUSTRALIA; 6Liverpool Hospital, Sydney, New South Wales/
AUSTRALIA; 7Auckland City Hospital, Auckland/NEW ZEALAND; 8Sir 
Charles Gairdner Hospital, Perth, Western Australia/AUSTRALIA
Purpose: To investigate the hypothesis that primary tumour volume is prog-
nostic independent of T and N stages in patients with non-small cell lung 
cancer (NSCLC) treated by deﬁnitive radiotherapy.
Methods: Multicenter prospective observational study. Patient eligibility: 
pathologically proven stage I-III NSCLC planned for deﬁnitive radiotherapy 
(minimum 50 Gy in 20 fractions) using CT-based contouring. Volumes of 
the primary tumour and enlarged nodes were measured according to a stan-
dardized protocol. Survival was adjusted for the effect of T and N stage.
Results: There were 509 eligible patients. Five-year survival rates for tumour 
volume grouped by quartiles were, for increasing tumour volume, 22%, 14%, 
15% and 21%. Larger primary tumour volume was associated with shorter 
survival (HR = 1.060 (per doubling); 95% CI 1.01 to 1.12; P = 0.029). This 
association, after adjusting for the effects of T and N stage, was not evident 
(HR = 1.029, 95% CI, 0.96 to 1.10, P = 0.39). There was evidence, however, 
that larger primary tumour volume was associated with an increased risk of 
dying, independently of T and N stage, in the ﬁrst 18 months but not beyond.
Conclusions: In patients treated by non-surgical means we were unable to 
show that lung tumour volume, overall, provides additional prognostic infor-
mation beyond the T and N stage (TNM , 6th edition). There is evidence, 
however, that larger primary tumour volume adversely affects outcome only 
within the ﬁrst 18 months. Larger tumour size alone should not by itself 
exclude patients from curative (chemo) radiotherapy.
Disclosure: None identiﬁed.
112-S12 
SURVIVAL ANALYSIS IN THE MODERN ERA
Barraclough H, MSc. Group Leader Asia Pacific Statistical Sciences, Eli-Lilly 
Australia
overall survival (oS) or Progression free survival (PFS) can be used as the 
primary endpoint in pivotal phase III randomized clinical trials (RCTs) for 
advanced stage solid cancers, according to the US FDA guidelines. At present 
there is much debate in the medical community about which is the most appro-
priate endpoint and whether therapies which only demonstrated a statistically 
signiﬁcant improvement in PFS but not in oS ultimately beneﬁt patients. This 
presentation reviews the pros and cons of oS and PFS in light of these discus-
sions and the challenges researchers face when designing a phase III RCT.
023-P12 
AN UNUSUAL CASE OF METASTATIC 
MALIGNANT MELANOMA PRESENTING AS 
PSEUDOMESOTHELIOMA
Bency R1, Bui C1, Morgan L2 1 Department of Nuclear Medicine & PET, Nepean 
Hospital, Kingswood, New South Wales/AUSTRALIA; 2 Department of Respiratory 
Medicine, Nepean Hospital, Kingswood, New South Wales/AUSTRALIA
A 75 year old man, previously ﬁt and a non-smoker, presented with one month 
history of rapidly progressive dyspnea on exertion, left pleuritic chest pain, 
and weight loss. His medical background included previous asbestos exposure 
and 2mm Clark IV cutaneous malignant melanoma in the right upper back, 
treated with wide excision (surgical margins clear of tumour and no axillary 
sentinel lymph node involvement) 15 months prior to the presentation.
CTPA demonstrated bilateral pulmonary emboli, massive left pleural effusion 
with collapse of the left lung, bilateral calciﬁed pleural plaques, left hilar and 
subcarinal lymphadenopathy, and left adrenal lesion. The bloodstained pleural 
fluid aspirate showed no lymphocytes, bacteria or malignant cells. The patient 
was anti coagulated.
Further evaluation with FDG PET-CT revealed extensive intense FDG uptake 
(SUVmax 14.1) throughout the pleura of the left hemi-thorax, bilateral hilar 
and mediastinal lymph nodes, bilateral adrenals and left gluteal musculature, 
highly suspicious of metastatic malignancy.
Mesothelioma was considered and the patient underwent thoracoscopic pleu-
ral biopsy. The biopsy was consistent with metastatic melanoma. The patient 
was referred for consideration of palliative therapy but died 10 days later.
Conclusion: The extensive intensely FDG avid pleural disease, with history of 
asbestos exposure and bilateral calciﬁed pleural plaques, is highly suggestive 
of mesothelioma. This case illustrates that other malignancies including meta-
static melanoma can have a similar appearance. The literature on metastatic 
malignant melanoma presenting as pseudomesothelioma will be reviewed.
102-P12 
DOCETAXEL VERSUS GEFTINIB IN PATIENTS WITH 
LOCALLY ADVANCED OR METASTATIC NSCLC PRE-
TREATED WITH PLATINUM-BASED CHEMOTHERAPY
Bhatnagar AR1, Singh DP1, Sharma R1, Kumbhaj P1 1Department of 
Radiotherapy & Oncology, S.M.S. Medical College & Attached Hospitals, 
Rajasthan/INDIA
Objective: To assess the safety and efﬁcacy of Docetaxel versus Geftinib 
therapy used as a second line treatment in patients who had progressed or had 
recurrence after previous platinum-based chemotherapy.
Materials and Methods: 30 patients with locally advanced or metastatic 
NSCLC previously treated with Cisplatin-based chemotherapy, who had pro-
gressive or recurrent disease and ECoG performance score 0-2, were ran-
domized to receive either Geftinib 250 mg /day or Docetaxel 75 mg/m2 every 
3 weeks. Tumor response was assessed with RECIST Criteria and adverse 
events were noted. Patients were followed for 2 years.
Results: Tumor response rates and disease-related symptom improvements 
were similar for Geftinib and Docetaxel . Signiﬁcantly more Geﬁtinib treated 
patients experienced a clinically relevant improvement in quality of life com-
pared to Docetaxel.
Conclusions: The study demonstrated non-inferiority of Geﬁtinib relative to 
Docetaxel in terms of tumor response. Also Geﬁtinib had a more favourable 
tolerability proﬁle than Docetaxel.
Disclosure of interest: None
Source of funding: None
029-P12 
ABORIGINAL CANCER CARE AT PETER MAC: 
CONNECTING AND RESPONDING (ACCAP)
Bird, L,1 Longo R1, Hocking A1, Watson F1, Joubert L1 1Peter MacCallum 
Cancer Centre
Aim: Peter Mac aims to provide a culturally sensitive and appropriate can-
cer care pathway within Peter Mac to coordinate and effectively coordinate 
and integrate effective and community linked cancer services to Aboriginal 
and Torres Strait Islander patients with cancer in Victoria. We will describe 
the development of an evidence informed pathway for Aboriginal and Torres 
Strait Islander lung cancer patients.
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Methodology: 
1. Undertake extensive internal and external stakeholder consultation.
2.  Analyse a retrospective consecutive sample of Aboriginal patients receiv-
ing services at Peter Mac using a clinical data mining methodology 
(Epstein 2004).
3.  Design, implement and analyse a staff survey addressing Aboriginal health.
4.  Develop an evidence informed appropriate and culturally sensitive 
Aboriginal lung cancer care pathway.
Results: Among other outcomes, ﬁndings from the three data sources indi-
cated that lung cancer was one of the most prevalent diagnoses with patients 
most usually receiving treatment via surgery and chemotherapy. In addition, 
36.5% of Aboriginal patients were smokers, with 17.1% seen by the Peter 
Mac Smoking Cessation Nurse.
A staff survey of 265 respondents indicated that 84% had a moderate to high 
interest in learning more about Aboriginal health and providing culturally 
sensitive care.
Conclusion: The results support the importance of a process of stakeholder 
consultation and staff feedback, analysis of referral patterns, assessment of 
clinical need as well as exploring the reasons for resisting hospital admis-
sion, to inform the process of creating a pathway to better support Aboriginal 
patients with lung cancer.
075-P12 
LUNG CANCER AS AN ALLIED HEALTH SPECIALTY: A 
CASE STUDY.
Blair E1, Muir L1, Hill A1, Palmer J1 1 Peter MacCallum Cancer Centre, East 
Melbourne, Victoria/AUSTRALIA
Aims: Allied health professionals are important members of the multidisci-
plinary team caring for patients with lung cancer. Lung cancer patients experi-
ence a high burden of symptoms which can result in rapid deterioration of health 
and functional status. The aim of allied health intervention is to provide client-
centred, family-focused care across the disease trajectory to address patient and 
family needs, negotiate changing goals, and address quality of life issues.
This case study illustrates how allied health intervention from Social Work, 
occupational Therapy, Physiotherapy and Nutrition supported a patient and 
his family through multiple hospital admissions culminating in enabling the 
eventual goal of end of life care in his own home.
Methods: A retrospective analysis of the care of a 56 year old male with 
NSCLC was undertaken. Data related to occasions of service and time usage 
was collected for each discipline.
An analysis of allied health input over time was also conducted to determine 
the type and intensity of interventions provided.
Results: A high level of input (occasions of service: Nutrition= 13, 
Physiotherapy= 18, occupational Therapy= 19, Social Work= 37) was 
required in the care of this patient over ﬁve hospital admissions. During this 
time there were multiple changes to needs and goals. Allied health provided 
ongoing assessment and flexible care to meet these fluctuating needs and 
enable end of life care at home.
Conclusions: A high level of specialist allied health input is required to meet 
the rapidly changing functional needs and goals of lung cancer patients and 
their families.
Disclosure: None of the above authors have concerns re: dualities or conflict 
of interest.
100-P12 
RETROSPECTIVE ANALYSIS OF NON-SMALL CELL 
LUNG CANCER (NSCLC) SURGICAL MANAGEMENT IN 
A SINGLE INSTITUTION STUDY.
Bowers PJB1, Dhital K1, Granger E1, Jansz P1, Spratt P1, Stone E1 1 St Vincent’s 
Public Hospital, Sydney, New South Wales/AUSTRALIA
Introduction: The surgical management of NSCLC, while relatively uncon-
troversial in earlier stage disease, can present management dilemmas in later 
stage disease. In this study we present the results of a single institution, retro-
spective analysis of surgically managed NSCLC with a focus on the evolution 
of stage with progression through staging modalities, surgical procedure and 
length of stay post-operatively for comparison with similar data from inter-
national series.
Methods: Data was drawn from the SVH Lung Cancer database, an inte-
grated database capturing information from thoracic surgical cases and cases 
presented to the campus multidisciplinary lung cancer team. Data analysis 
was restricted to cases appropriate for curative surgery with pre-operative 
stage I-IIIA. Measurable outcome endpoints included length of stay post-
surgery (LoS).
Results: Data was analysed from the time period 2006-2011. The database 
contained 252 cases of NSCLC. 31% (n=79) underwent surgery with a docu-
mented curative aim (pre-operative Stage Ia (n=33), Ib (n=10), IIa (n=15), 
IIb (n=8), IIIa (n=12) and IIIb (n=1)). 9% (n=7) of all patients who under-
went surgery were upstaged to Stage IIIa/b based on post-operative histology. 
Surgical management of pre-operative Stage IIIa included 10 lobectomies and 
2 pneumonectomies with curative intent. The average LoS for Stage III was 
13 days regardless of procedure. There were no in hospital mortalities or 30 
day mortalities.
Discussion: This retrospective, single-institution series, while small, demon-
strates that the St Vincent’s Hospital lung cancer surgery programme manages 
cases across the spectrum of early stage disease. In our institution’s experi-
ence surgical management of stage IIIA disease is consistent with interna-
tional best practice and that initial outcome measures are favourable.
Disclosure: Please note this abstract contains no issues of duality or conflicts 
of interest.
040-O12 
DO PATIENTS DISCUSSED AT MULTIDISCIPLINARY 
MEETINGS RECEIVE GUIDELINE-RECOMMENDED 
TREATMENT?
Boxer MM1, Duggan KJ2, Vinod SK1,3 1Collaboration for Cancer Outcome, 
Research and Evaluation, Liverpool Hospital, Liverpool, New South 
Wales/AUSTRALIA; 2Sydney & South West Sydney Local Health Districts 
Clinical Cancer Registry, Liverpool Hospital, Liverpool, New South Wales/
AUSTRALIA; 3South Western Sydney Clinical School, University of New 
South Wales, Sydney, New South Wales/AUSTRALIA
Aim: Australian practice guidelines recommend that all lung cancer patients 
should be discussed at a multidisciplinary meeting (MDM) to determine a 
management plan. Previous studies have shown that lung cancer MDM rec-
ommendations are largely concordant with guidelines. This study aimed to 
determine whether patients discussed at a lung cancer MDM actually received 
NHMRC guideline recommended treatment (GRT).
Method: The Liverpool/Macarthur lung cancer MDM collects data prospec-
tively on new lung cancer patients including patient and tumour characteris-
tics, staging investigations, referrals and treatment recommendations. All new 
lung cancer patients discussed at the MDM between 1/12/05 – 31/12/2010 
were identiﬁed. Details of patient demographics, tumour characteristics 
and treatment were obtained from the MDM database and the Area Clinical 
Cancer Registry. GRT was assigned to each patient according to pathology, 
stage and ECoG performance status as per the 2004 NHMRC Lung Cancer 
Guidelines. This was compared to actual treatment received to determine 
adherence to GRT.
Results: 808 patients were discussed at the MDM. 64% were male and the 
median age was 68years. 81% of patients had pathologically conﬁrmed 
NSCLC while 15% had SCLC. of those with NSCLC, 42% had stage IV 
disease. Most patients had both stage (99.8%) and ECoG performance 
status (98.2%) documented. GRT could therefore be assigned in 98% of 
patients. overall 51% of patients received GRT, and 47% of patients did 
not receive GRT.
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Conclusion: Although previous studies have shown that MDM recommenda-
tions are largely concordant with practice guidelines, this study shows that 
only 51% of patients actually received GRT. Further analysis will be done to 
determine factors influencing adherence to GRT.
Disclosure: There are no conflicts of interest.
033-O12 
LUX-LUNG 3: A RANDOMIZED, OPEN-LABEL, PHASE 
III STUDY OF AFATINIB VERSUS PEMETREXED AND 
CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS 
WITH ADVANCED ADENOCARCINOMA OF THE LUNG 
HARBOURING EGFR-ACTIVATING MUTATIONS
Boyer M1, Schuler M2, Yamamoto N3, O’Byrne K4, Hirsh V5, Mok T6, Massey 
D7, Zazulina V7, Shahidi M7, Sequist L8, Yang JC9 1Royal Prince Alfred 
Hospital, Camperdown New South Wales/AUSTRALIA; 2West German 
Cancer Center, University Duisburg-Essen, Essen/GERMANY; 3Shizuoka 
Cancer Center, Shizuoka/JAPAN; 4St. James’ Hospital, Dublin/IRELAND; 
5McGill University, Montreal, QC/CANADA; 6Prince of Wales Hospital, 
Shatin/HONG KONG; 7Boehringer Ingelheim Limited, Bracknell/UNITED 
KINGDOM; 8Massachusetts General Hospital, Boston, MA/UNITED STATES 
OF AMERICA; 9National Taiwan University Hospital, Taipei/TAIWAN
Aim: To investigate the efﬁcacy/safety of afatinib, a selective, orally bioavail-
able, irreversible ErbB Family Blocker of EGFR (ErbB1), HER2 (ErbB2) and 
ErbB4, compared with pemetrexed/cisplatin in patients with EGFR mutation 
positive advanced lung adenocarcinoma.
Methods: 345 EGFR mutation positive patients (Stage IIIB/IV, perfor-
mance status 0–1, chemo-naive) were randomized 2:1 to daily afatinib 40 mg 
(n=230) or intravenous pemetrexed/cisplatin (500 mg/m2 + 75 mg/m2 every 21 
days up to 6 cycles; n=115). Primary endpoint was progression-free survival 
(PFS) by central independent review.
Results: Baseline characteristics were balanced in both arms. Treatment with 
afatinib signiﬁcantly prolonged PFS versus pemetrexed/cisplatin (median 
11.1 vs. 6.9 months; HR 0.58 [0.43–0.78]; p=0.0004). In 308 patients with 
common mutations (Del19/L858R), median PFS was 13.6 versus 6.9 months 
(HR=0.47 [0.34–0.65]; p<0.0001). objective response rate was signiﬁcantly 
higher with afatinib (56% vs. 23%; p<0.0001). Signiﬁcant delay in time to 
deterioration of cancer-related symptoms of cough (HR=0.60, p=0.0072) and 
dyspnoea (HR=0.68, p=0.0145) was seen with afatinib versus pemetrexed/
cisplatin. Common drug-related adverse events (AEs) were diarrhoea (95%), 
rash (62%) and paronychia (57%) with afatinib, and nausea (66%), decreased 
appetite (53%) and vomiting (42%) with pemetrexed/cisplatin. Drug-related 
AEs leading to discontinuation were 8% (afatinib) versus 12% (pemetrexed/
cisplatin).
Conclusions: LUX-Lung 3 is the largest prospective trial in EGFR mutation 
positive lung cancer and the ﬁrst study using pemetrexed/cisplatin as a com-
parator. Treatment with afatinib signiﬁcantly prolonged PFS compared with 
pemetrexed/cisplatin, with signiﬁcant improvements in secondary endpoints, 
making afatinib a clinically relevant ﬁrst-line treatment option. AEs with afa-
tinib were manageable.
Research funding source: Boehringer Ingelheim Pharma GmbH & Co. KG, 
Germany
Disclosures:
M. Boyer: Advisory role, Boehringer Ingelheim, Pﬁzer; Honoraria, 
Boehringer Ingelheim, Eli Lilly, Pﬁzer; Research funding, Boehringer 
Ingelheim; other, Roche
M. Schuler: Advisory role, Boehringer Ingelheim; Research funding, 
Boehringer Ingelheim; other, Eli Lilly
N. Yamamoto: None
K. O’Byrne: Advisory role, Boehringer Ingelheim; Honoraria, Boehringer 
Ingelheim, Eli Lilly; Research funding, Boehringer Ingelheim; other, Eli 
Lilly, Boehringer Ingelheim
V. Hirsh: Advisory role, Boehringer Ingelheim
T. Mok:: Advisory role, Astra Zeneca, Eli Lilly, Merck Serono, Aveo, 
Boehringer Ingelheim, Pﬁzer, Eisai, Taiho, Roche, BeiGene; Honoraria, Astra 
Zeneca, Eli Lilly, Merck Serono, Aveo, Boehringer Ingelheim, Pﬁzer, Eisai, 
Taiho, Roche, BeiGene; Research funding, Astra Zeneca;
D. Massey: Employment, Boehringer Ingelheim; V. Zazulina: Employment, 
Boehringer Ingelheim; M. Shahidi: Employment, Boehringer Ingelheim
L. Sequist: Advisory role, Boehringer Ingelheim, Daichii Sankyo, 
Merrrimack, Clovis, Celgene; Research funding, Boehringer Ingelheim
J.C.-H. Yang: Advisory role, Boehringer Ingelheim; Honoraria, Boehringer 
Ingelheim
090-P12 
LINC: A PILOT LUNG CANCER INTERDISCIPLINARY 
CLINIC
Broderick C2, Blyth K1, Hunt C1, Jeffery E1, Page A1, Rigg D1, Witko S1 
1Sir Charles Gairdner Hospital, Western Australia/AUSTRALIA; 2Western 
Australia Cancer and Palliative Care Network, Western Australia/AUSTRALIA
Background: Cancer patients, and in particular lung cancer patients, have a 
high level of unmet psychological, physical and daily living needs causing 
personal distress. This distress would be best addressed by access to a combi-
nation of health professionals.
It is proposed that an interdisciplinary team located in an outpatient setting 
can better meet the needs of patients through a collaborative approach to treat-
ment, planning, supportive care and preserving current function.
Aim: To establish the level of distress by using Screening tool; increase 
access to outpatient interdisciplinary services ; To develop a referral pathway; 
To provide psychosocial support, practical assistance and education to lung 
cancer patients to prevent crisis
Design and method: A prospective cross sectional study of lung cancer 
patients will be undertaken. All new patients that are identiﬁed by the 
Lung CNC via the Lung Multidisciplinary clinic will be invited to attend 
the Lung Interdisciplinary Clinic (LINC). The clinic is an interdisciplinary 
team made up of lung cancer nurse, physiotherapists, occupational thera-
pists, social workers and dieticians. Patients will be invited to complete the 
distress thermometer screening tool. . Based on results of the screen referral 
will be made to the appropriate profession for follow up interventions. The 
aim will be to complete the intervention during this appointment or within 1 
week from the initial referral. A repeat conduction of the distress thermom-
eter screening tool will be completed within 4 weeks from the conclusion 
of interventions
Funding from CaPCREU will enable this study to take place. Planned to com-
mence in September 2012.
113-S12 
ROLE FOR PET BEYOND INITIAL STAGINS - FOR
Chatterton B, Senior Director Nuclear Medicine and PET, Royal Adelaide 
Hospital, South Australia/AUSTRALIA
The contribution of 18FDG PET (usually now PET CT) in combination with 
conventional imaging in improving staging is well established. Most com-
monly the cancer is upstaged, with improvement in prognostication related to 
stage migration and more targeted therapy, often changing management from 
potentially curative to palliative.
once the original management is planned, PET may have a further role in.
•  Detecting recurrence early in patients after potentially curative therapy.
•   Determining  at  an  early  stage  response  to  therapy  (chemotherapy,  radio-
therapy and radiofrequency ablation) allowing modiﬁcations.
•   Differentiating recurrence of tumour from post-surgical or post radiother-
apy changes
•   Molecular characterisation (eg EGF receptor targeting with 11C-erlotinib in 
planning therapy)
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•   Characterising  rare  tumours  (eg  bronchial  carcinoids  with  68Ga-DoTA) 
with potential for targeted therapy.
The Schedule of Medicare Beneﬁts in Australia (item 61529) allows for 
“Whole body FDG PET study, performed for the staging of proven non-small 
cell lung cancer, where curative surgery or radiotherapy is planned (R)”, but 
no other lung cancer indication hence the above are not currently rebatable.
It will be important to generate evidence that outcomes (survival or quality 
of life) are improved with the above uses before they become widespread. 
Currently, the evidence is not robust.
058-O12 
ZIC1 ACTS AS A TUMOUR SUPPRESSOR GENE 
AND IS SILENCED IN MALIGNANT PLEURAL 
MESOTHELIOMA
Cheng YY1, Kirschner MB1, Gattani S1, Klebe S2, Edelman JJB3, Vallely 
MP3, McCaughan BC3, Bowman RV4, Fong KM4, Moro L5, Mutti L6, Jin 
HC7, van Zandwijk N1, Reid G1 1Asbestos Diseases Research Institute 
(ADRI), University of Sydney, New South Wales/AUSTRALIA; 2Department 
of Anatomical Pathology, Flinders Medical Centre, Adelaide, South 
Australia/AUSTRALIA; 3Cardiothoracic Surgical Unit, Royal Prince Alfred 
Hospital, New South Wales/AUSTRALIA, The Baird Institute and Faculty 
of Medicine, University of Sydney, QL, New South Wales/AUSTRALIA; 
4University of Queensland Thoracic Research Centre, The Prince Charles 
Hospital, Brisbane, Queensland/AUSTRALIA; 5Department of Chemical, 
Food, Pharmaceutical and Pharmacological Sciences, Drug and Food 
Biotechnology Center, University of Piemonte Orientale A. Avogadro, Novara/
ITALY; 6Dept General Medicine, Lab of Clinical Oncology, Vercelli National 
Health Trust, Vercelli/ITALY; 7Biomedical Research Center, Sir Runrun Shaw 
Hospital, Zhejiang University, Hangzhou/CHINA
Epigenetic inactivation of tumour suppressor genes through DNA hypermethyl-
ation plays a crucial role in the progression of malignant pleural mesothelioma 
(MPM). ZIC1, a tumour suppressor gene silenced through promoter hypermeth-
ylation in gastric and colorectal cancer, was expressed at high levels in normal 
mesothelial cells. In contrast, ZIC1 was not expressed or was downregulated 
in MPM cell lines. Following treatment with decitabine, expression of ZIC1 
was signiﬁcantly up-regulated in all mesothelioma lines but was unchanged 
in MeT-5A and primary human mesothelial cells. MSP and CoBRA analysis 
revealed methylation of the ZIC1 promoter that correlated with ZIC1 mRNA 
expression, suggesting ZIC1 is silenced in MPM through DNA hypermethyl-
ation. Enforced ZIC1 expression inhibited cell migration and colony formation 
in H28, Ren and MM05 cell lines, and ZIC1 knockdown enhanced growth of 
MeT-5A in soft agar. In MPM tumour samples ZIC1 mRNA expression was 
present at low or undetectable levels, with promoter methylation observed in 16 
of 24 cases. Microarray analysis of MPM cell lines revealed that a number of 
miRNAs were overexpressed in the absence of ZIC1 expression. Upon enforced 
ZIC1 expression, levels of miR-23a and miR-27a were reduced, and cells trans-
fected with an inhibitor of miR-23a exhibited reduced colony formation. These 
miRNAs were expressed at higher levels in tumours from patients with shorter 
survival. our results show that ZIC1 behaves in MPM cell culture as a tumour 
suppressor gene that functions in part through downregulation of miR-23a.
073-P12 
EGFR MUTANT SPECIFIC IMMUNOHISTOCHEMISTRY 
HAS HIGH SPECIFICITY BUT ONLY MODERATE 
SENSITIVITY FOR DETECTING COMMON ACTIVATING 
EGFR MUTATIONS IN LUNG ADENOCARCINOMA
Cooper WA1,2, Yu B3,4, Yip PY5, Farzin M6, Clarkson A6, Kohonen-Corish 
MJ2,7,8, Horvath L4,5,7, Kench JG1,4,7, McCaughan B4,9, O’Toole SA1,4,7, Gill 
AJ4,6 Departments of 1Tissue Pathology and Diagnostic Oncology, 3Molecular 
and Clinical Genetics, 5Oncology and 9Cardiothoracic Surgery, Royal Prince 
Alfred Hospital, Sydney, New South Wales/AUSTRALIA; 2School of Medicine, 
University of Western Sydney, New South Wales/AUSTRALIA; 4Sydney Medical 
School, University of Sydney, New South Wales/AUSTRALIA; 6Department 
of Anatomical Pathology and Northern Cancer Translational Research 
Unit, Royal North Shore Hospital, Sydney, New South Wales/AUSTRALIA; 
7Kinghorn Cancer Centre and Garvan Institute of Medical Research, Sydney, 
New South Wales/AUSTRALIA; 8St Vincent’s Clinical School, University of 
NSW, Sydney, New South Wales/AUSTRALIA
Aim: We assessed the accuracy of EGFR mutant speciﬁc antibodies for 
detecting two common activating EGFR mutations.
Methods: Expression of mutant speciﬁc antibodies to EGFR exon 19 dele-
tion E746_A750 and exon 21 L858R point mutation were assessed in a cohort 
of 204 resected early stage node negative lung adenocarcinomas. Expression 
of mutant speciﬁc EGFR proteins was compared with standard mutation anal-
ysis (mass spectrometry).
Results: of 7 cases with L858R point mutation, 6 were positive by immu-
nohistochemistry (IHC). There were 2 false positive cases using L858R IHC 
(sensitivity 86%, speciﬁcity 99%, negative predictive value 99%). of 7 E746_
A750 exon 19 deletions identiﬁed by mutation analysis, 5 were positive by 
IHC. Three additional cases were positive for exon 19 IHC but negative by 
mutation analysis. The sensitivity of exon 19 IHC for E746_A750 was 71%, 
speciﬁcity 98% and negative predictive value 99%.
Conclusion: Mutant speciﬁc EGFR immunohistochemistry has good speci-
ﬁcity but only moderate sensitivity for identifying targeted activating EGFR 
mutations. The high negative predictive value of IHC means it could be a 
useful tool to screen out cases unlikely to harbour mutations. 
Disclosure: no dualities of interest identiﬁed. 
Funding: Cancer Institute of NSW and Lifehouse at Royal Prince Alfred 
Hospital.
089-O12 
BRONCHOSCOPY AND TRANSTHORACIC-NEEDLE 
ASPIRATION YIELD FOR HISTOMORPHO-
MOLECULAR DIAGNOSIS
Daniels MG1, Leong S1, Bowman RV1, Yang IA1, Masel P1, Fiene A1, Robinson 
P1, Burke A1, McKeon J1, Ayres J2, Duhig E3, Clarke B3, Tran K3, Godbolt D3, 
Dettrick A3, Fong KM3 1Department of Thoracic Medicine, The Prince Charles 
Hospital, Brisbane, Queensland/AUSTRALIA; 2Department of Radiology, The 
Prince Charles Hospital, Brisbane, Queensland/AUSTRALIA; 3Department of 
Anatomical Pathology, The Prince Charles Hospital, Brisbane, Queensland/
AUSTRALIA
Introduction: Somatically acquired mutations, including in the EGFR gene, 
drive many lung cancers. Since targeted therapies were introduced, diagnosis 
often requires sufﬁcient tissue for histomorphology and molecular analysis. 
We studied patterns of molecular analysis after conventional diagnosis.
Methods: Review of consecutive subjects undergoing ﬁbreoptic bronchos-
copy (FoB) and transthoracic-needle aspiration (TTNA) for suspected lung 
cancer over 3 months.
Results: 79 patients underwent 89 procedures; 68 FoB, 21 TTNA. 5/68 
patients who underwent FoB proceeded to TTNA, and 5 required repeat FoB. 
24/68 (35%) were diagnosed at FoB with primary lung cancer, 2 SCLC and 
22 NSCLC; others were metastases or benign. 8/22 (36%) NSCLC were squa-
mous cell carcinomas (SCC) and 14 demonstrated non-squamous histologies 
including 11 adenocarcinoma (50%) (AC). of 14 non-squamous carcinomas, 
9 had malignant cells in transbronchial biopsy (TBBx), 2 in transbronchial-
needle aspiration (TBNA), 2 in lymph node TBNA, 9 in wash (BrW), 4 in 
mini-bronchioloalveolar lavage and 7 in brushings. Cell-blocks were available 
for 13 /24 cytology samples. of the non-squamous NSCLC, 8 were incurable.
21 underwent TTNA, 15 (71%) with primary lung cancer; 2 (13%) 2 SCC, 
13 (87%) non-squamous including 7 AC. 1 diagnosed by core biopsy and 14 
by cytology from which 10 had cell-blocks. of the non-squamous NSCLC, 8 
had incurable disease.
From 16 incurable non-squamous tumours 5 specimens (3 TBBx, 2 BrW) 
were tested for EGFR exon 19 / 21 mutations; all were mutation negative.
Conclusions: There is need for a standardised approach to EGFR mutation 
analysis to guide lung cancer treatment.
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063-P12 
A PERSONALIZED VACUUM IMMOBILIZATION 
CRADLE REDUCES TUMOUR MOTION DURING 
STEREOTACTIC RADIOSURGERY OF PULMONARY 
TARGETS.
Devereux T1, Kron T2, Ball D3, MacManus M3, Foroudi F3, Hicks R4, Bressell 
M5, Callahan J4, Dang K1, Siva S1 1Department of Radiation Therapy 
Services Peter MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA; 
2Department of Physical Sciences, Peter MacCallum Cancer Centre, 
Melbourne, Victoria/AUSTRALIA; 3Department of Radiation Oncology, Peter 
MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA; 4Department 
of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria/
AUSTRALIA; 5 Centre for Biostatistics and Clinical Trials, Peter MacCallum 
Cancer Centre, Melbourne, Victoria/AUSTRALIA
Aim: To assess the impact of the Elekta BodyFix® system (Medical 
Intelligence, Schwabmünchen Germany) on tumour motion amplitude and 
direction of motion in the context of stereotactic radiosurgery.
Method: As part of a prospective pilot study of stereotactic radiosurgery 
for pulmonary oligometastases, 12 patients underwent both a 4D planning 
CT and a 4D PET/CT. For the planning CT patients were immobilised using 
the Bodyﬁx device. Patients also underwent a 4D PET/CT in the same posi-
tion without the immobilisation device. The centre point of the tumour was 
recorded for each phase of the breathing cycle for both scans. A volumetric 
bounding box encompassing the maximal tumour centroid excursion was 
generated for both datasets and tumour displacement was analysed in the 
medio-lateral (X), cranio-caudal (Y) and ventero-dorsal (Z) planes.
Results: The median (range) amplitude of displacement in the X, Y and 
Z planes when immobilized in the BodyFix® were 0.9mm(0.3-2.9mm), 
2.6mm(0.2-10.6mm) and 1.6mm (0.5-5.5mm) respectively. The median 
(range) amplitude of displacement in the X, Y and Z planes when not immo-
bilized was 1.1mm (0.3mm-6.1mm), 4.9mm (1.7mm-13.8mm) and 2.3mm 
(0-12.0mm) respectively. Maximum amplitude of tumour motion was statisti-
cally greater without immobilization in the Y-plane (p=0.011) and Z-plane 
(p=0.038) on Wilcoxon testing. The bounding box of tumour displacement 
was 6 times smaller when patients were in the BodyFix®.
Conclusion: The BodyFix® device signiﬁcantly reduces tumour motion in 
the cranio-caudal and ventero-dorsal planes. Immobilization had less impact 
on medio-lateral tumour excursion. Minimal tumour motion in the BodyFix® 
reinforces the view that narrow radiotherapy margins are appropriate for our 
technique.
Disclosure: S Siva has received scholarship support research funding from 
Elekta. Elekta had no input to study design analysis or abstract preparation. 
There are no other disclosures to declare.
064-P12 
A PERSONALIZED IMMOBILIZATION CRADLE 
FACILITATES ROBUST IMMOBILIZATION AND 
REPRODUCIBILITY DURING STEREOTACTIC 
RADIOSURGERY OF PULMONARY METASTASES
Devereux T1, Kron T2, Foroudi F3, MacManus M3, Pham D1, Chesson 
B1, Ball D3, Siva S1 1Department of Radiation Therapy Services, Peter 
MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA; 2Department 
of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Victoria/
AUSTRALIA; 3Department of Radiation Oncology, Peter MacCallum Cancer 
Centre, Melbourne, Victoria/AUSTRALIA
Aim: To assess the impact of the Elekta BodyFix® system (Medical 
Intelligence, Schwabmünchen Germany) in reproducing patient setup and 
minimizing intra-fraction motion.
Method: Single fraction stereotactic radiosurgery was delivered to 19 pul-
monary metastases using the BodyFix® cradle. A “mock-up” cone-beam CT 
(CBCT) scan was performed on the linear accelerator to assess the reproduc-
ibility of the set-up. Subsequently, on the day of treatment, a pre-treatment 
CBCT and a mid-treatment CBCT was performed to verify tumour posi-
tion with 0mm tolerance. All couch shifts were actioned and recorded in the 
medio-lateral (X), cranio-caudal (Y), and ventero-dorsal (Z) planes. 
Results: The median time to the mid-treatment CBCT was 24 minutes (range 
15-39 minutes). The median (0-90% range) shift required at mock-up / pre-
treatment in the X-plane was 2mm (0-3mm) / 1mm (0-3mm), in the Y-plane 
2mm (0mm-9mm) / 2mm (0-6mm) and in the Z-plane 2mm (0-6mm) / 4mm 
(0-8mm) respectively. The mean (± standard deviation) mid-treatment shifts 
were 0.3mm (±0.7mm), 1.1mm (±2mm) and 0.8mm (±1.5mm) in the X, Y 
and Z planes respectively. Mean shifts were signiﬁcantly <2mm (p=<0.0001, 
student’s t-test). Linear regression analysis showed no correlation with length 
of treatment and necessary mid-treatment shifts in the X (r2=0.096, p=0.198) 
and the Y (r2=0.012, p=0.653) planes but signiﬁcant correlation in the Z plane 
(r2=0.377, p=0.005).
Conclusion: Robust intra-fractional immobilization was achieved using the 
BodyFix® system with mean shifts signiﬁcantly <2mm. Patient set-ups were 
reproducible at a median of < 2mm in all directions. Reduction of overall 
treatment times may further improve intra-fractional immobilization particu-
larly in the ventero-dorsal direction.
Disclosure: S Siva has received scholarship support research funding from 
Elekta. Elekta had no input to study design analysis or abstract preparation. 
There are no other disclosures to declare.
103-O12 
CARING FOR THORACIC CANCER CAREGIVERS: 
EXPLORING PSYCHOLOGICAL AND SUPPORTIVE 
CARE NEEDS
Dhillon H1,2,3, Price M1,2, Wikaire E1, Vardy J2,3,4 1 POCOG, School of 
Psychology. Uni of Sydney, New South Wales/AUSTRALIA; 2 CeMPED, 
University of Sydney, New South Wales/AUSTRALIA; 3 Sydney Medical 
School, University of Sydney, New South Wales/AUSTRALIA; 4 Sydney Cancer 
Centre, Sydney, New South Wales/AUSTRALIA
Aim: The global aim was to explore the psychological and unmet needs of 
thoracic cancer caregivers and families. Speciﬁc aims were to establish the 
psychological impact of caring for people with thoracic cancer by: i) identify-
ing the psychological concerns, unmet supportive care needs, and priorities of 
caregivers and families of thoracic cancer patients; and ii) identifying strate-
gies to address these unmet needs.
Methods: A qualitative, grounded theory approach was taken. Caregivers of 
people with thoracic cancer were invited to participate in a single, in-depth 
interview. A semi-structured interview schedule was used to explore top-
ics including: a) Roles and identities; b) Diagnosis; c) Decision making; d) 
Relationships / family dynamics; e) Support and resources; f) Health care sys-
tem and treatment; and g) end of life. Interviews were transcribed verbatim, 
transcripts were analysed in NVivo software and coded according to themes 
identiﬁed during and after the interview process.
Results: 43 individuals were interviewed: 34 carers of current patients, and 
9 bereaved carers. Thirty-two carers were female;. Relationship to patient: 23 
spouses, 13 children, 3 siblings, 4 other. Employment status: 17 full-time, 17 
retired, 5 part-time, 4 other. Broad themes identiﬁed include: difﬁcult road 
to diagnosis, healthcare systems issues (communication between healthcare 
professionals, access to services), smoking, death (timeframe and feeling 
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unprepared), communication (carer vs patient information needs, translating 
for family members).
Conclusion: Carers of people with thoracic cancer have ongoing unmet 
needs. Future research aimed at addressing carer needs and supporting them 
in caring effectively is required.
069-P12 
DRAMATIC REDUCTION OF SEQUENCE ARTEFACTS 
FROM DNA EXTRACTED FROM FORMALIN-FIXED 
CANCER BIOPSIES BY TREATMENT WITH URACIL-
DNA GLYCOSYLASE
Do H1, Dobrovic A1,2 1Molecular Pathology Research and Development 
Laboratory, Department of Pathology, Peter MacCallum Cancer Centre, 
Melbourne, Victoria/AUSTRALIA; 2Sir Peter MacCallum Department 
of Oncology, University of Melbourne, Parkville, Victoria/AUSTRALIA; 
3Department of Pathology, University of Melbourne, Parkville, Victoria/
AUSTRALIA
Formalin-ﬁxed parafﬁn-embedded (FFPE) tissue is the most frequent source 
of DNA for mutation testing to stratify cancer patients for molecularly tar-
geted therapies. Artefactual sequence changes detected in FFPE DNA often 
hamper an accurate diagnosis of mutation status in clinical samples. The 
underlying causes of sequence artefacts arising from FFPE DNA are still 
poorly understood. To delineate the possible causes of sequence artefacts, we 
examined the types of sequence artefacts using two independent sets of lung 
FFPE DNA samples by Sanger sequencing; for EGFR exon 19 and BRAF 
V600 region respectively. Low copy number templates (100 pg) were used 
for PCR ampliﬁcation to enable artefact-bearing templates to be stochasti-
cally enriched and thus to be detected by Sanger sequencing. Multiple PCR 
products (9-10) were sequenced for each sample. In the sequencing for EGFR 
exon 19, 25 C:G>T:A sequence artefacts were detected in a total of 29 repli-
cates of three FFPE DNAs. Similarly, 15 C:G>T:A sequence artefacts were 
detected in the BRAF V600 region from ﬁve FFPE DNAs, indicating that 
C:G>T:A changes are the major type of sequence artefacts. We then exam-
ined whether uracil lesions due to cytosine deamination caused C:G>T:A 
artefacts by treating those artefact-detected FFPE DNAs with uracil-DNA 
glycosylase (UDG) which removes uracil bases in DNA. Treatment of FFPE 
DNA with UDG prior to PCR ampliﬁcation dramatically reduced sequence 
artefacts in all samples. When sequenced for EGFR exon 19 after UDG treat-
ment, only one C>T artefacts was detected in a total of 28 replicates of the 
three FFPE DNAs and no artefacts in 48 replicates of the ﬁve FFPE DNAs for 
BRAF V600 region. UDG treatment speciﬁcally suppressed the formation of 
artefacts in FFPE DNA as it did not affect the detection of true KRAS codon 
12 and true EGFR exon 19 and 20 mutations. our other studies also show 
that that uracil in FFPE DNA leads to a signiﬁcant proportion of sequence 
artefacts that can be minimised by a simple UDG pre-treatment. This ﬁnding 
has immediate and important implications to cancer diagnostics where FFPE 
DNA is used as the primary genetic material for mutational studies guiding 
personalised medicine strategies.
071-P12 
THE RISE AND FALL OF COMPANION DIAGNOSTICS.
Dobrovic A1,2,3 1Molecular Pathology Research and Development Laboratory, 
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, 
Victoria/AUSTRALIA; 2Sir Peter MacCallum Department of Oncology, 
University of Melbourne, Parkville, Victoria/AUSTRALIA; 3. Department of 
Pathology, University of Melbourne, Parkville, Victoria/AUSTRALIA
The emerging paradigm of companion diagnostics is that every drug should 
have a companion diagnostic based on a biomarker that predicts an individual 
patient’s response to that drug. However, the increasing amount of available 
drugs (each of which requires testing for an individual biomarker), the limited 
amount of tissue usually available, and the substantial cost of proprietary tests 
will inevitably lead to the demise of this concept. The future lies with meth-
odologies that enable multiple parallel analysis of the same sample aliquot. 
These include but are not restricted to ‘next generation’ sequencing protocols. 
The interpretation of the large amounts of data that will be generated will 
require the emergence of a new interpretative discipline of genomic pathology 
that will straddle bioinformatics and clinical medicine.
026-P12 
LUNG CANCER WAITING TIMES AT THE ROYAL 
ADELAIDE HOSPITAL
Dougherty BD1*,Oborn M1, Robinson PC1 1Department of Thoracic Medicine, 
Royal Adelaide Hospital, South Australia/AUSTRALIA
Introduction: Waiting times for cancer diagnosis and treatment are moni-
tored in the United Kingdom. This audit examines the performance of the 
Royal Adelaide Hospital (RAH) in diagnosis, staging and treatment of lung 
cancer.
Methods:We retrospectively identiﬁed 100 patients referred to the RAH 
between February and September 2010, with subsequently histologically con-
ﬁrmed lung cancer. We identiﬁed key dates in diagnosis and treatment. We 
calculated time intervals between these points.
Results:Complete data was available for 91 patients. The median time from 
GP referral to 1st appointment was 7 days, then 8 days to histological diagno-
sis. The median time for bronchoscopy was 4 days, CT-FNA 13 days, EBUS-
TBNA 10.5 days, PET scan 10 days, and lung function 7 days. The wait for a 
surgical oPD was 25.5 days from diagnosis, then 12 days to surgery. Medical 
oncology clinic from diagnosis 24 days, chemotherapy 13 days thereafter. 
Radiation oncology clinic 15 days, radiotherapy 12.5 days thereafter.
Discussion: The National Health Service in the UK sets 3 cancer waiting 
times targets : (1) suspected cancers be seen by a specialist within 14 days of 
GP referral ; (2)treatment begins within 31 days of diagnosis ; and (3) within 
62 days of GP referral. The RAH achieved the ﬁrst target in 7 days, but treat-
ment from diagnosis took 35 days, and from GP referral took 53.3 days. 
Conclusion: Although diagnostic performance is acceptable, there are delays 
in initiating lung cancer treatments. 
Disclosure: No Conflicts of interest
051-012 
HOW DO PATIENTS WITH LUNG CANCER EXPERIENCE 
RADIATION INDUCED OESOPHAGITIS?
Duffy M1*, Milne D1, Ball D1, Aranda S1 1Peter MacCallum Cancer Centre, 
Melbourne, Victoria/AUSTRALIA
Background: Radiation induced oesophagitis (RIo) is a signiﬁcant toxic-
ity of lung cancer treatment that has profound clinical, social and economic 
implications. The literature suggests there is minimal evidence to support cur-
rent analgesic regimes with the exception of systemic analgesia. More infor-
mation is required to better understand the patient experience of RIo and 
how it can be managed. Aim:To identify the properties and characteristics of 
RIo experienced by patients having radiotherapy to the chest for lung cancer.
Methods: A qualitative exploratory study conducted with patients with lung 
cancer receiving radiotherapy to the chest. Patients participated in semi-struc-
tured interviews exploring their experience of RIo. Interviews were recorded, 
transcribed and content analysed.
Results: Twenty six patients participated: six with grade 1; 14 with grade 2 
and eight with grade 3 RIo. Four key domains were identiﬁed: 1.Pain descrip-
tors such as “feels raw”, “burning”, “like reflux but worse” were reported 2. 
Swallowing difﬁculties varied over time and were described as “felt like there 
was a blockage, “afraid I would choke,” “unable to get anything through”. 3. 
Self care efforts employed by the patients to manage these difﬁculties ranged 
from diet modiﬁcation, allowing food and drinks to go cold before eating and 
eating slowly. 4. An aversion to taking regular analgesia was also evident. The 
overall impact on participants’ lives was often understated, even in the context 
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of hospital admissions, insertion of nasogastric tubes and poorly controlled 
pain.
Conclusions: This study demonstrates the complexity of RIo and suggests 
clinicians may underestimate the effect and severity of RIo. Given patients 
appear to continue to experience problems, despite treatment, better prophy-
laxis and management regimes are required.
084-O12 
INTEROBSERVER AGREEMENT OF LUNG 
ADENOCARCINOMA DIAGNOSIS WHEN APPLYING 
THE 2011 IASLC/ATS/ERS MULTIDISCIPLINARY 
CLASSIFICATION OF LUNG ADENOCARCINOMA
Duhig EE1, Clarke BE1, Godbolt D1, Dettrick A1, Pauli J1, Yang IA2,3, Bowman 
RV2,3, Fong KM2,3 1 Department of Anatomical Pathology, The Prince Charles 
Hospital, Brisbane, Queensland/AUSTRALIA; 2 Department of Thoracic 
Medicine, The Prince Charles Hospital, Brisbane, Queensland/AUSTRALIA; 
3 UQ Thoracic Research Centre, School of Medicine, The University of 
Queensland, Brisbane, Queensland/AUSTRALIA
A new histological classiﬁcation of primary lung adenocarcinomas was pro-
posed in 2011, based on a multidisciplinary approach. We tested the repro-
ducibility of scoring amongst experienced pathologists.
Methods: Patients who underwent lung resection surgery for lung adeno-
carcinoma were recruited. Histology slides of the resected carcinomas were 
scored independently by 5 anatomical pathologists, who had 3 to 25 years 
experience at reporting lung carcinoma. The percentage component of each of 
the proposed patterns (lepidic, acinar, papillary, solid and micropapillary) was 
recorded, with the lowest recorded component being 5%. The median score 
of the predominant pattern from the 5 readers was calculated for each patient, 
and taken as the consensus score.
Results: 176 patients with lung adenocarcinoma were studied (M/F 58%/42%, 
mean (SD) age 70(10) y, smoking 43(27) pack-years, tumour size 34(19) 
mm). 14 patients were never smokers. All except two patients had Stage I lung 
cancer. Intraclass correlation coefﬁcients for the 5 patterns ranged from 0.87 
to 0.98 (averaged measures). Tumours were categorised as well-differentiated 
(7%), moderately differentiated (64%) and poorly differentiated (28%). This 
classiﬁcation was associated with survival (P=0.032, log-rank test), with the 
main difference being worse survival for poorly vs moderately differentiated 
(P=0.021).
Conclusions: Pathologists of varying levels of experience can reproducibly 
apply the proposed IASLC/ATS/ERS classiﬁcation. This allows better subdi-
vision of the adenocarcinomas into prognostic tiers.
Support: NHMRC project grant, NHMRC Practitioner Fellowship (KF), The 
Prince Charles Hospital Foundation
085-P12 
THE APPLICATION OF FUHRMAN NUCLEAR GRADE 
TO LUNG ADENOCARCINOMA AND CORRELATION 
WITH THE IASLC/ATS/ERS MULTIDISCIPLINARY 
CLASSIFICATION OF ADENOCARCINOMA AND 
SURVIVAL IN STAGE 1 DISEASE
Duhig EE1, Clarke BE1, Godbolt D1, Dettrick A1, Pauli J1, Yang IA2,3, Bowman 
RV2,3, Fong KM2,3 1 Department of Anatomical Pathology, The Prince Charles 
Hospital, Brisbane, Queensland/AUSTRALIA; 2 Department of Thoracic 
Medicine, The Prince Charles Hospital, Brisbane, Queensland/AUSTRALIA; 
3 UQ Thoracic Research Centre, School of Medicine, The University of 
Queensland, Brisbane, Queensland/AUSTRALIA
A new classiﬁcation of primary lung adenocarcinomas was proposed in 2011. 
Several authors have demonstrated survival beneﬁt by assessing nuclear 
grade. The Fuhrman grade system is used to grade nuclear atypia in renal cell 
carcinoma. We sought to determine whether this system could be reproducibly 
applied to lung cancer and whether this correlated with survival in the context 
of the new classiﬁcation.
Methods: Patients who underwent resection for lung adenocarcinoma were 
recruited. Histology slides of the carcinomas were scored independently by 
5 anatomical pathologists. They recorded the highest nuclear grade in each 
of the tumours using Fuhrman criteria that were circulated at the commence-
ment of the project. The percentage component of each of the histological 
patterns was also recorded. Median scores of the predominant pattern were 
calculated, and taken as the consensus score. Grade and pattern were cor-
related with the survival.
Results: 176 patients with lung adenocarcinoma were studied (M/F 
58%/42%), mean (SD) age 70(10) y, smoking 43(27) pack-years, tumour 
size 34(19) mm). Classiﬁcation of Fuhrman grades was grade 2: 13 (7%), 
grade 3: 83 (47%), grade 4: 80 (45%). Intraclass correlation coefﬁcients for 
the Fuhrman grade was 0.82 (averaged measures). Decreasing differentiation 
of adenocarcinomas (well to moderate to poor) had worse Fuhrman nuclear 
grade (P<0.001, χ2). Fuhrman grade (2 or 3, vs 4) correlated with survival of 
patients after lung resection (P=0.036).
Conclusions: A modiﬁed Fuhrman nuclear grading system can be reproducibly 
applied by pathologists and is prognostically signiﬁcant. Further investigation 
is required to determine whether this is independent of architectural pattern.
Support: NHMRC project grant, NHMRC Practitioner Fellowship (KF), The 
Prince Charles Hospital Foundation
086-O12 
THE APPLICATION OF MITOTIC ACTIVITY 
AND NECROSIS TO LUNG ADENOCARCINOMA 
AND CORRELATION WITH THE IASLC/ATS/
ERS MULTIDISCIPLINARY CLASSIFICATION OF 
ADENOCARCINOMA IN STAGE 1 DISEASE
Duhig EE1, Clarke BE1, Godbolt D1, Dettrick A1, Pauli J1, Yang IA2,3, Bowman 
RV2,3, Fong KM2,3 1 Department of Anatomical Pathology, The Prince Charles 
Hospital, Brisbane, Queensland/AUSTRALIA; 2 Department of Thoracic 
Medicine, The Prince Charles Hospital, Brisbane, Queensland/AUSTRALIA; 
3 UQ Thoracic Research Centre, School of Medicine, The University of 
Queensland, Brisbane, Queensland/AUSTRALIA
A new classiﬁcation of primary lung adenocarcinomas was proposed in 2011, 
based on a multidisciplinary approach. We sought to determine whether 
parameters other than histological pattern, such as mitotic activity and necro-
sis, could be applied to lung cancer and whether this correlated with survival 
in the context of the classiﬁcation.
Methods: Patients who underwent resection for lung adenocarcinoma were 
recruited. Histology slides of the carcinomas had been scored independently 
by 5 anatomical pathologists for the percentage component of each of the 
histological patterns. one of the pathologists then performed mitotic counts 
of each of the carcinomas. Using a Leica DM LB2 microscope with the 40x 
objective, mitoses were counted in 10 high power ﬁelds (HPF) with a mini-
mum of 30 HPF counted in total. The highest number of mitoses in the 10HPF 
was recorded. The pathologist also estimated the percentage of necrosis.
Results: 176 patients with lung adenocarcinoma were studied (M/F 
58%/42%, mean(SD) age 70(10) y, smoking 43(27) pack-years, tumour size 
34(19) mm). Mitotic grades were: 0-10 per 10HPF: 99 (56%), >10-20 per 
10HPF: 40 (23%), >20 per 10HPF: 37 (21%). Median % necrosis was 1% 
(IQR 0-10%). Decreasing differentiation of adenocarcinomas (well to mod-
erate to poor) had worse mitotic grade (P<0.01, χ2), and higher % tumour 
necrosis (P<0.01, ANoVA).
Conclusions: High mitotic grade and tumour necrosis are associated with 
high grade adenocarcinoma architectural patterns. While they may contrib-
ute to future grading of resected adenocarcinomas of lung, further assess-
ment to determine whether these independently predict survival needs to be 
undertaken.
Support: NHMRC project grant, NHMRC Practitioner Fellowship (KF), The 
Prince Charles Hospital Foundation
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098-O12 
RADIATION “PNEUMONECTOMY” FOR LOCALLY 
ADVANCED MALIGNANT PLEURAL MESOTHELIOMA: 
ACCEPTABLE LOCOREGIONAL CONTROL AND 
TOXICITY OUTCOMES
Feigen M1, Lee S2, Lawlor M1, Scott AM2, Hamilton C1 1Radiation Oncology 
Centre, Austin Health, Heidelberg, Victoria/AUSTRALIA; 2Centre for PET, 
Austin Health, Heidelberg, Victoria/AUSTRALIA
Aims: Malignant pleural mesothelioma is an incurable disease where chemo-
therapy and conventional radiotherapy produce modest responses and fewer 
surgeons are undertaking extrapleural pneumonectomies (EPPs). We aimed 
to optimise palliative radiotherapy by using advanced technologies to maxi-
mise the planning target volume (PTV) and radiation doses without producing 
major toxicity.
Methods: Patients with mesothelioma localized to one hemithorax received 
radiotherapy utilizing 18F-FDG PET/CT scans to outline tumour volumes. 
There were no restrictions on prior surgery or chemotherapy. All CTCAE ver-
sion 4 toxicities were recorded.
 Results: From July 2003 to March 2012 we planned 50 patients for radiotherapy 
with doses of 45-60 Gy over 6 weeks. None had a prior EPP. 30 underwent pleu-
rectomy/decortication, 18 a pleurodesis and 2 only a biopsy. Patients were aged 
45-75, mostly males (84%) with right (58%) epithelioid (80%) mesotheliomas, 
and clinical stage III/IV disease (76%). 33 had prior chemotherapy, including 5 
trimodality cases. 17 received 3D-conformal radiotherapy and 33 IMRT, in 31 
cases to the complete hemithorax. Median followup post-radiotherapy was 9.4 
months (range 2-90), and 58 PET/CT scans were assessed 3-87 months after 
radiotherapy. 8 patients recurred within the PTV, all with concurrent metastases 
documented in unirradiated sites. 30 recurred only outside the PTV. There were 
no signiﬁcant acute or late toxicities and no radiation pneumonitis > grade 3 in 
the absence of disease spread to the contralateral lung.
Conclusions: For mesothelioma patients declining or unsuitable for EPP, a 
radiation “pneumonectomy” can be an effective alternative to achieve long-
term palliation and improved locoregional control. There were no fatal radia-
tion toxicities.
099-O12 
PROPHYLACTIC RADIOTHERAPY TO INTERVENTION 
SITES IN MESOTHELIOMA: CRITICAL ANALYSIS OF 
THE EVIDENCE
Feigen M1 1Radiation Oncology Centre, Austin Health, Heidelberg, Victoria/
AUSTRALIA
Aims: Many radiotherapy centres in Australia and other countries deliver low 
dose electron therapy to scar sites for mesothelioma patients who undergo 
diagnostic and therapeutic procedures, to prevent subcutaneous recurrences. 
Evidence for the clinical beneﬁt of this practice is controversial and warrants 
reevaluation.
Methods: All published systematic reviews, randomised and non-randomised 
trials, surveys, small institutional series and case reports on this subject 
were critically evaluated, and the clinical relevance of this approach was 
determined.
Results: Most of the publications advocating prophylactic radiotherapy have 
design flaws and there are signiﬁcant variations in radiation dose, fraction-
ation, ﬁeld size and placement, electron energies, timing of radiotherapy and 
followup assessments. The effect of disease stage, histological subtype and 
the addition of chemotherapy are not addressed. The administration of pro-
phylactic radiotherapy in patients with mesothelioma following pleural inter-
vention has no effect on changing the disease course and is not recommended. 
With changing biopsy procedures and surgical techniques, older studies are 
no longer relevant.
Conclusions: Instead of delivering prophylactic radiation, higher doses of 
radiotherapy should be considered to treat symptomatic tumour deposits, and 
include regions of major disease relapse inside the chest cavity. No further 
trials of prophylactic radiotherapy should be undertaken.
012-P12 
RETROSPECTIVE AUDIT OF OUTCOMES OF PATIENTS 
WITH LOCALLY ADVANCED NON-SMALL CELL LUNG 
CANCER (NSCLC) TREATED WITH CONCURRENT 
RADIOTHERAPY (RT) AND CHEMOTHERAPY AT 
PRINCE OF WALES CANCER CENTRE (POWCC)
Ferris L1, Wong W2, Lewis CR1,3 1 Prince of Wales Hospital Clinical Teaching 
Unit, UNSW, New South Wales/AUSTRALIA; 2 Department of Radiation 
Oncology, Prince of Wales Hospital Cancer Centre, Randwick, New South 
Wales/AUSTRALIA; 3 Department of Medical Oncology, Prince of Wales 
Hospital Cancer Centre, Randwick, New South Wales/AUSTRALIA
Purpose: Lung cancer is the most common cause of cancer-related death 
worldwide. The majority of patients present with locally advanced or meta-
static disease. This retrospective audit analysed survival and toxicity for 
patients with Stage IIIA (n=18), IIIB (n=34) or III(NoS) (n=3) inoperable 
NSCLC treated with concurrent chemoradiation at PoWCC. our results were 
compared with the literature to determine whether outcomes including pro-
gression free and overall survival are consistent, and with acceptable toxicity.
Methods: of 56 patients identiﬁed between 1999-2009 from in-house data-
bases, 55 were eligible and treated with concurrent chemoradiation. over the 
study period three chemotherapy regimens were used in combination with 
60 Gy RT including weekly docetaxel, weekly carboplatin/paclitaxel, and 
cisplatin with either etoposide or docetaxel. The audit was approved by the 
SESIAHS Research Ethics Committee. Eligible patients had inoperable stage 
IIIA and IIIB NSCLC; baseline lung function FEV1 >1; ECoG performance 
status 0 – 2. RT planning was optimised to ensure that V20 was <30%.
Results: At median follow-up of 13 months, median overall survival was 
10, 13.5 and 17 months for docetaxel, carboplatin/paclitaxel and cisplatin-
based therapy respectively and 12 months across all schedules. There were 
2 toxicity-related deaths from pulmonary toxicity, both treated with weekly 
docetaxel. Grade 3-4 oesophagitis was the main signiﬁcant toxicity with 6, 23 
and 36% of patients in docetaxel, carboplatin/paclitaxel and cisplatin-based 
schedules respectively.
Conclusion: Survival and toxicity outcomes in our audit align with the pub-
lished literature. The current practice of cisplatin-based therapy reflects the 
results in multicentre trials in concurrent chemoradiation. 
Disclosure: The authors have no conflicts of interest to declare
017-O12 
IMPLEMENTATION OF NEXT GENERATION 
SEQUENCING (NGS) AS A HIGH THROUGHPUT 
DIAGNOSTIC FOR EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATION ANALYSIS IN LUNG 
CARCINOMA
Fox SB2, Meldrum C1, 2, Fellowes A2, Bosma T2, Bell A2, Solomon B2 1 
Pathology North New South Wales/AUSTRALIA; 2Peter MacCallum Cancer 
Centre, Melbourne, Victoria/AUSTRALIA
Mutational analysis of lung cancers are problematic due to the paucity 
of tumour material in biopsies and dilution of signal by non-neoplastic. 
Diagnostic laboratories will also be under pressure to provide multiplex test-
ing on the same restricted tissue e.g. ALK. Thus, the current paradigm of 
testing each gene separately often using different assays is not feasible. We 
therefore used next generation sequencing (NGS) for EGFR testing as a clini-
cal diagnostic. DNA was extracted from two cell lines, eight FFPE NSCLC 
tumour samples, three of which were tested in duplicate. A two-fold cell line 
dilution was performed. The EGFR gene was ampliﬁed in a Fluidigm access 
array, pooled amplicons for each sample were tagged with sample speciﬁc 
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index and sequencing tags followed by NGS. Alignment against the target 
region and variant calling was performed using custom bioinformatics. of 
the 33/51 variants that were detected using NGS, there was 100% concor-
dance, including all tumour samples. A further 11/51 variants were detected 
by detailed analysis by eye but were not called automatically by bioinformat-
ics. only 7/51 variants were not detected by either eye or bioinformatics but 
these were cell line dilutions at 3.13% and 1.56%. All variant types were 
detected including substitutions, deletions, and insertions. This experiment 
demonstrates the validity of employing ultra-deep next generation sequenc-
ing in the clinical setting to proﬁle the mutational events underlying NSCLC 
tumours from diagnostic samples with >5% allele frequency. Implementation 
into the clinical laboratory is now being performed with an improved bioin-
formatic pipeline tool for variant detection.
043-P12 
IMPLEMENTING STANDARDISED PET PROCEDURES 
FOR SCANNING, DATA COLLECTION AND REPORTING 
IN PATIENTS WITH NSCLC ACROSS AUSTRALIA’S ALTG 
SITES: A FEASIBILITY STUDY
Francis RJ1,2, Long A3 and Davidson A3 1School of Medicine and Pharmacology, 
University of Western Australia, Western Australia/AUSTRALIA; 2Department 
of Nuclear Medicine, Sir Charles Gairdner Hospital, Western Australia/
AUSTRALIA; 3Department of Medical Oncology, Royal Perth Hospital, 
Western Australia/AUSTRALIA
Aim: FDG PET for response assessment to chemotherapy in NSCLC shows 
promise, but clinical trials have been limited by study size and variability in 
response evaluation. This study aims to gain information on current practice 
for FDG PET scanning in order to assess the feasibility of establishing a stan-
dardised protocol for multicentre clinical trial imaging in Australia.
Methods: 7 PET sites in 5 states (NSW, Victoria, SA, WA and Qld) were 
identiﬁed by ALTG members as potential clinical trial imaging sites and were 
sent a comprehensive questionnaire to complete.
Results: All 7 sites completed the questionnaire. There were 9 PET-CT cam-
eras at 7 sites, from 3 major manufacturers. The PET sites surveyed included 
public hospital (n=5), academic/ teaching hospital (n=1) and private prac-
tice (n=1). Patient preparation protocols were similar across sites, other than 
for pre-hydration and instructions for diabetic patients. 5 of 7 sites ensured 
consistency in imaging procedures for response scans in individual patients. 
All sites used proprietary software for image reconstruction. 3 sites routinely 
measure SUV, and all sites reported that they could measure SUVmax for 
clinical trials. All sites indicated they were willing to join a clinical trial co-
operative group. Stated obstacles to multicentre trials included variations 
in imaging protocols, monitoring for protocol violations, standardisation of 
SUV measurements, adequate stafﬁng and funding. Conclusion: Data col-
lected from this study supports the feasibility of performing multicentre FDG 
PET trials for response assessment in NSCLC across nominated Australian 
PET sites. This study was supported by an ALTG Concept Development Grant
008-O12 
ADVANCED CARE PLANNING IN LUNG CANCER 
PATIENTS
Fraser A¹, Manson L² ¹,² ADHB, Auckland, NZ
BACKGROUND: Advance care planning (ACP) is a process of discussion 
and shared planning for end of life care. It involves patient, family/whanau 
and health care professionals.
Auckland District Health has led ACP, resourcing training, dispelling the 
taboo around thinking and talking about end of life, encouraging research and 
attempting to ﬁnd clarity in the current legal framework.
In 2010, Temel et al published a paper that demonstrated survival was pro-
longed by almost two months for patients with metastatic NSCLC with early 
integration of palliative care alongside standard care. Furthermore patients 
were less depressed, requested less aggressive treatment and lived longer with 
early integration of palliative care (including ACP) alongside standard care.
Aim: To identify if the clinicians in the lung tumour stream introduced any 
form of ACP including hospice referral for patients newly diagnosed with 
lung cancer.
Method: Retrospective audit of all patients identiﬁed from ADHB records 
who had attended an FSA for medical oncology over six months.
Results: N= 127.
Adjuvant/combined = 10; Metastatic= 117.
offered referral to hospice= 56%
Refused hospice referral= 15%
Hospice refused referral= 0.8 %
RIP within 12 weeks of referral= 13 %
Mean days referral to RIP= 37
Mean days FSA to RIP = 55
offered referral and commencing treatment= 63%
Conclusions: Clinicians were referring patients to hospice early in the patient 
process regardless of intent to treat.
Expansion of the clinicians understanding of ACP needs to extend past hos-
pice referral. Furthermore, conversations around ACP need to be documented 
and captured more clearly.
014-O12 
ERLOTINIB: THE AUCKLAND EXPERIENCE
Fraser A¹, Sullivan R² ¹ ² ADHB, Auckland, NZ
Background: Currently there is no requirement for EGFR mutation testing in 
NZ, despite erlotinib funding. 
Aim: To review the Auckland experience of using erlotinib for advanced 
NSCLC patients. To evaluate total drug acquisition costs when used as per 
PHARMAC guidelines. 
Method: A retrospective audit of patients identiﬁed from ADHB records 
that have commenced erlotinib since october 2010 until Dec 31st 2011. 
Demographic information was collected. Patients were followed up until Jan 
31st 2012. We used application for funding renewal as a surrogate marker of 
tumour response. 
Results: Total of 42 patients.
Non responders=33% (14), Responders = 48% (20), others (treatment failure) = 
19% (8).
Mean days start of treatment to ﬁrst CT= 61(20-91).
Mean TTP=126 days; Mean drug acquisition cost=$17,775
Total days of treatment =5126; Total drug acquisition cost =$701,900.00
Response 365+ days=2 patients
28% of patients reported grade 3/4 AEs. SAE’s reported totalled 12% with 
one reported death related to treatment toxicity.
Conclusions: Since the introduction of Pharmac funding for erlotinib, 
patients with advanced NSCLC have had greater access to targeted therapy, 
previously ﬁnancially unattainable. Side effect proﬁle was acceptable.
EGFR testing is a validated predictive tool for response to EGFR TKIs. We 
recommend testing should be incorporated into the funding model to deliver 
more cost-effective, directed health care.
001-P12 
A RANDOMIZED PHASE 3 TRIAL COMPARING 
PEMETREXED/CARBOPLATIN (PC) AND DOCETAXEL/
CARBOPLATIN (DC) AS FIRST-LINE TREATMENT FOR 
ADVANCED, NON-SQUAMOUSNON-SMALL CELL LUNG 
CANCER (NSCLC)
Ganju V1, Pereira JR2, Kim JH3, Lee DH4, Wang J5, Barraclough H6, Holt S6, 
van Kooten M7, Orlando M8 1Peninsula Oncology Centre, Frankston, Victoria/
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AUSTRALIA; 2Oncopneumology Department, Institutodo Cancer Arnaldo 
Vieira de Carvalho, Sao Paulo/BRAZIL; 3Yonsei Cancer Center, Yonsei 
University College of Medicine, Seoul/SOUTH KOREA; 4Asan Medical 
Center, University of Ulsan College of Medicine, Seoul/SOUTH KOREA; 
5Department of Thoracic Medical Oncology, Beijing Cancer Hospital and 
Institute, Beijing/CHINA; 6Eli Lilly Australia Pty Limited, Sydney, New South 
Wales/AUSTRALIA; 7Janssen Oncology Asia-Pacific, Sydney, New South 
Wales/AUSTRALIA; 8Eli Lilly Interamérica Inc., Buenos Aires/ARGENTINA
Aims: The primary objective of this multicenter, randomized, phase 3 trial 
was to compare survival without grade 3 or 4 toxicity (SWT) following ﬁrst-
line treatment with PC versus DC in patients with advanced, non-squamous 
NSCLC.
Methods: Chemotherapy-naïve patients with stage IIIB/IV non-squamous 
NSCLC, aged ≥18 years, with an Eastern Cooperative oncology Group per-
formance status 0 to 2 were randomized to receive carboplatin (AUC 5) with 
pemetrexed (500 mg/m2) and standard vitamin supplementation or docetaxel 
(75 mg/m2) every 21 days for a maximum of 6 cycles. Patients in both arms 
received dexamethasone supplementation. SWT was deﬁned as the time from 
the date of randomization to the ﬁrst date of any Grade 3 or 4 treatment-
emergent adverse event (TEAE) or death due to any cause.
Results: Between october 2007 and April 2009,226 patients were enrolled 
in 6 countries, of whom 211 (93.4%) were evaluable. The median age was 
59.5 years, 41.7% were East Asian, 46.0% were females, and 35.5% were 
never-smokers. SWT was signiﬁcantly longer with PC than DC (median 3.2 
months vs. 0.7 months, log-rank p<0.001; unadjusted hazard ratio [HR] = 
0.45, 95% conﬁdence interval [CI]: 0.35 to 0.58]). There were no signiﬁcant 
between-arm differences in progression-free survival, response rate, duration 
of response, or overall survival. More patients in the DC arm than the PC arm 
had ≥1 Grade 3 or 4 adverse event(81.9% vs. 63.2%).
Conclusions: The favourable beneﬁt-to-risk proﬁle of PC indicates that PCis 
an appropriate ﬁrst-line treatment option for patients with advanced, non-
squamous NSCLC.
Conflicts of Interest: The study (H3E-CR-S380) was sponsored by Eli Lilly 
and Company, Indianapolis, Indiana, USA. H. Barraclough, S. Holt, and M. 
orlando are full-time employees of Eli Lilly and Company, the manufacturer 
of pemetrexed. M.vanKooten was an employee of Eli Lilly Australia Pty 
Limited during the conduct of the study and is now an employee of Janssen 
oncology Asia-Paciﬁc. M. orlando and H. Barraclough are shareholders of 
Eli Lilly and Company. V. Ganju, J. Pereira, J.H. Kim, D.H. Lee and J. Wang 
were clinical investigators in the study. J.H. Kim has been compensated for 
a consultant/advisory role for AstraZeneca; and has received honoraria from 
Roche, AstraZeneca, GlaxoSmithKline, and Eli Lilly.
025-P12 
OVERALL SURVIVAL (OS) IMPROVEMENT IN PATIENTS 
WITH LUNG CANCER TREATED WITH DENOSUMAB 
VERSUS ZOLEDRONIC ACID (ZA)
Presenter: A. Glennane18 Lipton L1, Scagliotti G2, Hirsh V3, Siena S4, Henry 
D5, Woll P6, Manegold C7, Solal-Celigny P8, Rodriguez G9, Krzakowski M10, 
Mehta ND11, García-Sáenz JA12, Pereira J13, Prabhash K14, Tudor-Eliade 
C15, Kanarev V16, Feng A17, Jacobs I17 1Western Hospital Footscray, Victoria/
AUSTRALIA; 2University of Turino, Orbassano, ITALY; 3McGill University 
Health Centre, Montreal/CANADA; 4Ospedale Niguarda Ca’ Granda, Milano/
ITALY; 5Joan Karnell Cancer Center, Philadelphia/UNITED STATES OF 
AMERICA; 6Weston Park Hospital, University of Sheffield, Sheffield/UNITED 
KINGDOM; 7Klinikum Mannheim, Mannheim /GERMANY; 8Clinique Victor 
Hugo, Le Mans/FRANCE; 9South Texas Oncology and Hematology, San 
Antonio/UNITED STATES OF AMERICA; 10The Maria Sklodowska-Curie 
Institute of Oncology Warsaw POLAND, 11. Oncology Hematology Associates 
of Northern Illinois Gurnee UNITED STATES OF AMERICA, 12. Hospital 
Clínico, San Carlos, Madrid/SPAIN; 13Instituto do Cancer Arnaldo Vieira de 
Carvalho, Sao Paolo/BRAZIL 14Tata Memorial Hospital, Mumbai/INDIA; 
15Institutul Oncologic I. Chiricuta Cluj-Naooca/ROMANIA; 16Regional 
Oncology Dispensary with Inpatient Sector, Plovdiv/BULGARIA; 17Amgen 
Inc., Thousand Oaks/UNITED STATES OF AMERICA; 18Amgen Australia Pty 
Ltd, Sydney, New South Wales/AUSTRALIA
*Presented on behalf of trial investigators.
Aims: Denosumab is a fully-human monoclonal antibody that targets a key 
regulator of bone destruction, RANK ligand. We report a post-hoc analysis of 
survival data among patients with lung cancer participating in a phase 3 trial 
of denosumab versus ZA for preventing SREs in patients with bone metasta-
sis from solid tumours (except breast or prostate) or multiple myeloma.
Methods: Patients were randomised 1:1 to receive subcutaneous denosumab 
120mg or intravenous ZA 4mg q4w (N=1776) in a double-blind fashion. 
Daily calcium and vitamin D supplementation were recommended. oS 
among patients with lung cancer (NSCLC or SCLC) was analysed.
Results: Among 811 patients with lung cancer, oS was prolonged by 1.2 
months with denosumab over ZA (median 8.9 months denosumab, 7.7 
months ZA; HR 0.80, 95% CI [0.67–0.95]; P=0.01). Improved survival was 
seen among patients with NSCLC (n=702) receiving denosumab (median 9.5 
months denosumab, 8.1 months ZA; HR 0.78 [0.65–0.94]; P=0.01). Further 
analysis by histological type showed denosumab was associated with pro-
longed survival over ZA in squamous cell carcinoma (8.6 months denosumab, 
6.4 months ZA; HR 0.68 [0.47–0.97]; P=0.035) and adenocarcinoma sub-
types (0.80 [0.62–1.02]; P=0.075). Survival in patients with SCLC (n=109) 
was 7.6 months with denosumab versus 5.1 months with ZA (0.81 [0.52–
1.26]; P=0.36). Incidence of adverse events was balanced between groups 
(96.8% denosumab, 95.4% ZA).
Conclusion: In this post-hoc analysis of patients with lung cancer, deno-
sumab was associated with improved oS compared with ZA.
Funding: provided by Amgen
096-P12 
SCREENING LUNG TUMOUR TISSUE FOR WHOLE 
GENOME SEQUENCING
Goh F1,2, Daniels M1,2, Shaw JG2, Courtney D2, Passmore L2, McCaul 
L2, Duhig E3, Clarke B3, Parsonson K2, Brady J2, Butler D3, Martins M3, 
Davidson M2, Wright CM1,2, Martin J2, Morrison L2, Relan V1,2, Savarimuthu 
FSM1,2, Windsor MN4, Matar KS4, Naidoo R4, Tam R4, Colosimo M4, Yang 
IA1,2, Bowman RV1,2 and Fong KM1,2 1 UQ Thoracic Research Centre, School of 
Medicine, The University of Queensland, Brisbane, Queensland/AUSTRALIA; 
2Thoracic Research Laboratory, Department of Thoracic Medicine, The 
Prince Charles Hospital, Brisbane, Queensland/AUSTRALIA; 3 Pathology 
Queensland, Department of Anatomical Pathology, The Prince Charles 
Hospital, Brisbane, Queensland/AUSTRALIA; 4 Department of Thoracic 
Surgery, The Prince Charles Hospital, Brisbane, Queensland/AUSTRALIA
Introduction: High quality tumours are required to identify cancer-driven 
mutations as potential therapeutic targets. We are collaborating with The 
Cancer Genome Atlas (TCGA) to contribute primary lung adenocarcinoma 
(AC) and squamous cell carcinoma (SCC) samples towards an international 
study to characterise cancer genomics through analysis of 500 cases per 
tumour type.
Aim: We aimed to identify high quality snap-frozen primary lung cancers for 
whole genome sequencing (WGS) from our tissue bank.
Methods: 470 AC and 310 SCC samples were available for study. After 
excluding secondary tumours and patients with prior neoadjuvant therapy, 
sections were taken to assess tumour and necrotic content by pathological 
scoring. According to TCGA criteria, suitable samples were: 1) ~150mg with 
flanking and diagnostic slides; 2) ≥20% tumour content and ≤80% necrosis; 
3) accompanied by clinico-pathological data; and 4) accompanied by either 
control blood lymphocyte DNA or uninvolved normal lung tissue.
Results: To date, we have submitted 62/(470-32) (~ 14%) primary AC and 
56/(310-4) (18%) primary SCC cases. of these, our TCGA acceptance rate 
is 28/39 (72%) AC and 33/56 (59%) SCC. Cases were disqualiﬁed due to 
low RNA integrity (14; 45%), normal-tumour genotyping mismatch (2; 6%), 
insufﬁcient DNA (3; 10%), insufﬁcient RNA (1; 3%), insufﬁcient tumour 
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nuclei (5; 16%), excessive necrosis (1; 3%), or insufﬁcient background data 
(5; 16%).
Conclusions: only a small proportion (61/95; 64%) of banked tumours quali-
ﬁed according to TCGA criteria. Future work will focus on identifying fac-
tors during tissue collection and processing that increases the number of high 
quality tumours for WGS.
Disclosure:The authors wish to state that there is no conflict of interest for 
the work presented here. This work was supported by: The Prince Charles 
Hospital Foundation Novice Researcher grant (FG), Cancer Council 
Queensland PhD scholarship (M Daniels), Cancer Council Queensland 
Senior Research Fellowship (KF), NHMRC Practitioner Fellowship (KF) and 
Queensland Clinical Research Fellowship (KF, IY).
007-P12 
CAN WE BUILD THE MODEL TO PREDICT LUNG 
CANCER GENES?
Gorlov IP1, Amos C2, Gorlova OY3, Logothetis C1 Departments of 
1Genitourinary Medical Oncology, 2Cancer Genetics and 3Epidemiology, 
The University of Texas MD Anderson Cancer Center, Houston, TX/UNITED 
STATES OF AMERICA
There was a substantial progress in identiﬁcation of cancer related genes. It 
is also apparent that not all cancer related genes have been identiﬁed yet. 
Can we use the known cancer genes to develop and train a statistical model 
to predict novel cancer genes? We believe that the answer to this question is: 
“Yes, we can”.
We focused on lung cancer (LC). First we have identiﬁed known LC genes 
using literature mining. A forward stepwise binary logistic regression model 
was used to discriminate known LC genes from non-LC genes, based on such 
predictors as the level of evolutionary conservation of the gene, expression 
level in normal tissue, gene ontology annotation, posttranslational modiﬁca-
tions, expression level in adjacent normal and tumor tissue, tissue speciﬁcity 
index and other characteristics (31 variables in total). We were able to cor-
rectly predict 96% of the non-LC genes and 48% of LC genes. The propor-
tion of genes predicted to be PCa associated was signiﬁcantly higher among 
putative lung cancer genes compared to the genes without any evidence being 
LC related. To validate the model we randomly chose 100 genes as “mock” 
LC-related and built the predictive models using the same variables as we 
have used for “real” LC genes. We found that we could correctly predict only 
0.5% of the mock LC genes on average. We found that the model also pre-
dicted known breast and prostate cancer genes though the accuracy was not 
as good as for LC genes.
031-P12 
INITIAL MEDICAL ATTENTION AT PATIENTS WITH 
EARLY-STAGE NON-SMALL CELL LUNG CANCER
Gorlova oY1, Chen X1, Gorlov IP2, Ying J1, Merriman KW1, Kimmel M3, Lu 
C4, Reyes-Gibby CC1 1Departments of Epidemiology, 2Genitourinary Medical 
Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, 
Texas/UNITED STATES OF AMERICA; 3Department of Statistics, Rice 
University, Houston, Texas/ UNITED STATES OF AMERICA;; 4Department 
of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. 
Anderson Cancer Center, Houston, Texas/UNITED STATES OF AMERICA
Background: Detection of early stage non-small cell lung cancer (NSCLC) 
is commonly believed to be incidental. Understanding the reasons that caused 
initial detection of these patients is important for early diagnosis.
Methods: We retrospectively reviewed medical records of patients diag-
nosed with stage I or II NSCLC between 2000 and 2009 at UT MD Anderson 
Cancer Center. Suggestive lung cancer (LC) symptoms or other reasons that 
caused detection were extracted from patients’ medical records. We applied 
univariate and multivariate analyses to evaluate the association of suggestive 
LC symptoms with tumor size and patient survival.
Results: of the 1396 early stage LC patients, 733 (52.5%) presented with 
suggestive LC symptoms as chief complaint. 347 (24.9%) and 287 (20.6%) 
were diagnosed because of regular check-ups and evaluations for other dis-
eases, respectively. The proportion of suggestive LC-symptom-caused detec-
tion had a linear relationship with the tumor size (correlation 0.96; with p < 
.0001). After age, gender, race, smoking status, therapy, and stage adjustment, 
the patients with symptom-caused detection showed no signiﬁcant difference 
in overall and LC-speciﬁc survival when compared with the patients diag-
nosed otherwise (not through LC-suggestive symptoms).
Conclusion: Symptoms suggestive of LC are the number one reason for 
detection of early NSCLC. They were also associated with tumor size at diag-
nosis, suggesting early stage LC patients are developing symptoms. Presence 
of symptoms in early stages did not compromise survival. A symptom-based 
alerting system or guidelines may be worth of further study to beneﬁt indi-
viduals at high risk for NSCLC.
032-P12 
GENOME-WIDE ASSOCIATION STUDY OF LUNG 
CANCER IN NEVER SMOKERS
Gorlova o1, Broderick P2, Field J3, Schwartz A4, Houlston R2, Ying J1, Yu X5, 
Zhao Y5, Wenzlaff A4, Zhang R6, Oloide R3, Petterson T7, Wang L7, Ruterbush 
J4, Wang Y2, Zhang D1, Liu G8, Wu X1, Amos C1, Christiani D5, Hung R6, Yang 
P7, Spitz M9 1M.D. Anderson Cancer Center, Houston, TX, USA; 2 Institute 
of Cancer Research, Sutton, UK; 3 Roy Castle Lung Cancer Research 
Programme, University of Liverpool, UK; 4Wayne State University School of 
Medicine, Karmanos Cancer Institute, Detroit, MI, USA; 5Harvard School 
of Public Health, Boston, MA, USA; 6Samuel Lunenfeld Research Institute, 
Toronto, Canada; 7Mayo Clinic, Rochester, MN, USA; 8 University of Toronto, 
Toronto, Canada; 9Baylor College of Medicine, Houston, TX, USA
Background: Although tobacco smoke is the predominant risk factor for 
lung cancer, about 10–15% of all lung cancer deaths in the US occur among 
lifetime never smokers. To analyze the genetic component of lung cancer risk 
in never smokers, we performed a genome-wide association study comparing 
1,396 Caucasian cases from North America and the UK to 1,667 controls 
utilizing the Ilumina omniExpress genotyping chip.
Methods: Cases (initial n=1,544) and controls (initial n=1700) were obtained 
from six institutions from the US, UK, and Canada. After applying quality 
control measures to the genotyping data (tests for HWE, failed missingness 
and frequency tests), 656,891 SNPs were evaluated. After eliminating dupli-
cates, gender discrepancies, those with call rates <95%, and individuals iden-
tiﬁed as non-Caucasians by the PC analyses, 1,396 cases and 1,667 controls 
remained, with the genotyping rate of 98.11%.
Results: The most signiﬁcantly associated SNPs were those located in the 
TERT/CLPTM1 region (Chr 5), which conﬁrms previous observations, 
with the lowest p-value of 1.22x10-7 associated with rs380286. Additionally, 
4 genes/gene regions previously not considered showed an association at 
a p<10-5. The replication phase currently is underway to further test these 
associations.
Conclusion: This is the largest GWAS study performed to date on lung can-
cer in Caucasian never smokers. We conﬁrm the association with the TERT/
CLPTM1 region. In addition, multiple other gene regions, not previously con-
sidered as susceptibility factors for lung cancer, have been suggested.
The study is supported by NCI R01 CA149462 to oG.
035-O12 
PHYSICAL ACTIVITY LEVELS AND FUNCTIONAL 
CAPACITY OF PEOPLE WITH NON-SMALL CELL LUNG 
CANCER: PRELIMINARY RESULTS
Granger CL1, McDonald CF2,3, Irving L4, Clark R1, Mileshkin L5, Krishnasamy 
M5, Murnane A5, Denehy L1,3 1 Department of Physiotherapy, School of Health 
Sciences, The University of Melbourne, Melbourne, Victoria/AUSTRALIA; 2 
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Department of Respiratory and Sleep Medicine, Austin Health, Melbourne, 
Victoria/AUSTRALIA; 3 Institute for Breathing and Sleep, Melbourne; 4 
Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, 
Melbourne, Victoria/AUSTRALIA; 5Peter MacCallum Cancer Centre, 
Melbourne, Victoria/AUSTRALIA
Aims: 1) To identify levels of physical activity in people with lung cancer 
and to compare these with recommended physical activity guidelines for 
Australians. 2) To identify any change in physical activity or functional capac-
ity over six months following diagnosis.
Design: Prospective longitudinal cohort study.
Participants: Thirty ﬁve people (22 male), mean±SD age 67.5±9.2years, 
FEV
1
 76.9±21.2% predicted, BMI 27.6±6.9kg/m2 with stage I-IIIb non-small 
cell lung cancer recruited to date from three tertiary hospitals.
Outcome measures: Steps per day measured with accelerometer worn 
over a ﬁve day period; self-reported physical activity measured using 
Physical Activity Scale for the Elderly and functional capacity measured 
with the 6-minute walk test (6MWT) were assessed baseline (pre-treat-
ment n=35), 10 weeks (during-treatment n=30), six months post-diagnosis 
(n=22).
Results: Preliminary analyses demonstrate at baseline 40.0%, 37.1% and 
22.9% of participants were engaged in ‘sufﬁcient’, ‘insufﬁcient’ and ‘sed-
entary’ levels of physical activity respectively. Mean steps per day at base-
line were 5283±2944steps. At baseline, fewer participants were engaged 
in ‘sufﬁcient’ levels of activity (compared with 54.1% aged-matched 
Australian data) and more participants were classiﬁed as ‘sedentary’ (com-
pared with 17.9% Australian data). At 10 week and six month follow-up 
only 26.7% and 31.8% of participants were engaged in ‘sufﬁcient’ levels 
of activity respectively. At baseline mean±SD 6MWT was 417.7±115.0m. 
This declined to 391.5±107.5m at 10 week and 388.4±194.5m at six month 
follow-up.
Conclusion: At diagnosis most participants did not meet physical activity 
guidelines and took less than the recommended number of steps per day. 
Updated follow-up data will be presented. 
Funding: Victorian Cancer Agency and Eirene Lucas Foundation. 
Disclosure: The authors declare no conflicts of interest.
010-P12 
COMPARING THE CANCER CARE COORDINATOR’S 
(CCC) MODEL OF CARE IN TASMANIA AND 
QUEENSLAND; PARTNERING UP TO PROMOTE 
OPTIMAL PATIENT OUTCOMES
Grundy R¹, Bedwell, D² ¹Royal Hobart Hospital, Hobart, Tasmania/
AUSTRALIA; ²Royal Brisbane, Brisbane, Queensland/AUSTRALIA
Intro / background: Cancer Care Coordinators (CCC) utilise an area wide 
approach to optimise cancer care for patients, provide patient centred care 
and promote multidisciplinary care. This role varies according to the area in 
which they work.
Objectives / aims: To determine if Tasmania and Queensland can learn from, 
and support each other to improve patient outcomes. This will be done by 
benchmarking, comparing and contrasting the CCC model of care from two 
hospitals based in two states.
Methodology: All new patients with lung cancer referred to each CCC in 
February 2012 will be reviewed. Statistics compared will include; geographic 
area, staging, proposed treatment, referral source, allied health access, avail-
able resources and patient needs.
Results: Statistics will be shown and analysed, we will discuss any aspects 
of our role we have changed in our model based on the others, aspects of our 
roles that are working well for both of us, aspects of our roles that need to be 
different based on work places.
Conclusions: Although geography and resources determine the ﬁne tuning of 
the CCC role to individual hospitals, essentially both models of care promote 
improved patient outcomes.
015-O12 
THE PREVALENCE OF INCIDENTAL PULMONARY 
NODULES ON COMPUTED TOMOGRAPHY OF THE 
CHEST IN TRAUMA PATIENTS
Hammerschlag G1, Cao J1, Steinfort D1, Irving L1 1 The Royal Melbourne 
Hospital, Melbourne, Victoria/AUSTRALIA
Background: Lung cancer is the most prevalent type of cancer worldwide 
and the leading cause of cancer related death. Early detection of potentially 
cancerous pulmonary lesions enables early management and improves clini-
cal outcomes.
Methods: A computerized search is performed through the Trauma Registry 
data of the hospital, which registers patient information from all trauma 
patients admitted. All CT thorax radiology reports of the identiﬁed patients 
were reviewed and the number of incidental pulmonary nodules and their 
descriptions (largest diameter, location, morphology) were recorded.
Results: 21 of the 248 patients were found to have incidental pulmonary nod-
ules, giving a prevalence of 8.5%. 12 subjects (4.8%) had a single nodule, 
while 9 subjects (3.6%) had multiple nodules. 17 of the 21 patients (77.7%) 
with incidental pulmonary nodules required follow-up according to the 
Fleischner Society recommendations. All 17 patients were high risk for pul-
monary malignancy and had one or more signiﬁcant risk. The 4 subjects that 
did not require follow-up were all young patients (less than 35 years of age) 
and had no oncological history.
Conclusions: The ﬁnding of incidental pulmonary nodules in patients under-
going CT thorax as part of their initial trauma evaluation is common. Most 
of these nodules required further follow-up and management based on the 
Fleischner Society recommendations. A system needs to be in place to ensure 
that individual care providers are assigned responsibilities in identifying and 
following-up these patients to potentially improve mortality and/or morbidity.
013-P21 
CLINICIANS’ EXPERIENCE OF QUALITATIVE LUNG 
CANCER RESEARCH AND ITS VALUE IN CLINICAL 
PRACTICE
Hardie C1, Winter H1 & Batten L2 1Regional Cancer Treatment Service, 
MidCentral Health, Palmerston North/NEW ZEALAND; 2Research Centre 
for Ma¯ori Health and Development, Massey University, Palmerston North/
NEW ZEALAND
Aim: We present our experience of a collaborative research project with a 
signiﬁcant qualitative component and its impact on our clinical practice. 
Methods: In collaboration with the Research Centre for Māori Health and 
Development we performed a qualitative study funded by the Health Research 
Council to ascertain the experiences and opinions of Māori patients and their 
whānau (family) around a diagnosis of lung cancer. It was part of a larger 
study exploring the issues regarding epidermal growth factor receptor test-
ing in New Zealand. Qualitative, semi-structured, in-depth interviews were 
undertaken with Māori lung cancer patients and their whānau by Māori inter-
viewers. Interviews were recorded and transcripts thematically analysed. The 
research ﬁndings were disseminated back to the participants. At a “living with 
cancer” meeting on the local marae we presented the information to the local 
Māori community. We present our reflections on the utility and impact of this 
qualitative research in lung cancer from a clinician’s perspective. 
Results: This qualitative research has provided important insights into the 
Māori experience of lung cancer, a community with the poorest outcomes for 
this disease. This information is not readily accessible without the qualita-
tive research method and highlights the strengths of collaboration between 
researchers and clinicians. As clinicians, we have strengthened relationships 
with the Māori community and their care workers and have a deeper under-
standing of the needs of our Māori patients and their whānau. 
Conclusions: Qualitative lung cancer research has had a direct impact on 
our day to day clinical practice to improve the cancer journey for our Māori 
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patients. Disclosure: Dr Claire Hardie – no conflicts of interest; Dr Helen 
Winter – no conflicts of interest; Dr Lesley Batten – no conflicts of interest
037-P12 
PATTERNS OF CARE IN LUNG CANCER IN NORTHERN 
SYDNEY, AUSTRALIA
Hasovits C1,2, Pavlakis N1,2, Heron N3, Clarke S1,2 1Department of Medical 
Oncology, Royal North Shore Hospital, Sydney/AUSTRALIA; 2Bill Walsh 
Cancer Research Laboratory, Kolling Institute of Medical Research, Sydney/
AUSTRALIA; 3Area Cancer Services, Royal North Shore Hospital, Sydney/
AUSTRALIA
Aims: To assess patterns of care received by lung cancer patients in the 
Northern Sydney Central Coast area health network (NSCCH)
Methods: Patients diagnosed with lung cancer in NSCCH between 2008 and 
2010 were identiﬁed from the local Clinical Cancer Registry, which receives 
coded data for public sector admissions and treatments.
Results: 1498 patients were identiﬁed: 63% non-small cell lung cancer 
(NSCLC), 12% small cell lung cancer, 7% mesothelioma, 1% carcinoid, 17% 
not speciﬁed. 57% of cases were male and 35% born overseas. The median 
age at diagnosis was 72yrs.
There were 945 NSCLC cases, by stage: 11% stage I, 6% stage II, 9% stage 
IIIA, 56% stage IIIB/IV at diagnosis, 18% not stated; subtypes: 40% adeno-
carcinoma, 24% squamous cell carcinoma, 18% not otherwise speciﬁed, 16% 
large cell, 2% mixed.
31% received any chemotherapy, 23% radiotherapy and 11% surgery. For 
stages I-IIIA disease, 31% underwent deﬁnitive surgery and 2% deﬁnitive 
chemo-radiotherapy. 9 patients underwent EGFR mutation testing. 36 (7%) 
stage IIIB/IV patients received a targeted agent as ≥ 2nd-line treatment. 20 
(2%) patients were enrolled in a clinical trial.
Median survival was 11mo overall; 21mo for stages I-IIIA and 7mo for stages 
IIIB/IV. 61% of stage III/IV cases were referred to a palliative care service. 
Median time between diagnosis and referral was 8wks and between referral 
and death, 6wks.
Conclusions: The survivorship of this cohort appears low, possibly due to 
the high proportion of advanced cases, however is comparable to published 
national cohorts. Highlighted areas for improvement include increased 
molecular testing, clinical trial participation and early palliative care referral.
Disclosure: The authors have no conflicts of interest, dualities or funding 
sources to declare.
087-P12 
DEVELOPMENT OF AN ONLINE LUNG CANCER 
PATIENT INFORMATION RESOURCE DIRECTORY
Hatton A1*, Mileshkin L1, Webb R1, Callaghan K2 1 Department of Nursing 
and Supportive Care Research, Peter MacCallum Cancer Centre, East 
Melbourne, Victoria/AUSTRALIA; 2 The Australian Lung Foundation, 
Brisbane, Queensland/AUSTRALIA
Project Aim: To develop an online Australian Lung Cancer Patient 
Information Directory that provides high quality online resources and links 
to paper-based resources on one site. The directory will provide recom-
mended resources to complete our previously produced DVD “Lung Cancer, 
Understanding, Managing, Living”. 
Methods: Resources available to lung cancer patients were identiﬁed through:
• A survey completed by attendees at the 2010 Australian Lung Cancer 
Nurses Conference.
• Lung cancer patient information resources available through Peter 
MacCallum Patient Information and Support Centre, Australian and State 
Cancer Councils and Australian Lung Foundation.
• Internet search of lung cancer information/support websites.
Lung cancer speciﬁc resources were evaluated by an oncologist, cancer nurse 
and two consumers using the ‘Ensuring Quality Information for Patients’ 
(EQIP) tool. EQIP assesses quality of patient information. Resources that met 
EQIP criteria were included.
General cancer patient resources relevant to lung cancer were included if pre-
viously developed by a recognised provider of quality cancer information.
Results: 31 Lung cancer speciﬁc and 63 general resources met the inclusion 
criteria. Resources were linked into an on-line directory at the Kylie Johnston 
Lung Cancer Network http://www.kjlcn.org.au/patient-resources-and-support/
online-resource-directory.
Additionally resources were linked as recommended reading under each 
chapter of the DVD http://www.kjlcn.org.au/patient-resources-and-support/
lung-cancer-dvd/97-01-introduction
The directory is being evaluated through an online survey as well as monitor-
ing ‘hits’ to the online site.
Key Conclusions: An online Australian Lung Cancer Patient Information 
Resource Directory has been created to provide access to high-quality infor-
mation relevant to people affected by lung cancer all on one website.
This project has been funded through a Cancer Australia grant.
030-P12 
VOLUMETRIC ARC THERAPY FOR STEREOTACTIC 
BODY RADIOTHERAPY IN EARLY LUNG CANCER
Hegi-Johnson F1,2, West K1, Small K1, White S1, Barber J1, Van Tilburg K1, 
Yeghiaian-Alvandi R1 1Nepean Cancer Care Centre, Radiation Oncology 
Network, Sydney/AUSTRALIA; 2Department of Medicine, Sydney University, 
Sydney/AUSTRALIA
Introduction: Stereotactic body radiotherapy(SBRT) for early lung can-
cer results in excellent local control and potentially improved survival. 
3D-conformal radiotherapy(3D-CRT) delivery requires long treatment times, 
increasing the risk of patient motion. Volumetric arc therapy(VMAT) may 
result in improved dosimetric outcomes, and potentially reduced treatment 
time.
Methods: The Pinnacle 3D-CRT and VMAT plans for delivery on Elekta 
Linacs of 2 patients were compared for the following dosimetric character-
istics: target coverage (coverage with the prescribed dose and 98% coverage 
of the PTV), low dose wash (dose at 2 cm from target) and organs at risk 
(volume of lung receiving 20 Gy). 
Results: Radiotherapy target coverage was improved with VMAT, com-
pared to 3D-CRT (98% vs. 89% of PTV receiving 100% of the prescribed 
dose), with 98% dose coverage also higher for VMAT (>99% as compared 
with 92% of PTV). This was achieved without any signiﬁcant increase in 
low dose wash, with D2cm being 28.1 Gy versus 35.0 Gy . V20 for VMAT 
plans was higher (7.94% versus 6.85%), and more monitor units were 
required (3300 versus 2200). Due to the small number of patients examined 
the results were not statistically signiﬁcant. Clinical VMAT treatment with 
one of these plans required 8 minutes beam-on time, with total treatment 
taking 35 minutes.
Conclusions: VMAT radiotherapy for SBRT lung is feasible, and results in 
potential improvements in dosimetry, including improved radiotherapy target 
coverage, with no increase in low dose wash in the lung. However, it may 
result in small increases in the V20. Despite increased monitor units, VMAT 
plans may be delivered rapidly due to reduced gantry and couch movements.
Disclosure: All authors have indicated that they have no conflicts of interest. 
There was no commercial sponsorship for this research. Dr Hegi-Johnson is 
supported by a Cancer Institute NSW Translational Centre Research Grant 
Fellowship.
056-P12  
ENTERAL NUTRITION IN LUNG CANCER PATIENTS 
UNDERGOING RADIOTHERAPY 
Hill A1, Muir L1 1 Peter MacCallum Cancer Centre, East Melbourne, Victoria/
AUSTRALIA 
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Background: Lung cancer patients are a patient group at particular nutri-
tional risk which is often further compounded by toxicities of radiotherapy 
(RT) and/or chemotherapy. 
Aim: To investigate the use of enteral nutrition (EN) in patients undergoing 
RT +/- chemotherapy for lung cancer and explore associated treatment and 
nutritional factors.
Methods: A retrospective audit was conducted on 48 lung cancer patients 
receiving a minimum of three weeks RT (±concurrent chemotherapy) between 
February 2011–April 2012. Data was collected on: demographics, treatment 
prescription, presence and severity of oesophagitis, nutritional status (Patient-
Generated Subjective Global Assessment, PG-SGA), weight change and EN 
usage. 
Results: of the sample audited (63% male, mean age= 62 years, 56% receiv-
ing combined ChemoRT, median RT dose= 60/30/5), 17% (n=8) of patients 
required EN as assessed by the dietitian, with 15% (n=7) commencing EN 
(n=1 patient refused). Eighty-six percent of feeding tubes were nasogastric 
tubes (NGT) inserted during treatment, with 14% (n=1) requiring a percuta-
neous endoscopic gastrostomy (inserted pre-RT due to oesophageal stricture). 
NGTs were inserted at a median time-point 1 week post RT for a median 
duration of 15 days and required to provide 100% nutrition. At time of NGT 
insertion, all patients had lost weight (mean -3.4% body weight), all were 
malnourished according to the PG-SGA and all experienced oesophagitis 
(median severity= grade 2). 
Conclusions: Results suggest a more proactive approach is required for pre-
vention and management of malnutrition in lung cancer patients. Early identi-
ﬁcation of high risk patients and timely NGT placement would help optimise 
nutritional status in this vulnerable group.
095-P12 
EVALUATION OF AN EVIDENCE-BASED NUTRITION 
CARE PATHWAY FOR LUNG CANCER PATIENTS 
UNDERGOING RADIOTHERAPY
Hill A1, Kiss N1 1 Peter MacCallum Cancer Centre, East Melbourne, Victoria/
AUSTRALIA
Background: Care pathways help to standardise management, reduce varia-
tion in practice, translate evidence-based guidelines into local protocols and 
improve patient care. As lung cancer patients undergoing radiotherapy are a 
group at particular nutritional risk, a nutrition care pathway was developed 
and implemented in 2010. 
Aim: This project aimed to evaluate compliance with each compo-
nent of the lung nutrition care pathway and make recommendations for 
improvement. 
Methods: A retrospective audit was conducted on 29 patients commencing 
radical radiotherapy from February-october 2011. Compliance with patient 
screening (high risk patients identiﬁed and referred), timing of ﬁrst contact 
(week 1 radiotherapy), Patient-Generated Subjective Global Assessment 
(PG-SGA) completion (week 1 and ﬁnal week radiotherapy), frequency of 
review (minimum fortnightly) and post treatment follow up (minimum once) 
was examined. 
Results: Compliance with components of the pathway varied: 79% of 
patients were correctly screened and booked for dietitian assessment, 
69% were seen in week 1 radiotherapy, 90% had PG-SGA completed on 
initial assessment (dropping to 21% in ﬁnal week), 76% were seen mini-
mum fortnightly during radiotherapy and 62% had nutrition follow up post 
treatment. 
Conclusions: To improve compliance, feedback was provided to the nutrition 
department and is to be presented to the multidisciplinary team to improve 
awareness. To increase completion of PG-SGA in ﬁnal week, forms are now 
being attached to outpatient notes (as in week 1). To improve follow up post 
treatment, dietitian reviews are recommended to be scheduled together with 
post radiotherapy medical review. ongoing monitoring and regular evaluation 
of the pathway is also recommended.
091-P12  
CONCAVE: A PHASE II STUDY OF CONCURRENT 
INTRAVENOUS CISPLATIN & VINORELBINE WITH 
RADIOTHERAPY PLUS CONSOLIDATION ORAL 
VINORELBINE FOR STAGE III NSCLC
Horwood K 1* , Hughes B 2 , Lehman M 1, Pratt G 2 , Dauth M1, Horn J2 
1Princess Alexandra Hospital, Brisbane, Queensland/AUSTRALIA; 2Royal 
Brisbane Hospital, Herston, Queensland/AUSTRALIA
Aims: To evaluate the response rate, toxicity and survival outcome for this 
concurrent chemo-radiation and oral chemotherapy consolidation approach 
in adequately staged, good performance status patients with stage III NSCLC. 
Methods: Twenty-seven patients with PET-staged IIIA/B NSCLC were recruited 
until June 2010. Participants received cisplatin IV 40mg/m2 and vinorelbine IV 
20mg/m2 day1,8,22,29 concurrent with thoracic RT 60Gy/ 30fr. Four weeks 
later they received oral vinorelbine 20mg/m2 day 1 & 8 q3weeks x 3 cycles. 
Results: The median age was 63yrs (42-72), M/F 16/11, ECoG PS 0/1 14/13, 
stage IIIa/b 15/12, histology SCC/ non-SCC/ NoS 5/13/9. Response rate 
23/27 (7 CR+ 16 PR) = 85%. With a median follow-up of 25 months there 
are 9 patients alive and disease free with an overall median PFS= 11 months 
and median oS= 14 months. Toxicity data will be presented in detail. Three 
patients withdrew before completing all treatment because of toxicity. There 
were 3 early deaths (1 PE, 2 pneumonia). 
Conclusion: CoNCAVE achieved a high response rate and survival results 
comparable to other chemo-radiotherapy protocols but the rates of withdrawal 
for toxicity and early mortality are concerning.
Pierre-Fabre Medicament provided funds for data management.
111-P12  
OCCUPATIONAL LUNG DISEASE: ASBESTOS DISEASES
Ivimey B1, Ahilas T2, 1Prince of Wales Hospital, Sydney, New South Wales/
AUSTRALIA; 2Maurice Blackburn, Sydney, New South Wales/AUSTRALIA
occupational lung disease, particularly asbestos induced, continues to touch 
the lives of many Australians and their families. Tragically, Australia remains 
a world leader for rates of asbestos disease, particularly mesothelioma and 
asbestos induced lung cancer.
Australians are in the midst of the “third wave” of asbestos exposure which 
involves persons exposed as a result of DIY home renovations and as bystanders. 
Victims of the third wave are predominantly women and, increasingly, children.
Unfortunately, what is also tragic about this data is that the general awareness 
about victims’ legal entitlements continues to be poor. This is largely due to 
the complex nature of those entitlements and a fundamental lack of under-
standing about them.
our aim is to provide newly diagnosed patients and their families with 
a snap shot of their legal entitlements upon diagnosis of asbestos disease. 
These patients are given the tools to make an informed and educated decision 
regarding the legal entitlements they may wish to pursue.
This tool will be at the ﬁngertips of the health professionals involved in the 
patients’ care and will be available to GPs, physicians and nurse care co-
ordinators to give to the patient and family at the time of diagnosis. As these 
health care professionals are at the forefront of patient care, they may be the 
only ones from whom patients seek advice regarding diagnosis. our hope is to 
have this template duplicated into many languages so that all people will have 
access to the same information regarding their legal entitlements.
021-O12  
WHO PROVIDES EMOTIONAL SUPPORT WHEN AN 
ASBESTOS-RELATED DISEASE IS DIAGNOSED? AN 
EXPLORATORY STUDY INVESTIGATING PATIENTS AND 
THEIR CAREGIVERS SOURCES OF EMOTIONAL SUPPORT
Jacomos P J, BA (SocWk), MA 1, Burns C M, BA, BSocAdmin, MPhil,PhD 
2, 3, 1Clinical social worker, Asbestos Diseases Society of South Australia 
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(ADSSA), South Australia/AUSTRALIA; 2 School of Medicine, Department 
of Palliative and Supportive Services Flinders University, Adelaide, South 
Australia/AUSTRALIA; 3Social Work Program, School of Humanities and 
Social Sciences, University of Newcastle, New South Wales/AUSTRALIA
A recent meta-analysis conﬁrmed having high levels of perceived social sup-
port, larger social network, and being married was associated with decreases 
in relative risk for mortality of 25%, 20%, and 12%, respectively. An Adelaide 
practice-based study explored the social experience of people diagnosed with 
asbestos related diseases (ARD) including mesothelioma and their family 
caregivers. This presentation reports on the comparison of emotional support 
between ARD Victims and their Bereaved relatives
The cross-sectional study, using data from 97 respondents between June 
2005 and December 2008, included 42 bereaved from the non-government 
organisation, Asbestos Diseases Society of South Australia (ADSSA). The 
Victims and the Bereaved completed the Index Source of Emotional Support 
(Canberra Cancer Quality of Life Study).
Descriptive analysis showed that 90% could share their feelings with some-
one, with almost no difference between the 2 sub-populations. However, one 
third of Victims could not share their feelings with their spouse. Although all 
those with the life-threatening condition mesothelioma (100%) were signiﬁ-
cantly (p=0.006) more able to share their feelings with their family. The GP 
was important (39%) for both populations and 20% of both populations could 
share with the social worker.
The results of this exploratory and descriptive study add to the literature by 
enunciating who these populations source their emotional support from. In 
particular, they alert health professionals to the reality that many spouses are 
unable to share their feelings in times of serious illness. These results will 
be discussed in terms of their implications for clinical practice within the 
healthcare team.
003-P12 
INCIDENCE OF CODON 72 POLYMORPHISM TUMOR 
SUPPRESSER GENE P53 IN NON SMALL CELL LUNG 
CANCER PATIENTS
Jamsheed Javid1, AB Rashid Mir1, Imtiyaz Ahamad1, Shazia Rashid1 , Prasant1, 
Maryam1 , P.C Ray1 , P.K Julka2 , Anand Mohan3 , M. Maqbool lone4 , Alpana 
Saxena1 . 1Department of Biochemistry , Maulana Azad Medical College , 
New Delhi , 2 Department of radiotherapy and Oncology , All India Institute 
of Medical Sciences, New Delhi, 3Department of Medical Oncology , All India 
Institute of Medical Sciences, New Delhi, 4Department of Radiation Oncology 
SKIMS , Srinagar .
Background: The tumor suppressor TP53 pathway plays a crucial role in 
preventing carcinogenesis through its ability to impose cell cycle arrest and 
apoptosis following DNA damage and oncogene activation. Single nucleotide 
polymorphism at codon 72 leads to substitution of arginine for prolin, has been 
suggested to affect cancer predisposition. However, ﬁndings have been incon-
sistent in various cancers, and ethnicity appears to be a critical factor influenc-
ing the effects of the SNP on cancer risk. An increasing trend has been observed 
in the prevalence of lung cancers, though the underlying genetic basis is unclear.
Methods: A total of 200 samples were studied among which 100 were from 
NSCLC patients and 100 were collected from healthy controls from three 
hospitals. The p53 codon 72 genotyping was studied by high sensitive ASo-
PCR assay. Associations between genotypes and survival were assessed using 
Kaplan-Meier method. Cox proportional hazard models were performed to 
identify signiﬁcant variables.
Results: The genotype distribution of p53 codon 72 polymorphism was 
signiﬁcantly different between bladder cancer patients and controls (p = 
0.039). In logistic regression, diagnostic age and genotype Pro/Pro were the 
risk factors for developing an invasive tumor (oR51.47, 95% CI51.17–1.85, 
P50.003) compared to the Arg/Arg genotype.A 4.526-fold risk was estimated 
for the patients with Pro/Pro genotype as opposed to non-Pro/Pro genotype to 
develop invasive tumors. However, the extent of p53 codon 72 polymorphism 
did not predict NSCLC adder cancer prognosis. Taken together, p53 codon 
72polymorphism may be associated with NSCLC cancer incidence and pro-
gression, but not prognosis. Further study is needed to evaluate the usefulness 
of the constructed model in risk assessment.
Conclusions: These ﬁndings suggest that genetic polymorphisms in the 
P53 pathway may be promising biomarkers for risk of developing NSCLC 
patients. ASo-PCR proved to be a very economical, sensitive and rapid tech-
nique for detection of Arg/Pro codon 72 p53 gene polymorphism.
057-O12 
ENHANCING PSYCHOLOGICAL SERVICES FOR 
PEOPLE WITH LUNG CANCER
Jones T1, Ftanou M1, Pollard A1, Duffy M1, Ball D1 1 Peter MacCallum Cancer 
Centre, Melbourne, Victoria/AUSTRALIA
Background: Lung cancer patients have a higher level of disease burden, 
higher unmet psychosocial needs and lower uptake of psychological services 
compared with other cancer groups. The Department of Clinical Psychology, 
in collaboration with the lung cancer service at PeterMac, revised the model of 
psychological care to optimise access and improve psychosocial well-being.
Method: This revised model of care involved realigning the Psychology 
outpatient Clinic to run in parallel with the Lung outpatient Clinic. The aims 
were to: 1) provide a timely and early intervention service; 2) increase patient 
access to psychology services; 3) reduce the burden of accessing psychology 
services; and 4) assess psychological needs of patients and provide appro-
priate psychological interventions. Patient demographics, uptake, referral 
information and session data were collected for a three month period and 
compared to data from the same period in the previous year.
Results: our sample included a total of 37 patients with lung cancer. The 
results indicated that the revised model of service delivery led to: a 21% 
increase in new lung patient referrals for psychology services; an almost 
100% uptake of services; and a 186% increase in the number of scheduled 
sessions attended by lung patients. The main reasons that patients attended 
sessions were to address mood fluctuations, loss and grief issues, relationship 
and existential concerns.
Conclusion: The revised model made a signiﬁcant impact on meeting the 
previously unmet needs of this patient group through providing timely assess-
ments and interventions. This highlights the potential effectiveness of inte-
grating psychology services within medical cancer streams.
Disclosure: We received no funding and there was no duality or conflict of 
interest.
097-P12 
CIGARETTE SMOKE CONDENSATE INDUCES THE 
EXPRESSION OF SPLA2 ISOFORMS IN HUMAN 
MACROPHAGE LIKE THP-1 CELLS
Kaur B1*, Subodh K Yadav1, Sanjeev K Sharma1, Shalmoli Bhattacharya1, K. 
L. Khanduja1 and C. M. Pathak1 1Department of Biophysics, Post Graduate 
Institute of Medical Education and Research, Sector-12, Chandigarh, 
India-160012
Aim: To evaluate the expression of secretory PLA
2
 isoforms in cigarette 
smoke condensate-induced molecular changes in human macrophage like 
THP-1 cells. 
Methods: THP-1 cells were differentiated with 10 nm PMA in RPMI-1640 
media. Cigarette smoke condensate –induced molecular changes at differ-
ent concentrations were assessed in differentiated THP-1 cells after 24 hour 
treatment by measuring cell viability, reactive oxygen species generation, cell 
membrane integrity and the extent of apoptosis by MTT assay, DHE stain-
ing, FDA-EtBr staining and Annexin-PI staining respectively. Expressions of 
secretory PLA
2
 groups using RT-PCR were also screened. 
Results: The cell viability and cell membrane integrity deteriorated with increas-
ing cigarette smoke condensate concentrations from 1µg/ml to 100µg/ml, which 
may be due to increased RoS production leading to apoptosis. Differentiated 
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THP-1 cells revealed a signiﬁcant mRNA expression of sPLA
2
 groups: IB and 
IID at 75µg/ml, III at 10µg/ml of cigarette smoke condensate concentrations. 
Conclusion: CSC contributes towards oxidative stress in differentiated 
THP-1 cells thereby inducing sPLA
2
s expression which may be responsible 
for the regulation of inflammatory cascade leading to pathological conditions.
049-O12  
CIRCULATING MIR-625-3P: A POTENTIAL BIOMARKER 
FOR MALIGNANT PLEURAL MESOTHELIOMA
Kirschner MB1*, Cheng YY1, Badrian B2, Kao SC1,3, Creaney J4,5, Edelman 
JJB6, Harvie R7, Armstrong NJ8, Vallely MP6, Musk AW4,5,9, Robinson BWS4,5, 
McCaughan BC6, Pavlakis N7, Klebe S10, Mutsaers SE2, van Zandwijk N1, Reid 
G1 1 Asbestos Diseases Research Institute, University of Sydney, New South 
Wales/AUSTRALIA; 2 Lung Institute of Western Australia, Centre for Asthma, 
Allergy, and Respiratory Research and Pathwest Laboratories of Medicine, 
University of Western Australia, Western Australia/AUSTRALIA; 3 Department 
of Medical Oncology, Concord Hospital, Sydney, New South Wales/
AUSTRALIA; 4 National Research Centre for Asbestos Related Diseases, 
School of Medicine and Pharmacology, University of Western Australia, 
Western Australia/AUSTRALIA; 5 Sir Charles Gairdner Hospital, Department 
of Respiratory Medicine, , Western Australia/AUSTRALIA; 6 Cardiothoracic 
Surgical Unit, Royal Prince Alfred Hospital; The Baird Institute and Faculty 
of Medicine, University of Sydney, New South Wales/AUSTRALIA; 7 Bill Walsh 
Cancer Research Laboratories, Kolling Institute of Medical Research and 
Department of Medical Oncology, Royal North Shore Hospital, University of 
Sydney, New South Wales/ AUSTRALIA; 8 Cancer Research Program, Garvan 
Institute for Medical Research and School of Mathematics and Statistics, 
University of New South Wales, New South Wales/AUSTRALIA; 9 Department 
of Population Health, University of Western Australia, , Western Australia/
AUSTRALIA; 10Department of Anatomical Pathology, Flinders Medical 
Centre, South Australia/AUSTRALIA
The deﬁnitive diagnosis of malignant pleural mesothelioma (MPM) will often 
depend on the availability of a biopsy of sufﬁcient size. The identiﬁcation of a 
biomarker that can be easily measured in blood would represent an important 
step forward. In this study we investigated the ability of microRNAs (miR-
NAs) in plasma/serum to serve as a diagnostic marker for MPM.
Microarray-based miRNA proﬁling of plasma samples from 5 MPM patients 
and 3 healthy controls identiﬁed 17 miRNAs with signiﬁcantly differen-
tial abundance in patients and controls. Validation by quantitative real-time 
PCR in a series of plasma samples from 15 MPM patients and 13 controls 
revealed that levels of one of these miRNAs, miR-625-3p, were signiﬁcantly 
elevated in plasma of MPM patients (4-fold, p=0.004), and able to discrimi-
nate between MPM patients and controls (accuracy 82.4 %). Assessing lev-
els of miR-625-3p in serum of an independent series of MPM (N=30) and 
asbestosis (N=10) patients revealed that miR-625-3p was signiﬁcantly (3.8-
fold, p=0.023) elevated in serum of the MPM patients and able to discrimi-
nate between cases and controls (accuracy 79.3 %). Finally, miR-625-3p was 
found to be present at signiﬁcantly higher levels (2-fold, p=0.006) in surgi-
cal (MPM) tumour specimens than in normal mesothelium. Preliminary data 
from a third series of serum samples from 32 MPM patients and matched 
healthy controls so far conﬁrm our observation that miR-625-3p is elevated at 
least 3-fold in blood from MPM patients.
Taken together these data provide evidence that miR-625-3p has the potential 
to serve as a novel blood-based biomarker for MPM.
038-O12 
MODULATION OF AQUAPORIN 1 AS A NOVEL 
TREATMENT STRATEGY FOR MALIGNANT 
MESOTHELIOMA
Klebe S1,2, Griggs K1, Henderson DW1,2 Yool AJ3, 1Dept of Anatomical 
Pathology, Flinders University, Bedford Park, South Australia/AUSTRALIA; 
2SA Pathology, Flinders Medical Centre, Bedford Park, South Australia/
AUSTRALIA; 3Department of Physiology, Adelaide University, Adelaide, 
South Australia/AUSTRALIA;
Background: Malignant mesothelioma (MM) is an aggressive tumour of 
serosal membranes with a poor prognosis. We have identiﬁed aquaporin 1 
(AQP1) as a signiﬁcant prognostic marker and have shown a positive correla-
tion between AQP1 protein expression measured by immunohistochemistry 
and patient-derived MM cell proliferation rate. 
Aims: To investigate whether alteration of AQP1 function by a pharmaco-
logical blocker inhibits cell proliferation, motility and metastasis-forming 
potential in vitro. 
Methods: Primary MM cells were harvested from malignant pleural effu-
sions. AQP1 expression and mesothelial phenotype were determined by 
immunohistochemistry. Cell proliferation was measured with and without 
altered AQP1 channel function using an MTS assay. Individual cell motility 
was measured using time-lapse photography. Metastatic growth potential was 
assessed by an anchorage-independent assay. 
Results: AQP1 modulation by a pharmacological blocker decreases meso-
thelial cell proliferation, motility and anchorage-independent growth without 
inducing nonspeciﬁc cytotoxicity or increasing apoptosis. 
Conclusions: AQP1 is a prognostic marker for MM. Targeted pharmacologi-
cal modulation of AQP1 function can signiﬁcantly alter MM cell behavior in 
vitro. This observation has treatment potential. AQP1 inhibition by siRNA 
will further clarify the molecular mechanisms leading to speciﬁc AQP1 
modulation. 
Funding: This work was supported by CoMCARE and the FMC Foundation. 
Disclosure: There are no conflicts of interest.
041-P12  
COMPARATIVE STUDY OF TWO 
HYPOFRACTIONATED PALLIATIVE RADIOTHERAPY 
REGIMEN IN LOCALLY ADVANCED NON SMALL 
CELL LUNG CARCINOMA
Kumbhaj P1*, Rameshwaram Sharma1,D.P.Singh1,O.P.Sharma1,Aseem Rai 
Bhatnagar1 1 Department of radiotherapy and oncology SMS Medical College 
& Attached hospitals, Jaipur, Rajasthan/INDIA.
Aims: To discover the most effective and least toxic regimens of palliative 
radiotherapy for non small cell lung cancer, and here we study of two pallia-
tive radiotherapy fractionation schedule. 
Methods: Biopsy proven non small cell carcinoma of lung: stage IIIb, 
IV and IIIa with poor performance status patients coming to the depart-
ment of radiotherapy and oncology sms hospital Jaipur were included in 
the study, two radiotherapy schedules were followed : (a) 18.75Gy in 3 
#{625cGy/week for 3 weeks} (b)30Gy in 10 #. At base line ,symptoms 
such as cough, hemoptysis, and dysphagia were categorised for quality 
of life assessments, the European organisation for research and treatment 
of cancer(EoRTC) quality of life questionnaire(QLQ)-C30 and the lung 
cancer speciﬁc module QLQ-LC13 were used, and imaging at 2,6,14 weeks 
which is optional. 
Results: There is no strong evidence that any regimen gives better pal-
liation .Higher dose regimen give acute palliation of symptoms but more 
acute toxicity, especially oesophagitis, while the lower dose regimen 
takes longer time to palliate but the effects lasts longer ,there is evidence 
for a modest increase in survival in patients with better performance 
status(PS) 
Conclusion: The majority of patients should be treated with short courses 
of palliative radiotherapy of 2 or 3 fractions. Care should be taken with the 
dose to the spinal cord .The use of high dose palliative radiotherapy should be 
considered for and discussed with selected patients with good performance 
status. More research is needed into reducing the acute toxicity of large frac-
tion regimens. 
Disclosure: No Conflicts of interest
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054-O12 AWARENESS ABOUT THE SIGNS AND 
SYMPTOMS OF LUNG CANCER IN AT RISK 
POPULATIONS IN NSW
Lafontaine M1, Crane M1, Kite J1, Scott N1, O’Hara B1 1Cancer Institute NSW, 
Sydney, New South Wales/AUSTRALIA
Background: Evidence suggests that knowledge about the warning signs and 
symptoms of lung cancer may encourage early presentation, diagnosis and 
better treatment opportunities. 
Methods: Sixteen focus groups (6-8 participants) were conducted in met-
ropolitan and regional NSW to investigate public awareness of lung cancer 
amongst high risk populations (n=125). Quota sampling was used to recruit 
groups characterised by age (40-64 years, 65+years), smoking status (ex-
smoker, current, never) and socioeconomic status. 
Results: There was a widespread awareness of coughing up blood as a sign of 
lung cancer. other respiratory symptoms were also assumed to be symptoms 
of lung cancer, among other causes. Most participants accepted that smok-
ing increased the chance of developing lung cancer however current smokers 
commonly rejected the idea despite stating that health authorities warn of the 
contrary. other risk factors mentioned included air pollution, asbestos, work-
place and household exposure to chemicals/sprays, an unhealthy lifestyle, 
poor diet, stress and family history. Smokers tended to attribute symptoms 
to these alternatives and downplay the risk due to smoking. All participants 
felt they were at some risk of developing lung cancer. Smokers believed that 
reducing their cigarette intake lessened their risk and that adopting a healthier 
lifestyle signiﬁcantly offset risk. Ex-smokers believed their risk had been 
reduced to that of a never-smoker. 
Conclusion: There is limited understanding about the warning signs and sus-
ceptibility of developing lung cancer amongst those at risk More information 
is needed in the wider community to increase knowledge and awareness about 
lung cancer.
114-S12 
IMAGING GUIDED BIOPSY- WHAT A RADIOLOGIST 
GIVES?
Lau WF Eddie, Peter MacCallum Cancer Centre & University of Melbourne
With recent advances in target therapy and personalised treatment for lung 
cancer, there is an increasing role for the radiologist to perform imaging 
guided biopsy to provide representative tumour tissue not only for histologi-
cal conﬁrmation of malignancy, but also for molecular and mutation analyses. 
The role of the radiologist in imaging guided biopsy is three-fold:
I. Biopsy Planning. Biopsy is now a multidisciplinary procedure and can be 
performed by various specialists using modalities including EBUS, EUS, 
VATS. It is important for the radiologist to work within the multidisci-
plinary model to review the imaging ﬁndings to help select the appropri-
ate lesion and optimal approach for biopsy, considering the advantages, 
limitations and complications of each technique. Increasingly, FDG PET/
CT is being used to guide biopsy to the most accessible and metabolically 
active lesion to maximize the return of representative tissue sample.
II. Biopsy Procedure. When imaging guided biopsy is indicated, this is often 
performed by the radiologist, especially in CT guided biopsy of lung and 
mediastinal lesions. The advent of real time CT fluoroscopy has made 
biopsy more efﬁcient and safer. Core biopsy using biopsy gun provides 
larger specimen and multiple specimens can be safely obtained with a 
single pleural puncture using a coaxial technique. Good communication 
between oncologists, pathologists and radiologist is essential to ensure 
appropriate and adequate tissue sample is obtained. It is also important 
for the radiologist to be aware of various CT biopsy techniques and the 
local complication rates, especially in lung biopsy, and benchmark with 
the accepted standard, so patients can be suitably prepared and allowed 
informed consent.
III. Post Biopsy Care. This involves the provision of post biopsy observation 
and management of acute complication, such as aspiration or drainage 
of pneumothorax using a Heimlich valve. Biopsy outcomes should be 
audited for quality assurance.
052-O12  
DEVELOPMENT OF PRIMARY XENOGRAFTS 
USING LUNG CANCER SPECIMENS OBTAINED 
BY ENDOBRONCHIAL ULTRASOUND-GUIDED 
TRANSBRONCHIAL NEEDLE ASPIRATION
Leong TL1,2*, Strzelecki A1, Steinfort D2,4, Kumar B2, Russell P3, Wright G3, 
Irving L4, Watkins DN1,2, Szczepny A1 1Monash Institute of Medical Research, 
Monash University, Melbourne, Victoria/AUSTRALIA; 2Monash Medical 
Centre, Southern Health, Melbourne, Victoria/AUSTRALIA; 3St Vincent’s 
Hospital, Melbourne, Victoria/AUSTRALIA; 4Royal Melbourne Hospital, 
Melbourne, Victoria/AUSTRALIA
Background: over 40% of lung cancers present as inoperable, locally 
advanced disease. Current diagnosis is based on endobronchial biopsy 
or cytology, which results in advanced stage lung cancer being markedly 
under-represented in conventional tissue banks of surgically resected stage 
1 tumours. Accurate preclinical models of advanced stage disease are needed 
for testing of new therapeutic agents, as well as for the development of bio-
markers. Here we describe a novel preclinical model using samples obtained 
by the minimally invasive technique of endobronchial ultrasound-guided 
transbronchial needle aspiration (EBUS-TBNA) in patients with locally 
advanced lung cancer. 
Methods: Cell suspensions from samples obtained by EBUS-TBNA were 
implanted directly into the flanks of NSG (Non-obese Diabetic, Severe 
Combined Immune Deﬁcient, IL2Rγ knockout) mice to generate primary 
xenografts. once engrafted, serial passage was performed in nude athymic 
mice. Results: Freshly obtained samples from EBUS-TBNA typically con-
tained over 100,000 viable tumour cells, with less then 10% stromal contami-
nation. Engraftment and serial passage were achieved in 5 of 15 (33%) cases. 
The mean duration from implantation to engraftment was 99 days. In all 5 
cases, the histological subtype was identical in patient and xenograft tumours 
despite serial passage. 
Key conclusions: This is the ﬁrst report of the generation of a mouse xeno-
graft model using fresh human EBUS-TBNA samples. The primary xenograft 
lines derived from these specimens may provide the much-needed basis for 
more accurate preclinical modeling of locally advanced lung cancer and a 
means to investigating targeted therapeutic regimens. 
Disclosure: No duality or conflict of interests
093-P12  
THORACIC DIGITAL TOMOSYNTHESIS: A SINGLE 
CENTRE EXPERIENCE
Leong S.C.1*, Bowman R.V.1, Yang I.A.1, Marshall H.M.1, Bennett J.A.2, Fong 
K.M.1 1Department of Thoracic Medicine, The Prince Charles Hospital, 
Brisbane/AUSTRALIA; 2Department of Medical Imaging, The Prince Charles 
Hospital, Brisbane/AUSTRALIA
Introduction: Thoracic digital tomosynthesis (DT) is a radiographic tech-
nique that may offer an alternative to computed tomography (CT) for follow up 
of peripheral pulmonary lesions (PPL) and for clariﬁcation of suspicious chest 
xray (CXR) ﬁndings. Aim: To describe our early experience of DT. Method: 
Retrospective observational study. Consecutive DT scans performed at the 
Prince Charles Hospital between March 2011 and May 2012 were selected by 
searching our Picture Archiving and Communication System. Request forms, 
accompanying CXR and CT scans (if available) and radiologist reports were 
reviewed. Results: 35 DT scans were performed. 16 (45%) were to clarify 
suspicious CXR ﬁndings. DT characterized these changes sufﬁciently in 7 /16 
patients (43%) to avoid CT scan. Final diagnoses were: atelectasis (1), pleural 
plaque (1), pulmonary vein (1), healed rib fracture (1), thin-walled cyst (1), 
no focal lesion (composite shadow, 2). 19 patients (55%) had DT scans for 
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PPL assessment. 38 PPLs were visible on prior CT . 10/38 (26%) PPLs were 
visible on CXR (median diameter 18.2mm) whereas 24/38 (63%) PPLs were 
visible on DT (RUL (8), RML (4), RLL (5), LUL (5), LLL (2)). Median diam-
eter of DT-detected PPLs was 13.0mm (range 3.4-47.0mm); median diameter 
of 14 PPLs not seen on DT was 4.0mm (range 4.0-7.9mm). These PPLs were 
located in RUL (5), RML (1), RLL (2), LUL (1), LLL (5). 
Conclusion: DT is more likely to detect PPLs than CXR. DT can character-
ise suspicious CXR ﬁndings, in some cases avoiding the need for CT scan. 
Disclosure: No authors have any conflicts of interest to disclose 
Funding: S.C. Leong is the recipient of an Australian Postgraduate Award 
PhD scholarship
This work was supported by: NHMRC project grants; NHMRC Practitioner 
Fellowship (KF), NHMRC Career Development Fellowship (IY); Cancer 
Council Queensland PhD scholarship (Marissa Daniels), Cancer Council 
Queensland Senior Research Fellowship (KF), Cancer Council Queensland 
project grants; NHMRC NCARD project grant; Cancer Australia project 
grants; Queensland Clinical Research Fellowship (KF, IY); Australian Lung 
Foundation / Boehringer Ingelheim CoPD Research Fellowship (IY).
105-P12  
FIRST 24 CASES FROM A HEALTH TECHNOLOGY 
ASSESSMENT FIELD EVALUATION OF 
ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY
Leong SC1, Marshall HM1, Bowman RV1, Yang IA1, Ree AM1, Hong J2, 
Hewson K2, Fong KM1 1Department of Thoracic Medicine, The Prince Charles 
Hospital, Brisbane, Queensland/AUSTRALIA; 2Access Improvement Services, 
Queensland Health, Brisbane, Queensland/AUSTRALIA
Introduction: Electromagnetic navigation bronchoscopy (ENB) (superDi-
mension, Minneapolis, Minnesota) is a diagnostic tool that promises “GPS-
like” targeting of peripheral pulmonary lesions (PPLs). Through the use of 
virtual bronchoscopy software and an eight way steerable catheter passed 
through the bronchoscopic working channel, the system guides the bronchos-
copist through the bronchial tree to the target lesion. our aim was to assess 
the utility and safety of this novel technique. 
Methods: ENB was introduced at The Prince Charles Hospital as part of a 
Queensland Policy and Advisory Committee on Technology (QPACT) ﬁeld 
evaluation project. We retrospectively reviewed all ENB procedures per-
formed at our institution since its introduction in August 2010. 
Results: 24 ENB procedures were performed between August 2010 and 
January 2012. Mean age was 69, 14 of the 24 lesions were right sided. Mean 
maximal dimension was 24.07mm (9.9-56mm). 10 lesions were <20mm. 
Mean distance from pleura was 13.67 mm (0-59mm). Lesion location was 
as follows: LUL (4), LLL (1), RUL (6), RML (2), RLL (5). Mean procedure 
time was 63 minutes. ENB obtained true positive results in 4/18 cases - mean 
lesion size in these cases was 31.625mm. Final diagnoses were: cancer (16), 
hamartoma (1), organising pneumonia (1), and diagnosis unknown (6). All 
four ENB true positive cases demonstrated a bronchus sign. No complica-
tions were seen. 
Conclusion: ENB is a safe bronchoscopic method for diagnosing peripheral 
pulmonary lesions.
080-O12  
BARRIERS TO THE EARLY DIAGNOSIS AND 
MANAGEMENT OF LUNG CANCER AND DESCRIPTION 
OF BEST PRACTICE SOLUTIONS
Lewis CA2,3, Stevens W1, Stevens G1, Garrett JE4, Aitken D5, Kolbe J1,3 
1Department of Medicine, University of Auckland/NEW ZEALAND; 2 Northern 
Cancer Network/NEW ZEALAND; 3 Respiratory Services, Auckland District 
Health Board/NEW ZEALAND; 4Respiratory Services, Counties Manukau 
District Health Board, Auckland/NEW ZEALAND; 5 Medical Services, Lakes 
District Health Board, Rotorua/NEW ZEALAND
Background: Patients in Auckland are often diagnosed with lung cancer only 
at the time of an acute admission and with advanced disease, rather than as a 
consequence of primary care referral to outpatient services.
Aim: To map the patient pathway from presentation with lung cancer-related 
symptoms to diagnosis, and evaluate barriers present.
Methods: There were several components to this study including (1) a lit-
erature review, (2) audit of patients presenting with lung cancer in the year 
2008, (3) interviews with patients presenting to secondary care via an acute 
admission, (4) survey and focus groups of GPs and (5) survey and stocktake 
of primary and secondary care services for lung cancer
Results: The audit of lung cancer presentations in 2008 yielded very similar 
results to a 2004 study, except that more patients were discussed at a multi-
disciplinary meeting (56% compared to 28% in 2004). Although 76% of 
patients presented initially to primary care, 44% of these cases subsequently 
were admitted or self-presented acutely to hospital. once again, patients pre-
senting to secondary care directly had more advanced disease but achieved 
diagnosis faster. Patient-related delays were identiﬁed in 11% and system 
delays in 10%. The secondary services stocktake identiﬁed commendable 
but patchy lung cancer initiatives in New Zealand. Patient and GP interviews 
and focus groups identiﬁed a number of perceived problems including fatal-
istic attitudes, system barriers and poor or delayed access to investigations. 
Conclusions: Numerous barriers to the early diagnosis of lung cancer have 
been identiﬁed. Eighteen recommendations for change have been drafted. 
Supported by: Health Research Council of New Zealand 
Conflict of interest: No
059-P12  
THE PROGNOSTIC ROLE OF EXPRESSION OF POLO-
LIKE KINASE 1 (PLK1) AND CELL DIVISION CONTROL 
2 (CDC2), TWO POTENTIAL THERAPEUTIC TARGETS 
IN MALIGNANT PLEURAL MESOTHELIOMA
Linton A1,2,3,, Griggs K4,5, Kao S1,2,3, Vardy J2,3, Clarke S3,6, Henderson D4,5, 
McCaughan B7, Van Zandwijk N1,3 , Klebe S4,5, Reid G1 1Asbestos Diseases 
Research Institute, Sydney, New South Wales/AUSTRALIA; 2Concord 
Repatriation General Hospital, Sydney, New South Wales/AUSTRALIA; 
3University of Sydney, Sydney, New South Wales/AUSTRALIA; 4SA Pathology, 
Flinders Medical Centre, Adelaide, South Australia/AUSTRALIA; 5Flinders 
University of South Australia, Adelaide, South Australia/AUSTRALIA; 6Royal 
North Shore Hospital, Sydney, South Australia/AUSTRALIA; 7Royal Prince 
Alfred Hospital, Sydney, South Australia/AUSTRALIA;
Background: Increased expression of PLK1 and CDC2 is associated with 
poor prognosis in cancer, and both genes were upregulated in previous stud-
ies of malignant pleural mesothelioma (MPM).We assess the effects of target 
knockdown on MPM cell growth and determine whether PLK1 and CDC2 
expression is associated with overall survival (oS) in MPM patients.
Methods: Tissue microarrays were constructed using samples from patients 
diagnosed with MPM who underwent surgery. PLK1 and CDC2 immunohis-
tochemistry was performed and their prognostic role reviewed, adjusting for 
known prognostic factors, utilising a Cox regression model.
Proliferation of MPM cell lines was measured after transfection with PLK1- 
or CDC2-speciﬁc siRNA, or treatment with small molecule drugs BI 2536 or 
Roscovitine. 
Results: In 155 patients, median PLK1 and CDC2 expression was 3% (Range 
0-42.5%) and 15.8% (Range 0.5–96%) respectively.
Median oS was 14.3 months (95% CI: 10.6-18.0). on univariate analysis, 
greater PLK1 expression, non-epithelioid histology, age and male gender 
were associated with worse outcomes. CDC2 expression was not associated. 
on multivariate analysis, PLK1 expression (HR 1.87; 95% CI 1.23-2.83; 
p=0.003), subtype (HR 3.05; 95% CI 2.08-4.46; p<0.001) and age (HR 1.22; 
95% CI 1.01-1.48; p=0.036) remained signiﬁcant.
In cell lines, PLK1 and CDC2 knockdown led to siRNA dose-dependent 
growth inhibition. Small molecule inhibitors of PLK1 (BI 2536) and CDC2 
(Roscovitine) also inhibited proliferation.
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Conclusion: We have identiﬁed PLK1 expression as an independent prog-
nostic factor in MPM. Furthermore, inhibition of PLK1 and CDC2 is growth 
inhibitory in MPM cells, suggesting PLK1 and CDC2 as potential therapeutic 
targets.
Disclosure statement: The authors report no possible dualities or conflicts of 
interest associated with the conduct of this study.
092-O12  
THE QUEENSLAND LUNG CANCER SCREENING 
STUDY: RISK STRATIFICATION USING 
PARTICIPANT DATA AND LUNG FUNCTION TESTS 
CAN SIGNIFICANTLY INCREASE SCREENING 
EFFECTIVENESS
Marshall HM1,4, Bowman RV1,4, Crossin J2, Lau MA2, Slaughter RE2, Ayres J2, 
Passmore LH1, McCaul EM1, Leong SC1,4, Courtney DA1, Windsor MN3, Yang 
IA1,4, Zimmerman PV1, Hayes TJ2, Redmond SJ2, Lam SC5, Tammemagi MC6, 
Fong KM1,4 Departments of 1Thoracic Medicine, 2Medical Imaging, 3Thoracic 
Surgery and 4The University of Queensland Thoracic Research Centre, The 
Prince Charles Hospital, Chermside, Queensland/AUSTRALIA; 5Department 
of Integrative Oncology, British Columbia Cancer Agency, Vancouver, and 
6Department of Community Health Sciences, Brock University, St. Catharines, 
Ontario/CANADA.
Introduction: Screening with low-dose computed tomography (LDCT) 
reduces lung cancer (LC) mortality in participants aged 55-74 with ≥30 pack 
year smoking history.
25-50% of screenees have “positive” scans requiring further evaluation, but 
>95% of these ﬁndings are benign; cancer detection rates are only 1-2%. 
Further risk stratiﬁcation may help deﬁne the highest-risk population, allow-
ing better targeting of screenees and ultimately more efﬁcient and cost-effec-
tive screening.
Aim: Explore the potential of risk modelling with lung function and 
patient variables to improve the positive predictive value of screening in the 
Queensland Lung Cancer Screening Study cohort.
Methods: Participants received up to 3 annual LDCT scans. Lung function 
data were collected at entry. Risk stratiﬁcation was determined retrospectively 
using a published model based on PLCo Trial data (age, socioeconomic sta-
tus, positive family history, body-mass index, CoPD diagnosis, chest x-ray 
within last 3 years, smoking history). Lung function thresholds were deter-
mined by RoC analysis (%predicted FEV1 and KCo; FEV1*KCo product).
Results: 256 participants were followed for a median of 30 months. Ten LC 
were detected (1565 LC per 100,000 patient-years; 3.9% yield). Using a 
model combining thresholds of 5-year LC risk ≥2% and FEV1*KCo product 
≤0.85, only 129 participants would have needed to be screened in order to 
detect all 10 cancers, improving the potential yield to 7.8%.
Conclusions: Lung cancer screening efﬁciency can be enhanced using easily 
obtainable patient and physiological data. These ﬁndings need validation in 
larger cohorts.
Disclosure: Supported by a Queensland Smart State Grant, NCARD & 
NHMRC.
044-P12  
THE EFFICACY OF ROUTINE EGFR MUTATION 
TESTING OF LUNG CANCERS
Metcalf C1, Bentel JM1,2, Thomas MA1,2, Sadowska A,1 1Anatomical Pathology, 
PathWest Laboratory Medicine, Royal Perth Hospital, Western Australia/
AUSTRALIA; 2 School of Pathology and Laboratory Medicine, University of 
Western Australia, Western Australia/AUSTRALIA
Background: The introduction of epidermal growth factor receptor tyrosine 
kinase inhibitors (EGFR TKIs) into clinical practice has signiﬁcantly altered 
treatment of Australian lung cancer patients. Due to the selective responsive-
ness to EGFR TKIs of lung tumours carrying EGFR but not K-RAS mutations, 
EGFR mutation testing has been implemented at a number of Australian hospi-
tals. Guidelines for EGFR mutation testing have not been developed. 
Aim: To evaluate routine EGFR mutation testing of lung cancers. 
Methods: Parafﬁn-embedded biopsy, surgical and cytology specimens from 
Royal Perth Hospital taken over two calendar years were evaluated for EGFR 
(exons 18-21), K-RAS (exons 2, 3) and BRAF (exon 15) mutations using 
routine PCR and Sanger sequencing. 
Results: EGFR mutations were identiﬁed in 18/184 (10%) cases, K-RAS 
mutations in 43 (25%) cases and BRAF mutations in 3 (1.6%) cases. The 
histological classiﬁcation of lung tumours carrying EGFR mutations included 
adenocarcinoma (12), bronchioalveolar carcinoma (2), papillary adenocarci-
noma (2), NSCLC (1) and small cell carcinoma (1). 
Key conclusions: Similar to other western countries, the EGFR muta-
tion frequency in lung cancers is ~10% in a typical Australian population. 
EGFR mutation testing frequency could be reduced by ~25% if cases were 
prescreened for K-RAS/BRAF mutations. The proportion of cases (EGFR, 
K-RAS or BRAF mutation positive) providing additional information for 
treating physicians is consistent with that of other routinely performed molec-
ular tests (eg. HER2 CISH for breast cancer) and may optimise treatment or 
expedite entry of lung cancer patients into clinical trials. 
Funding: Boehringer Ingelheim, Anatomical Pathology, RPH
005-P12 
A MULTI-CENTER RANDOMIZED, OPEN-LABEL 
PHASE II TRIAL OF TARCEVA IN SEQUENTIAL 
COMBINATION WITH GEMCITABINE COMPARED 
TO GEMCITABINE MONOTHERAPY AS FIRST-LINE 
THERAPY IN ELDERLY OR ECOG PS OF 2 PATIENTS 
WITH ADVANCED NSCLC
Michael M1*, White S2, Abdi E3, Nott L4, Clingan P5, Zimet A6, Gregory D7, 
Solomon B8, Clarke S.9 1 Peter MacCallum Cancer Centre, East Melbourne, 
Victoria/AUSTRALIA; 2Austin Health, Heidelberg, Victoria/AUSTRALIA; 3 
The Tweed Hospital, Tweed Heads, New South Wales/AUSTRALIA; 4 Royal 
Hobart Hospital, Hobart, Tasmania/AUSTRALIA; 5Southern Medical Day 
Care Centre, Wollongong, New South Wales/AUSTRALIA; 6Epworth Hospital, 
Richmond, Victoria/AUSTRALIA; 7Roche Products, Pty. Limited, Dee Why, 
New South Wales/AUSTRALIA; 8 Peter MacCallum Institute of Cancer 
Research, East Melbourne, Victoria/AUSTRALIA; 9 Concord Repatriation 
General Hospital, Concord, New South Wales/AUSTRALIA;
Aim: The beneﬁcial interaction between erlotinib and chemotherapy requires 
pharmacodynamic separation. The aim of this study was to evaluate the 
relative efﬁcacy and tolerance of sequential erlotinib with gemcitabine ver-
sus gemcitabine monotherapy as ﬁrst-line therapy in elderly or ECoG PS 2 
patients with chemonaïve advanced NSCLC.
Methods: GATE is a multi-center, randomized, Phase II study. Primary 
objective was progression free survival (PFS). Secondary objectives were 
overall Response Rate (oRR), Disease Control Rate; duration of response, 
overall survival, and safety. Patients were randomized to either gemcitabine 
(1000 mg/m2 Day 1,8 q28 days) followed by erlotinib (150 mg/day on day 15 
through day 28), (EG), or gemcitabine monotherapy (1000 mg/m2 Days 1,8, 
15 q28 days), (G); for up to 6 cycles.
Results: Fifty-four patients were recruited, 28 to G arm and 26 to EG arm. 
overall, efﬁcacy results were not signiﬁcantly different between study arms. 
Median PFS and oRR for the G vs EG arms were 8.0 vs 10.3 months (HR 
1.3;95% CI [0.63;2.68]; p=0.4798) and 7.1% vs 3.8% (95% CI [17.5;10.9]) 
respectively. The majority of AEs in both arms were Grade 1-2. The com-
monest AEs recorded for patients in the EG and G arms were rash-like events 
(65%) and nausea (42%) respectively. Four patients (17%) in EG arm and 5 
(16%) in G arm experienced at least one treatment related SAE.
Conclusion: Sequential erlotinib in combination with gemcitabine demon-
strated no unexpected safety ﬁndings in patients with NSCLC at ECoG PS 2 
or aged ≥70 years; efﬁcacy advantage could not be conﬁrmed.
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046-P12  
IMPACT OF AN ONCOLOGY PHARMACIST 
ATTENDANCE AT A MULTIDISCIPLINARY LUNG 
CLINIC
Mileshkin L, Walter C, Rice C, Ball D, Duffy M, Kirsa S, Mellor D Peter 
MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA
Background: Medication misadventure contributes to unplanned hospi-
tal admissions in cancer patients. Numerous medications may be added to 
existing ones and general practitioners (GPs) may lack experience in manag-
ing cancer-related medication. Inpatient clinical pharmacy services impact 
on patient care and morbidity. This project aimed to evaluate the effects of 
extending this service to outpatients.
Method: An oncology pharmacist attended lung outpatients for 6 months. 
Consented patients completed assessments of medication adherence (using 
Morisky tool) and satisfaction with medicines information at baseline and 
within 30 days of review. Post pharmacist review, a list of medications and 
recommendations were provided to patients, and community and hospi-
tal healthcare providers. Uptake of recommendations was evaluated after 7 
days. Interventions were categorized and graded according to risk avoided. 
Unplanned admissions and clinic attendance rates were compared to the pre-
vious year using the Rate Ratio Test assuming Poisson counts. GPs opinion of 
the service was evaluated via survey.
Results: 48 patients were recruited. Self-reported medication adherence 
(p=0.007) and patient satisfaction (p<0.001) signiﬁcantly improved. 154 
pharmacist interventions were made: 4.5% extreme risk avoided and 43.5% 
high risk avoided. Ratios of unplanned admissions and clinic attendances 
decreased; 0.3 to 0.26 (p=0.265) and 3.32 to 2.98 (p=0.004) respectively. 31 
of 48 GPs completed the survey, 74% of whom found the service useful.
Conclusions:Adding a pharmacist to the outpatient lung team led to signiﬁ-
cant improvements in patient medication adherence. Both patients and GPs 
were highly satisﬁed with the service. Medication misadventure, unplanned 
admissions and clinic attendances were reduced. 
Funding: provided by an educational grant from Roche
Disclosure: The authors have no conflicts of interest to report
110-O12  
MEASURING THE FUNCTIONAL DECLINE OF PEOPLE 
WITH ADVANCED STAGE NON-SMALL CELL LUNG 
CANCER (NSCLC)
Mileshkin L1, Murnane A1, Krishnasamy M1, Gough K1, Granger C2, 
Denehy L2 1Department of Nursing and Supportive Care Research, Peter 
MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA; 2Department 
of Physiotherapy, The University of Melbourne, Victoria/AUSTRALIA
Background: People affected by lung cancer maybe highly symptomatic. 
This study aimed to quantify changes in physical function and health-related 
quality of life (HRQoL) in patients with advanced NSCLC. 
Methods: Patients with stage III and IV NSCLC were prospectively recruited 
when starting treatment. HRQoL and functional status were measured using 
the EoRTC QLQ-C30, 6-minute walk test (6MWT) and timed up and go 
test (TUG) at baseline, 2, 4 and 6 months or until they became too unwell. 
Comparisons between baseline and follow-up assessments were carried out 
by ﬁtting linear mixed models to each outcome separately. 
Results: 39 patients (21 male) recruited; median age of 63 (range 40-80). 
28% had stage 4 disease with 26% deceased by 4 months. The mean 6MWT 
at baseline was signiﬁcantly lower than predicted for the age, sex and height of 
the cohort (417.9 versus 550.4 metres, p<0.0005). Signiﬁcant decline in mean 
6MWT distance was seen at 2 (-42.4m; p<0.0005) and 4 months (-63.6m; 
p<0.0005) compared to baseline. Signiﬁcant increases in time taken to com-
plete the TUG was seen at 2 (+0.76 sec; p<0.0005) and 4 months (+1.01 sec; 
p<0.0005). In contrast, self-reported global health status and physical func-
tioning showed small but signiﬁcant decreases at 2 months, but no signiﬁcant 
differences between baseline and 4 months. 
Conclusions: Patients with advanced NSCLC show clinically and statistically 
signiﬁcant decrements in physical function at treatment commencement. This 
continues to decline rapidly and signiﬁcantly over time, despite small changes 
in self-reported HRQoL. Interventions to address this problem are urgently 
needed. 
Funding: for this study was provided by a NHMRC Palliative Care Grant. 
Disclosure: The authors have no conflict of interest to report.
101-O12  
INTRA-OPERATIVE SCANNING CONFOCAL 
ENDOMICROSCOPY OF PLEURAL DISEASE: IN VIVO 
DIAGNOSIS OF MALIGNANCY
Mitchell P1, Knight S2, Crowley P3, Putt F1, Gooi J2, Seevanayagam S2, 
Barnett S2, McDonald C4, Delaney P5 Departments of 1 Medical Oncology, 
2 Thoracic Surgery, 3 Anatomical Pathology, 4 Respiratory Medicine, Austin 
Health, Melbourne and 5 Optiscan, Melbourne, AUSTRALIA
The intra-operative diagnosis of pleural malignancy may facilitate surgi-
cal decision making including the need for pleurodesis. A scanning laser 
confocal endomicroscopy device has been developed which allows histo-
logical detail optical imaging of subsurface tissues in vivo. Confocal laser 
microscopy illuminates a ﬁxed point of a specimen which, when coupled 
with the capacity to scan across a tissue plane and control the depth of imag-
ing, provides a 3D structural view in a living body. Applied to screening of 
polyps in patients with hereditary polyposis, endomicroscopy obviates the 
need for tissue biopsy and operators can rapidly learn to identify malignant 
tissues. We performed the ﬁrst intra-operative examination of pleural tissues 
using a thoracoscope-mounted endomicroscope device with patients admin-
istered iv fluorescein prior to imaging. Intra-operative endomicroscopic 
images were correlated with biopsies of pleural tissues. Thirteen patients 
were imaged: including mesothelioma 5 (2 biphasic) and pleural carcinoma 
metastases from lung 2, ovary 2, breast 1 and parotid 1. We were able to 
image and identify normal mesothelium, sub-mesothelium, connective tis-
sues and blood vessels (including RBC). Malignant cells and clusters of 
cells had a characteristic appearance including poor uptake of fluorescein. 
Appearances of mesothelioma correlated closely with histology. Glandular 
and papillary structures were identiﬁed in metastatic pleural tumour. In 
ovarian cancer calciﬁcation was readily identiﬁed as were psammoma bod-
ies, while the typical cystic spaces mirrored closely the histological appear-
ances of adenoidcystic carcinoma. We plan now to extend our experience of 
malignancy and also the ability to discriminate between benign disease and 
malignancy of the pleura.
Supported by a Tumour Stream Grant from the Victorian Cancer Agency.
009-O12  
FROM CLINIC TO CLASSROOM: HEALTH PROMOTION 
FOR HIGH SCHOOL STUDENTS
Mooney K, King A Western Australian Cancer and Palliative Care Network, 
Perth, Western Australia/AUSTRALIA
Introduction: Lung cancer is in the top four most common cancers and is 
the most common cause of cancer related death worldwide. At least eighty 
percent of lung cancer patients are current or former smokers1. The younger 
a person starts smoking along with the number of years they smoke for, sig-
niﬁcantly increases their chances of developing cancer2. An integral part of 
the Cancer Nurse Coordinator’s role is health promotion. A new initiative 
was developed to inform a younger audience about the devastating effects of 
smoking particularly in relation to lung cancer. 
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Objectives/Aims: To increase awareness to high school students on the harm-
ful effects of smoking. 
Methodology: Engagement with key stakeholders within the education 
department and the Chronic Diseases Network, before the implementation 
of the program ensured that it complemented the education curriculum. 
Presentations have been delivered to fourteen high schools in the Perth met-
ropolitan area. The presentations were interactive and featured a power-point 
presentation with graphic pictures and real patient stories. Evaluation forms 
were completed by both students and teachers. 
Results: The quality improvement initiative demonstrated a positive response 
to the presentation with the majority of the audience expressing a strong anti-
smoking sentiment. 
Conclusions: As health professionals we need to advocate that “prevention 
is better than cure”. As cancer nurses we are ideally placed to combine an 
evidence and experience-based approach to education our future generation. 
References:
1) http://www.who.int/tobacco/research/cancer/en/
2) Department of Education and Training New South Wales (2001). Stage 4 
Smoke screen: a smoking prevention resource. Department of Education 
and Training
028-O12  
LIVING WITH LUNG CANCER - A PERSONAL 
PERSPECTIVE ON THE MYTHS, MISPERCEPTIONS 
AND STIGMA
Moore o oAM1*, Julie Marker1 1Cancer Voices South Australia/
AUSTRALIA
Aim: To outline a consumer advocate’s perspective of lung cancer including 
myths, misperceptions and stigma. 
Method: personal perspective supplemented by connections made worldwide 
via social media, and open-access literature sources. 
Results/ Conclusion: Ashleigh Moore will present his personal perspective of 
the experience of lung cancer (twice), after surviving Head and Neck cancer. This 
personal account is supplemented by his connections with other survivors around 
the world via social media (FaceBook & Twitter). As a non-smoker, cyclist, father 
and husband, walk briefly in his shoes as he discovered the stigma and myths 
around lung cancer. There are surprising community misperceptions and misun-
derstandings of lung cancer despite it being the leading cause of cancer deaths.
These misperceptions contribute to a shortfall in funding for lung cancer 
research, which flows on to poor survival outcomes which (unlike most other 
cancers) have not substantially improved in the past 20 years. Average 5 year 
survival remains low at 9-12%. Support for patients and families is limited.
There is much that lung cancer survivors can do to dispel myths and inspire 
change. Clearly something must be done to erase the stigma, educate the pub-
lic, and to inform service delivery, policy and research funders.
Funding: Cancer Voices South Australia is a 100% volunteer organization.
Disclosure statement: The authors have no dualities or conflicts of interest 
to declare.
016-P12  
PLEURX CATHETERS PROVIDE SAFE AND EFFECTIVE 
CONTROL OF MALIGNANT PLEURAL EFFUSION
Morgan L, Goh C, Kamal R, Daniels R, Ng B, Wilson P, Flynn P Nepean Lung 
Cancer Group, Nepean Hospital, Kingswood, New South Wales/AUSTRALIA
Aim: To audit our experience with tunnelled indwelling catheters inserted for 
the management of malignant effusions.
Methods: A retrospective review of clinical outcomes for patients managed 
between 2008-2011
Results: 63 patients had 74 PleurX catheters inserted between 2008 and 2011 
for malignant effusions (71 pleural, 3 peritoneal). M:F, 19:44. Mean age 66 
y (32-96 y). All fluid collections were known to be malignant prior to PleuX 
insertion. All were inserted under local anaesthetic with awake sedation. The 
primary malignancy was breast carcinoma in 26, NSCLC (Non-Small Cell 
Lung Cancer) in 15, gastric carcinoma in 5, adenocarcinoma of unknown pri-
mary in 5, mesothelioma in 4, ovarian cancer in 3, small cell lung cancer in 2 
and 11 had other malignancies. All achieved control of fluid. 59 subjects have 
since died (50 died with PleurX in situ) with 3 lost to follow-up and 1 subject 
with breast cancer is still alive (PleurX removed after pleurodesis). Mean time 
from insertion to death or removal was 49 days. of the 18/68 PleurX removed, 
6 had achieved pleuradesis, 1 was blocked (and reinserted), 1 was leaking 
around the insertion site (and was replaced), 4 were removed for infection. All 
complications occurred prior to 2009.
Conclusions: PleurX catheters are used regularly in our unit in the early man-
agement of malignant effusions. In our experience they provide safe, deﬁni-
tive control of pleural fluid for patients with advanced malignancy with much 
lower rates of discomfort and time in hospital than repeated aspirations or 
talc pleuradesis.
Disclosure: No
024-O12  
LIMITING THE FUNCTIONAL DECLINE OF PATIENTS 
WITH ADVANCED NON-SMALL CELL LUNG CANCER 
(NSCLC): A HOME BASED EXERCISE PROGRAM (HEP)
Murnane A1*, Krishnasamy M1, Denehy L2, Granger C2, Mileshkin L1 1 Peter 
MacCallum Cancer Cetre, Melbourne, Victoria/AUSTRALIA; 2 Department 
of Physiotherapy, The University of Melbourne, Victoria/AUSTRALIA
Background: Phase I of this study showed that 50% of (n=28) advanced 
stage NSCLC patients demonstrated a clinically meaningful functional 
decline from commencement of treatment to T2 (2months) follow up. This 
study (phase II) set out to pilot test a HEP, to lessen functional decline and its 
impact on this patient group.
Methods: A descriptive cohort study. Patients with stage III and IV NSCLC 
were recruited within one month of starting treatment and completed assess-
ments bi-monthly to six months or until they became too unwell. The HEP is 
modelled on pulmonary rehabilitation principles and patients completed the 
program for 8 weeks. Functional status data was collected using the 6-minute 
walk distance (6MWD) and timed up and go test (TUG). Preliminary results 
are presented.
Results: 31 patients met inclusion criteria and were approached to take part 
in the study with11 patients (7 males) consenting. Patients who completed the 
intervention (n=10) from baseline to T2, resulted in only 10% having demon-
strated a clinically meaningful functional decline on the 6MWD (-50m). 60% 
of the sample have maintained or improved their functional performance on 
the TUG and 6MWD from baseline to T2.
Conclusions: Preliminary data suggests that advanced stage NSCLC patients 
can remain active during the treatment phase to help lessen the functional 
decline associated with cancer treatments and the disease process. Strategies 
to increase uptake into the program need to be explored to improve the feasi-
bility of the program in a clinical setting.
Funding for this study was provided by an ALTG concept development grant
115-S12 
THE MOLECULAR PATHOLOGIST IN 2012
o’Toole SA, Department of Tissue Pathology and Diagnostic Oncology, 
Royal Prince Alfred Hospital, Sydney Medical School & The Garvan Institute 
of Medical Research, AUSTRALIA
Personalised medicine is the application of genomic and molecular data 
to target the delivery of optimal health care. A vital part of personalized 
medicine is the development of suitable companion diagnostics, so spe-
ciﬁc molecular assays can be utilised to stratify disease status and identify 
the most appropriate therapy to ensure the best outcome and to potentially 
minimise side effects. This is of particular relevance to lung cancer where a 
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signiﬁcant proportion of lung adenocarcinomas harbour biologically relevant 
and/or targetable somatic genetic changes such as mutations, ampliﬁcations 
or translocations in a number of genes including KRAS, EGFR, ALK, MET, 
PIK3CA, RET, AKT1, ERBB2 & BRAF. A particular challenge in lung cancer 
is developing and applying robust diagnostic assays that can identify clini-
cally important changes in a number of genes on the very small amount of 
material, often with suboptimal quality DNA, that is available for analysis. 
Accurate and sensitive testing is essential to ensure patients with this poor 
prognosis disease receive the correct therapy and there is also a pressing 
need to triage patients for trials of novel targeted therapeutics. Integration of 
traditional tissue pathology with molecular studies and high quality biopsy 
material obtained through a multidisciplinary approach between oncologists, 
pathologists, respiratory physicians and radiologists is critical to ensure opti-
mal diagnosis and therapy of patients with this poor prognosis disease. our 
own experience suggests that multigene assays may offer signiﬁcant advan-
tages to the personalisation of lung cancer, maximising the yield of clinically 
relevant information on small and precious tissue biopsies.
055-P12  
KNOWLEDGE, ATTITUDES AND PRACTICES ABOUT 
LUNG CANCER AMONG MEDICAL STUDENTS IN 
KATHMANDU UNIVERSITY SCHOOL OF MEDICAL 
SCIENCES
Pant P1*, Khatiwada P2, Kayastha SR1, Shrestha S1, Khanal KR1, Shrestha A1, 
Katwal PC1 1 Kathmandu University School of Medical Sciences, Dhulikhel, 
Nepal; 2 Richa Bajimaya Memorial Foundation, Kathmandu, Nepal
Aims: often, lung cancer is diagnosed at terminal stages. Poor awareness 
about the symptoms or risk factors of lung cancer among medics may be one 
of the factors for delayed diagnosis. We explored the knowledge of medical 
students and their behavior with the patients of lung cancer. 
Methods: Qualitative and quantitative approaches were used for data collec-
tion from 153 medical student of Kathmandu University School of Medical 
Sciences from December 2011 to May 2012. Questionnaires were handed out 
to the participants, and discussions were carried out in ﬁve groups of these 
students. 
Results: The majority of the students had good knowledge of lung cancer. 
40% of them knew someone who had ever suffered from cancer. Eighty-nine 
students had over 80% knowledge of the 14 cancer warning signs, among 
them 83% knew the nine risk factors for lung cancer. Twenty-three students 
told lung cancer can be hereditary. 65% of all participants believed that it 
can be detected at early stage; of them 81% told that it can be treated. About 
24% of the total students were current or ex-smokers and about half of them 
believed that lung cancer does not occur in light smokers. only 10% have 
heard of Framework Convention on Tobacco Control in Nepal. 
Conclusion: All medical students who know about any cancers may not nec-
essarily have knowledge about lung cancers. Their perception about the cause 
of lung cancer may be influenced by their smoking behavior. Awareness about 
national policies needs to be increased. 
Disclosure: No conflict of Interest 
Source of Funding: – Self Funding
047-P12  
UTILITY OF TESTING FOR NON-SMALL CELL LUNG 
CANCER (NSCLC) EPIDERMAL GROWTH FACTOR 
RECEPTOR (EGFR) MUTATIONS IN AN AUSTRALIAN 
TESTING PROGRAM
Peters M*1, Solomon B2, Bowden J3, Lewis J4, Carpenter P4. 1Dept of Thoracic 
Medicine, Concord Hospital, New South Wales/AUSTRALIA; 2Dept of 
Medical Oncology, Peter McCallum Cancer Centre, Victoria/AUSTRALIA; 
3Dept of Respiratory Medicine, Flinders Medical Centre, South Australia/
AUSTRALIA; AstraZeneca, New South Wales/AUSTRALIA
Introduction: Treatment of NSCLC with EGFR tyrosine kinase inhibitors 
should be guided by the presence of activating mutations of EGFR in tumour 
tissue. 
Aim: To evaluate rate and utility of testing when cost as an access barrier is 
removed, to determine what tissues are sampled and test outcomes. 
Methods: In 2010, AstraZeneca initiated this program. Partnering Australian 
laboratories were funded for provision of EGFR mutation testing results. For 
patients, the test charge was supported by the program. Mutation testing was 
performed using Sanger sequencing. No clinical or personal details were 
gathered. 
Results: Through March 2012, 2012 samples had been submitted. 69% of 
samples were from solid tissue, 16% from ﬁne needle aspiration(FNA) and 
14% from other cell blocks (washings/brushings/fluid). 51% of samples were 
from lung, 12% from lymph nodes, 10% from pleura/pleural fluid and 7% 
each from bronchus and brain. 14.8% could not be fully sequenced for exons 
18-21. 43% of these had no tissue or no tumour tissue in the block submit-
ted, DNA ampliﬁcation failed in 25% and not all exons could be sequenced 
in 31%. A failed/incomplete test was more likely in samples derived from 
FNA – oR 3.1 (95% CI 1.9-5.2) compared to other samples. We estimate 
that EGFR mutation testing was performed on approximately 20% of incident 
cases of NSCLC in this period. 
Conclusions: EGFR mutation testing is feasible on samples from across 
Australia. The rate of valid test outcomes is high but FNA samples are associ-
ated with more frequent test failure. Sending high quality samples is critical. 
Conflict of interest: PC and JL are employees of AstraZeneca. BS and MP 
have participated in advisory boards, and JB has received honoraria from 
AstraZeneca.
060-P12  
SUICIDAL IDEATION IN PATIENTS WITH LUNG 
CANCER: USE OF A SUPPORTIVE NEEDS SCREENING 
TOOL
Rao A*, Urban D, Duffy M, Breen S, Solomon B, Mileshkin L Department of 
Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria/
AUSTRALIA
Background: Patients with lung cancer are at a substantially higher risk of 
suicide than the general population. This study aims to identify clinical and 
demographic characteristics of patients expressing suicidal ideation. 
Methods: Between August 2009 and September 2010, 78 patients with newly 
diagnosed lung cancer were screened with the Supportive Needs Screening 
Tool (SNST) by the lung nurse coordinator. We analysed responses with 
regards to suicidal ideation and any associated demographic/clinical factors. 
Medical records were accessed for clinical details, including management and 
outcomes. 
Results: Five (6.4%) patients completing the SNST expressed self-harm 
and/or suicidal ideation. Suicidal ideation was more common in males 
(60% versus 51%) and those with a younger median age (54 versus 68 
years). on univariate analysis, the only factor associated with suicidal 
ideation was feeling sad/depressed (p<0.05). Avoidant behaviour; diffi-
culty concentrating; not having someone to talk to and difficulty coping 
with treatment showed a trend to significance (p<0.065). of particular 
concern, these patients were more likely to have thoughts of giving up 
treatment (60% vs 5.6%; p=0.005). of interest, three patients had been 
diagnosed with cerebral metastases and were on dexamethasone. All 
patients with suicidal ideation were referred to support services; 4 to 
psychology/psychiatry and 1 to social work. None of the patients com-
mitted suicide. 
Conclusions: Administration of the SNST allowed identiﬁcation of patients 
with suicidal ideation. Albeit from a small sample size, this study highlights 
characteristics that may alert clinicians to patients at increased risk of suicidal 
ideation, facilitating referral to psychosocial support services. 
Disclosures: The authors indicated no potential conflicts of interest.
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082-O12  
THE MICRORNA MIR-16 IS A NOVEL TUMOUR 
SUPPRESSOR GENE IN MALIGNANT PLEURAL 
MESOTHELIOMA
Reid G*1, Pel M1,2, Kirschner M1, Williams M1, Wright C1, Cheng YY1, 
McCaughan B3, Edelman J3, Vallely M3, Bowman R4, Klebe S5 van Zandwijk 
N1 1Asbestos Diseases Research Institute, University of Sydney, New South 
Wales/AUSTRALIA; 2Academic Medical Centre, University of Amsterdam, 
THE NETHERLANDS; 3Cardiothoracic Surgical Unit, Royal Prince Alfred 
Hospital; The Baird Institute and Faculty of Medicine, University of Sydney, 
New South Wales/AUSTRALIA; 4Thoracic Research Centre, The Prince 
Charles Hospital, University of Queensland, Queensland/AUSTRALIA; 
5Department of Anatomical Pathology, Flinders Medical Centre, South 
Australia/AUSTRALIA
MicroRNA expression in malignant pleural mesothelioma (MPM) is signiﬁ-
cantly altered, with previous studies identifying microRNAs with tumour-
suppressor or oncogenic functions. The expression of miR-16 is frequently 
lost in a variety of cancers, and we demonstrate that miR-16 is also down-
regulated in MPM, where it seems to function as a tumour-suppressor gene. 
The expression of miR-16 was signiﬁcantly (p = 0.01) down-regulated 
(20-fold) in MPM tumours compared with pericardial tissue. In cell lines, 
miR-16 expression in MPM lines was 2 to 4-fold down-regulated compared 
with MeT-5A. The restoration of miR-16 expression with mimic resulted in 
growth inhibition in all MPM lines, with as little as 1 nM mimic leading to 
signiﬁcant effects on proliferation and the ability to form colonies at low 
density. In contrast, use of miR-16 mimic at 5 nM did not alter the growth of 
MeT-5A cells. Transfection with miR-16 also led to a 2 to 5-fold sensitiza-
tion of MPM cells to gemcitabine but did not affect MeT-5A sensitivity. The 
expression of miR-16 target genes related to gemcitabine resistance were 
down-regulated in transfected cells. The down-regulation of miR-16 in MPM 
tumour samples and cell lines, together with the growth inhibitory effects of 
restoring miR-16 expression suggests a tumour suppressor function in MPM. 
Together with its ability to sensitize MPM cells to gemcitabine treatment, 
this suggests miR-16 replacement should be explored as a novel therapeutic 
approach in MPM.
042-P12  
THE NEW MODEL OF LUNG CANCER CARE IS 
MULTIDISCIPLINARY: THE SOUTH AUSTRALIAN 
EXPERIENCE OF PATHWAY DEVELOPMENT
Reinbrecht S1*, Zwart E2*, Robinson P3, Brown MP2 1Oncology Department, 
Flinders Medical Centre, South Australia/AUSTRALIA; 2Royal Adelaide 
Hospital Cancer Centre, Adelaide, South Australia/AUSTRALIA; 3Royal 
Adelaide Hospital Thoracic Medicine, Adelaide, South Australia/AUSTRALIA
Aim: To develop a comprehensive clinical pathway to standardise lung cancer 
care and optimise outcomes for all South Australians, regardless of location, 
ethnicity, age, or ﬁnancial status. 
Methods: From 2010-2012, collaborative efforts by a dedicated working 
group engaged public and private sector health professionals including lung 
cancer specialists, allied health professionals, general practitioners, consum-
ers and non-government organisations to produce a guiding document. A 
state-wide consultative workshop provided opportunity for review, feedback, 
and revision of this document. 
Results: Key pathway recommendations resulted:
1. Establish and maintain state-wide systems for collection and analysis of 
clinical data.
2. Identify a care coordinator for lung cancer patients along the care con-
tinuum to ensure that care aligns with pathway recommendations.
3. Evaluate the supportive care needs and functional status of SA lung cancer 
patients using validated screening tools.
Conclusion: These key recommendations were considered to be prerequisites 
for successfully implementing the lung cancer pathway. These recommenda-
tions also indicate that changes at a systems level are required to deliver the 
desired improvements in the patient-focussed management of lung cancer 
in South Australia. Best practice in cancer management depends on a mul-
tidisciplinary approach to treatment planning and care delivery. The South 
Australian experience of lung cancer pathway development reinforces this 
view and reflects a commitment to the ongoing efforts needed to implement 
the pathway.
039-P12  
IDENTIFYING ADDITIONAL MOLECULAR TARGETS 
FOR CRIZOTINIB IN NON-SMALL CELL LUNG 
CANCER (NSCLC)
Rogers TM1*, Russell P2, Wright G3, Wainer Z3, Fox SB1, Solomon B4 
1Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, 
Victoria/AUSTRALIA; 2Department of Anatomical Pathology, St Vincent’s 
Hospital, Fitzroy, Victoria/AUSTRALIA; 3The University of Melbourne, 
Department of Surgery, St Vincent’s Hospital, Fitzroy, Victoria/AUSTRALIA; 
4Department of Haematology and Medical Oncology, Peter MacCallum 
Cancer Centre, East Melbourne, Victoria/AUSTRALIA.
Crizotinib is effective treatment for NSCLC patients exhibiting ALK trans-
locations. Crizotinib may also be beneﬁcial for patients with aberrations in 
MET or RoS. The aims of this study, funded partly by Pﬁzer, were to deter-
mine the frequency of MET ampliﬁcations, RoS and ALK translocations in 
NSCLC and to correlate mutation with clinicopathological parameters. Tissue 
microarrays were constructed from 368 formalin-ﬁxed parafﬁn-embedded 
tumours obtained from NSCLC patients treated at Peter
MacCallum Cancer Centre and St Vincent’s Hospital. Fluorescence in situ 
hybridisation was used to detect MET ampliﬁcation, RoS and ALK trans-
locations. MET ampliﬁcation was identiﬁed in 4/331 cases (1.2%) and high 
polysomy in 15/331 cases (4.5%). All ampliﬁed cases were male. 2/4 were 
adenocarcinoma and 2/4 squamous cell carcinoma. 3/4 were former smokers 
and 1/4 a current smoker. RoS translocations were identiﬁed in 1/322 cases 
(0.3%) while 3/322 cases (0.9%) exhibited an atypical signal pattern. The 
patient exhibiting the RoS translocation was a never smoking female with 
adenocarcinoma. ALK translocations were identiﬁed in 3/334 cases (0.9%). 
A further case contained a small break which did not meet the criteria as posi-
tive. All ALK translocated patients were female. 2/3 were adenocarcinoma 
and 1/3 a pleomorphic carcinoma. The ALK positive patients were a never, 
former and current smoker. The small number of positive patients makes it 
difﬁcult to draw conclusions with regards to associations with clinical fea-
tures of NSCLC. In conclusion, MET ampliﬁcations and RoS and ALK trans-
locations are each found in approximately 1% of resected NSCLC.
Disclosure: The authors declare no dualities or conflicts of interest.
050-P12  
SINGLE-CENTRE EXPERIENCE OF EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) TESTING 
IN NEPEAN BLUE MOUNTAINS LOCAL HEALTH 
DISTRICT (NBMLHD)
Saghaie T1*, Abbott A1, Morgan L1 1 Nepean Lung Cancer Group, New South 
Wales/AUSTRALIA
Mutations in EGFR predict a response to targeted therapies in non-squamous 
NSCLC. our aim is to describe the utility of EGFR mutation testing within 
NBMLHD. This is a retrospective audit of cases with conﬁrmed non-squa-
mous NSCLC where samples were sent for EGFR mutation testing between 
october 2010 and March 2012. 
Results. Twenty-two patients (13F), had tumour samples sent for EGFR 
mutation testing. These were obtained by tumour or LN resection (n=10), 
Fine Needle Aspiration (FNA) (n=5), endobronchial ultrasound guided trans 
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bronchial needle aspiration (EBUS-TBNA) (n=2), core (n=3) and endobron-
chial (n=2) biopsies. Eighteen were conﬁrmed Adenocarcinomas. Additional, 
postdiagnostic procedures were required in 8 patients to obtain sufﬁcient tis-
sue for EGFR mutation analysis. Four samples contained insufﬁcient cells for 
testing, 3 obtained by FNA and 1 by EBUS-TBNA. EGFR mutations were 
detected in 6 samples; 3 on exon 19, 3 of Asian origin, 5 females and 5 non-
smokers. 2 out of 5 patients with activating EGFR mutations did not ﬁt the 
classical phenotype of Asian female nonsmokers. 
Conclusion. Asian, female, non-smokers are one signiﬁcant phenotypic sub-
group of patients with non-squamous NSCLC in our LHD. Samples obtained 
by FNA are less likely to yield enough tissue for EGFR mutation analysis 
than other sampling methods. Additional tissue sampling after diagnosis of 
non-squamous NSCLC is often required.
Conflict of interest: No.
072-O12  
ANAPLASTIC LYMPHOMA KINASE (ALK) 
REARRANGEMENT IN LUNG ADENOCARCINOMAS – A 
LARGE MULTICENTRE STUDY OF FISH AND IHC.
Selinger CI1*, Rogers T2, Russell P3, Yip P4, 5, O’Toole S1, 5, 6, Horvath L4, 
5, 6, Boyer M4, 5, McCaughan B7, Kohonen-Corish M6, 8, Fox S2, Cooper 
W1,9, Solomon B10 1 Department of Anatomical Pathology and Diagnostic 
Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales/
AUSTRALIA; 2 Department of Pathology, Peter MacCallum Cancer Centre, 
East Melbourne, Victoria/AUSTRALIA; 3 Anatomical Pathology, St Vincent’s 
Hospital, Fitzroy, Victoria/AUSTRALIA; 4 Sydney Medical School, University 
of Sydney, Camperdown, New South Wales/AUSTRALIA; 5 Sydney Cancer 
Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales/
AUSTRALIA; 6 Cancer Research Program, Garvan Institute of Medical 
Research, Darlinghurst, New South Wales/AUSTRALIA; 7 Department of 
Cardiothoracic Surgery, Royal Prince Alfred Hospital, Camperdown, New 
South Wales/AUSTRALIA; 8 Faculty of Medicine, University of NSW, Sydney, 
New South Wales/AUSTRALIA; 9 Discipline of Pathology, School of Medicine, 
University of Western Sydney, Cambelltown, New South Wales/AUSTRALIA; 
10 Department of Haematology and Medical Oncology, Peter MacCallum 
Cancer Centre, East Melbourne, Victoria/AUSTRALIA
Aims of Study: Non-small cell lung cancer (NSCLC) has the highest cancer-
related mortality globally. Rearrangements of Anaplastic lymphoma kinase 
(ALK) with the Echinoderm microtubule-associated protein-like 4 (EML4) 
gene in NSCLCs deﬁne a subgroup of patients with speciﬁc clinical, patho-
logical and molecular characteristics and are associated with sensitivity to an 
ALK/MET inhibitor, with promising response rates. We aimed to assess the 
clinical utility of ALK translocation screening and to identify the frequency 
and clinicopathological features of lung adenocarcinomas harbouring ALK 
translocations, using immunohistochemistry (IHC) and fluorescence in situ 
hybridisation (FISH). 
Methods: NSCLC tissue was obtained from patients treated at the Royal 
Prince Alfred Hospital and Concord Repatriation Hospital, Sydney, and St 
Vincent’s Hospital and Peter MacCallum Cancer Centre, Melbourne with a 
total of 661 cases evaluated. Tissue microarrays were screened using ALK 
IHC (Clone ALK-1, Dako; Clone 5A4, Novocastra) and ALK break-apart 
translocation FISH (Abbott Molecular). 
Results: ALK rearrangements were found in 5 cases (1%) by FISH. The 
5A4 ALK antibody identiﬁed all 5 ALK positive cases (100% sensitivity). 
Two false negatives resulted from the ALK-1 antibody (60% sensitivity). 
Conclusions: We have identiﬁed ALK translocation in a large Australian 
cohort occurring at a frequency of 1%, which is low, but within the range 
of reported percentages of 0.4%-13.5%. We believe ALK IHC represents an 
effective complement to testing selected NSCLC patients for ALK rearrange-
ment using FISH. 
Disclosure statement: No conflicts of interest are declared.
Sources of funding of presenting author: Cancer Institute NSW, LifeHouse 
RPAH, Sydney Breast Cancer Foundation.
066-O12  
TECHNICAL CONSIDERATIONS AND PRELIMINARY 
EXPERIENCE OF A PILOT STUDY OF GALLIUM-68 VQ 
4D-PET/CT IN LUNG RADIOTHERAPY
Siva S1*, Callahan J2, Hofman MS2, Eu P2, Martin O1, Pope K1, Ball D1, 
MacManus M1, Kron T3 , Hicks RJ2 1Department of Radiation Oncology, 
Peter MacCallum Cancer Centre, Victoria/AUSTRALIA; 2Department of 
Cancer Imaging, Peter MacCallum Cancer Centre, Victoria/AUSTRALIA; 
3Department of Physical Sciences, Peter MacCallum Cancer Centre, Victoria/
AUSTRALIA
Aims: Ventilation/perfusion (VQ) scanning can assess pulmonary pathophys-
iology in a spectrum of diseases. We sought to evaluate the utility of serial VQ 
using inhaled 68Ga labelled carbon nanoparticles(Galligas)and injected 68Ga 
labelled macro-aggregated albumin(MAA), acquired on respiratory-gated 
PET/CT (4D-VQ), in patients receiving radiotherapy (RT). 
Methods: Preliminary experience of 4D-VQ was evaluated in a prospec-
tive study examining serial pulmonary function in patients undergoing cura-
tive intent RT (+/-concurrent chemotherapy). Radiation was delivered over 
6 weeks in 30 fractions of 2Gy via a 3-ﬁeld technique. Patients underwent 
4D-VQ at baseline, 4 weeks into RT, and 3 months after RT. Additionally, a 
FDG-PET/CT was performed at 3 months after RT.
Results: Six participants have completed baseline and four week 4D-VQ 
scans and three have completed all PET studies. The use of 4D-VQ PET and 
4D-CT enabled precise co-registration and accurate attenuation correction, 
minimising artefact otherwise prevalent at the lung bases. Both ventilation 
and perfusion are markedly decreased at 3 months within irradiated portals 
but minimal changes have been observed at 4 weeks. Tumour regression at 4 
weeks and 3 months is not associated with perfusion or ventilation recovery in 
the immediate peri-tumoural region. No patient has had clinical grade 3 pneu-
monitis, although one patient had radiological pneumonitis demonstrated on 
FDG-PET at 3 months. 
Conclusion: 4D- VQ PET/CT is technically feasible and can demonstrate 
sub-acute changes in VQ both during and after RT seemingly independent of 
severe clinical pneumonitis. Preliminary ﬁndings suggest that neither venti-
lation nor perfusion recover in the region around regressing tumour up to 3 
months after RT.
067-P12  
RESPONSE ASSESSMENT OF STEREOTACTIC 
ABLATIVE BODY RADIOTHERAPY (SABR) FOR 
PULMONARY METASTASES: UTILITY OF 4D-FDG-PET 
AND CT PERFUSION
Siva S1*, Hicks RJ2, Sawyer B2, Pun E2, Samuel M2, Wright G3, Antippa P3, 
Callahan J2, Kron T4, Barnett SA3, MacManus M1, Ball D1 1Department of 
Radiation Oncology, Peter MacCallum Cancer Centre, Victoria/AUSTRALIA; 
2Department of Cancer Imaging, Peter MacCallum Cancer Centre, Victoria/
AUSTRALIA; 3Department of Surgical Oncology, Peter MacCallum Cancer 
Centre, Victoria/AUSTRALIA; 4Department of Physical Sciences, Peter 
MacCallum Cancer Centre, Victoria/AUSTRALIA
Aim: To evaluate the utility of 4D-FDG-PET/CT and CT perfusion after sin-
gle fraction SABR for inoperable pulmonary oligometastases. 
Methods: Eligible patients had 1-2 pulmonary metastases with no extratho-
racic disease on staging FDG-PET. Imaging studies were performed at base-
line, 14 days and 70 days after therapy. Two independent radiologists reported 
CT perfusion scans. 
Results: At a median follow-up of 11 months (range 1-26), 20 patients with 
24 metastases received SABR, of which 10 patients were enrolled into the 
prospective imaging protocol. All patients are alive, with 2/24 local failures 
and 7/20 patients with distant progression. The most severe toxicities were 
transient cough and chest wall pain (grade 2). SUVmax differed between 3D 
and 4D-PET by a mean of 20.6% (range 0.2%-47.2%) at 14 days and 14.8% 
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(range 0-37.8%) at 70 days. Signiﬁcant discordance in 3D and 4D response 
assessment was noted in one case with 12mm tumour motion, where the day 
70 scan 3D-SUVmax increased by 38% whilst no change was observed in 
4D-SUVmax. This metastasis was clinically controlled. overall SUVmax 
increased at 14 days (mean 104.9%, p<0.001) and decreased at 70 days 
(mean=55.5%, p=0.005). A linear correlation to metabolic response at 70 
days ﬁt 4D-SUVmax (r2=0.566, p=0.001) more reliably than 3D-SUVmax 
(r2=0.407, p=0.011). There was strong level of inter-observer agreement of 
CT perfusion interpretation with a median intraclass correlation coefﬁcient of 
89%(range 57%-98%). Perfusion analysis is ongoing. 
Conclusions: SABR appears safe and affords promising local control. 
Increased SUVmax at 2 weeks post-RT is likely due to an inflammatory 
response to large single dose radiotherapy. 
Disclosure statement: - there are no disclosures to declare by any of the 
authors.
079-O12  
THE EXPRESSION OF EPITHELIAL MESENCHYMAL 
TRANSITION MARKERS IN EARLY STAGE NON-SMALL 
CELL LUNG CANCER
Shaw E1, Wright C2, Bowman RV2,3, Yang IA2,3, Duhig E4, Clarke L4 , Fong 
KM2,3 1University of Queensland, St Lucia, Queensland/AUSTRALIA; 2 UQ 
Thoracic Research Center, University of Queensland, Brisbane, Queensland/
AUSTRALIA; 3 Thoracic Medicine Department, The Prince Charles Hospital, 
Chermside, Queensland/AUSTRALIA; 4 The Department of Anatomical 
Pathology, The Prince Charles Hospital, Chermside, Queensland/
AUSTRALIA;
Aims: This study aimed to describe expression patterns of sentinel epithelial 
mesenchymal transition (EMT) markers in early stage lung cancers and cor-
relate these with histopathologic features associated with poorer prognosis.
Methods: 46 resected non-small cell lung carcinomas with clinic-patholog-
ical annotation from The Prince Charles Hospital Lung Tumour Bank were 
included; mean age at resection was 68.21 years, with a male/female ratio of 
25/21. 29 adenocarcinomas, 15 squamous cell carcinomas, 1 large cell neu-
roendocrine and 1 carcinoid were analysed. Haematoxylin and eosin stained 
sections from embedded parafﬁn blocks conﬁrm that each section contained 
cancer cells. Immunohistochemistry for E-cadherin (ECAD), Vimentin, 
β-catenin and cytokeratin 7 (CK &) were performed using standard immu-
nohistochemical procedures and appropriate controls. ECAD and β-catenin 
staining were scored on an intensity scale of 0-3 with 0 being entirely negative 
and 3, representing high intensity. CK 7 and Vimentin antibodies were scored 
as negative or positive.
Results: Positive staining for Vimentin was demonstrated in tumours with 
vascular (9/18 cases), perineural (1/2 cases) or pleural invasion (6/11 cases). 
There was no correlation between EMT biomarker expression patterns for 
ECAD, CK7, β-catenin and histopathologic invasion phenotypes in these 
samples.
Conclusions: This study showed a correlation between Vimentin staining and 
mesenchymal EMT orientation. This correlation was not seen with ECAD, 
β-catenin and CK7. However, the small sample size in this pilot study is 
unable to provide a deﬁnitive answer into the role of EMT in invasion and 
metastatic behaviour of lung cancers.
011-P12  
INHALED CORTICOSTEROIDS (ICS) ATTENUATES 
EPITHELIAL MESENCHYMAL TRANSITION (EMT) 
IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
(COPD) – IMPLICATIONS FOR LUNG CANCER 
PROPHYLAXIS
Sohal SS1, Reid DW 1, Soltani A1, Ward C2, Weston S1, Muller HK 1, Wood-
baker R 1 & Walters EH 1 * 1NHMRC Centre of Research Excellence in Chronic 
Respiratory Diseases, School of Medicine, UTAS, Tasmania/AUSTRALIA; 
2Institute of Cellular Medicine, Newcastle/UNITED KINGDOM
Introduction: Smokers with CoPD are at especial risk of lung cancer. We 
have recently published that EMT-type-III is active in the airways of CoPD 
patients; in this process epithelial cells change shape and become motile, then 
digest through the reticular basement membrane (Rbm) which becomes frag-
mented. The epithelial cells transition to form a mesenchymal ﬁbroblast-like 
cell, with associated increase in angiogenesis. Type-III EMT is a dangerous 
pre-malignant condition. We have now assessed the effects of ICS on markers 
of EMT in bronchial biopsies (BB) from CoPD patients. 
Methods: Double-blind, randomised, placebo-controlled study assessing the 
effects of inhaled fluticasone propionate (FP; 500µg twice daily) on EMT 
in 34 CoPD patients. BB were stained for the markers of EMT, S100A4 (a 
ﬁbroblast epitope) and MMP-9 (matrix-metalloproteinase-9) and the marker 
of epithelial activation, epidermal growth factor receptor (EGFR). 
Results: Rbm “fragmentation” markedly improved with ICS, with a signiﬁ-
cant change compared to placebo (p<0.03). There were also signiﬁcant reduc-
tions in S100A4 (p<0.004), MMP-9 (p<0.02) and EGFR (p<0.03) staining in 
both basal epithelial cells and in the Rbm comparing ICS with placebo. 
Conclusions: This is the ﬁrst study reporting an anti-EMT effect of FP in 
CoPD airways. EMT may well be a link between smoking, CoPD and lung 
cancer, and these ﬁndings may underlie the published anti-cancer effects of 
ICS in CoPD. our study suggests EMT in smokers to be an important thera-
peutic target. 
Supported by: NHMRC project grant 490023 
Conflict of interest: Nil
048-O12  
FREQUENCY AND SPECTRUM OF EPIDERMAL 
GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS 
IN LUNG CANCER IN AN AUSTRALIAN TESTING 
PROGRAM.
Solomon B*1, Peters M2, Bowden J3, Lewis J4, Carpenter P4, 1Dept of Medical 
Oncology, Peter McCallum Cancer Centre Victoria/AUSTRALIA; 2Dept 
of Thoracic Medicine, Concord Hospital New South Wales/AUSTRALIA; 
3Dept of Respiratory Medicine, Flinders Medical Centre3, South Australia/
AUSTRALIA; AstraZeneca New South Wales/AUSTRALIA
Introduction: The presence of activating mutations of EGFR in NSCLC 
tumour tissue is predictive of treatment response to EGFR-tyrosine kinase 
inhibitor (TKI). Few data have been reported about these mutations in an 
Australian population. 
Aim: To gather information on the frequency and spectrum of mutations seen 
from Australian lung cancer cases. 
Methods: In october 2010, AstraZeneca initiated a program to gather data 
on EGFR mutation testing outcomes in Australia. outcomes of mutation test-
ing were provided from 1727 samples whose tumour DNA was sequenced 
from exons 18 to 21. No clinical or personal details including treatment or 
responses were gathered. 
Results: 359 mutations were seen in 337 samples, a mutation frequency of 
19.6%. of major activating mutations, exon 19 deletions were seen in 8.9% 
and L858R point mutations in 5.6%. other activating mutations (L861Q/
G719) were found in 1.0%. Two samples showed exon 19 deletions with 
T790M mutations conferring resistance. There were non-sensitising exon 20 
insertions in 1.4% and a variety of single and double mutations of uncer-
tain signiﬁcance in 2.6%. Activating EGFR mutations were more frequently 
identiﬁed in lung tissue (17.2%), than bone (15.6%), pleura/pericardium or 
fluid(14.1%), brain (9.2%) or lymph nodes (8.3%). 
Conclusions: There is a clinically meaningful yield of “classical” activat-
ing EGFR mutations in samples submitted for testing in Australia but also 
the not infrequent identiﬁcation of mutations associated with uncertain or 
poor response to EGFR-TKI. We found a similar spectrum of mutations in 
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Australian patients to those reported internationally. EGFR mutation results 
should be used to guide treatment with EGFR-TKIs. 
Conflict of interest: PC and JL are employees of AstraZeneca. BS and MP 
have participated in advisory boards, and JB has received honoraria from 
AstraZeneca.
061-P12  
TELOMERE LENGTH IN PLEURAL FLUID IS NOT 
DIFFERENT BETWEEN MALIGNANT AND BENIGN 
EFFUSIONS
Sriram KB*1,2, Relan V1,2, Clarke BE3, Duhig EE3, Windsor MN4, Matar KS4, 
Naidoo R4, Passmore L1,2, McCaul E1,2, Courtney D1,2, Yang IA1,2 Bowman 
RV 1,2 Fong KM1,2 1 UQ Thoracic Research Centre, School of Medicine, 
The University of Queensland, Queensland/AUSTRALIA; 2 Department of 
Thoracic Medicine, The Prince Charles Hospital, Queensland/AUSTRALIA; 
3Department of Anatomical Pathology, The Prince Charles Hospital, 
Queensland/AUSTRALIA; 4Department of Thoracic Surgery, The Prince 
Charles Hospital, Queensland/AUSTRALIA
Background: Alterations in telomere length (increased and shortened) in 
peripheral blood leucocytes and tumour tissue have been associated with 
malignancies. The aim of this study was to quantitatively measure absolute 
telomere length in pleural fluid cell-free DNA in subjects with malignant 
compared with benign pleural effusions.
Methods: We studied pleural fluid samples from 96 consecutive subjects (68 
malignant and 28 benign effusions). Absolute telomere length was measured 
in pleural fluid cell-free DNA (cfDNA) using a modiﬁed quantitative PCR 
method. Median absolute telomere length was compared in the pleural fluid 
cfDNA between subjects with malignant and benign effusions. 
Results: The median absolute telomere length measured in pleural fluid 
cfDNA was not signiﬁcantly different in MPEs compared to benign effusions 
(9.7kb per diploid genome vs. 8.5kb per diploid genome, p=0.488). There was 
no difference in pleural fluid cfDNA absolute telomere length when stratiﬁed 
for age <60 years vs. age > 60 years (8.0kb vs. 9.7kb, p=0.187), females vs. 
males (9.5kb vs. 9.9kb, p=0.548), malignant cytology positive vs. cytology 
negative (8.99kb vs. 9.38kb, p=0.924) or smokers compared with non-smok-
ers (9.0kb vs. 12.3kb, p=0.076). 
Discussion: In this study we found that it was technically possible to measure 
absolute telomere length in pleural fluid cfDNA but there was no correlation 
with malignancy. Pleural fluid cfDNA contains variety types of blood, meso-
thelial and tumour cells. Further study is required to determine the absolute 
telomere length in malignant cells, possibly by initial cell-sorting the by flow 
cytometry. 
Disclosure: No Conflict of interest
This work was supported by: NHMRC Postgraduate Medical Scholarship 
(KBS); UQ PhD Scholarship (KBS); The Prince Charles Hospital 
Foundation Novice Researcher Grant (KBS); NHMRC Practitioner 
Fellowship (KF), NHMRC Career Development Fellowship (IY), Cancer 
Council Queensland Senior Research Fellowship (KF);UQ Early Career 
Researcher Fellowship (VR).
062-P12  
PLEURAL FLUID CELL-FREE DNA INTEGRITY INDEX 
AND MESOTHELIN TO IDENTIFY CYTOLOGICALLY 
NEGATIVE MALIGNANT PLEURAL EFFUSIONS 
INCLUDING MESOTHELIOMAS
Sriram KB*1,2, Relan V1,2, Clarke, BE3, Duhig EE3, Windsor MN4, Matar KS4, 
Naidoo R4, Passmore L1,2, McCaul E1,2, Courtney D1,2, Yang IA1,2 Bowman 
RV 1,2 Fong KM1,2 1 UQ Thoracic Research Centre, School of Medicine, 
The University of Queensland, Queensland/AUSTRALIA; 2 Department of 
Thoracic Medicine, The Prince Charles Hospital, Queensland/AUSTRALIA; 
3Department of Anatomical Pathology, The Prince Charles Hospital, 
Queensland/AUSTRALIA; 4Department of Thoracic Surgery, The Prince 
Charles Hospital, Queensland/AUSTRALIA
Background: The diagnosis of malignant pleural effusions (MPE) is clini-
cally challenging if the cytology is negative for malignant cells. Recently, 
cell-free DNA integrity index as represented by the ratio of longer to shorter 
DNA fragments has been reported to be a marker of malignancy. The aim of 
this study was to evaluate the utility of pleural fluid cfDNA integrity index in 
the diagnosis of MPE. 
Methods: We studied pleural fluid from 100 consecutive subjects. Pleural 
fluid cfDNA ALU DNA repeats [115bp, 247bp and 247bp/115bp ratio 
(cfDNA integrity index)] were assessed by real-time quantitative PCR. 
Pleural fluid mesothelin levels were quantiﬁed using ELISA. 
Results: Based on clinico-pathological evaluation, 72 subjects had MPE 
(including 23 mesotheliomas) and 28 had benign effusions. Pleural fluid 
cfDNA integrity index was higher in MPE compared with benign effusions 
(1.2 vs. 0.8; p<0.001). In cytology-negative (35 MPE and 28 benign effu-
sions), elevated pleural fluid cfDNA integrity index had 80% positive predic-
tive value in detecting MPEs. In the detection of mesothelioma, pleural fluid 
cfDNA integrity index had comparable sensitivity to pleural fluid mesothelin 
(81% and 81% respectively). 
Conclusion: Pleural fluid DNA integrity index is a promising diagnostic bio-
marker for identiﬁcation of MPEs, including mesothelioma. This biomarker 
may be particularly useful in cases of MPE where pleural aspirate cytology is 
negative, and could guide the decision to undertake more invasive deﬁnitive 
testing. A prospective validation study is to be undertaken to validate our ﬁnd-
ings and test the clinical utility of this biomarker for altering clinical practice. 
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053-O12  
RAPID ON-SITE EVALUATION OF BRONCHIAL 
BRUSHINGS DURING INVESTIGATION OF 
PERIPHERAL PULMONARY LESIONS
Steinfort D1, Tsui A2, Irving L1 1Dept. Respiratory Medicine, Royal Melbourne 
hospital, Parkville, Victoria/AUSTRALIA; 2Dept. Pathology, Royal Melbourne 
hospital, Parkville Victoria/AUSTRALIA
Background: Rapid on-site evaluation (RoSE) of transbronchial needle aspi-
rates is cost-effective due to its ability to reduce biopsy number and complica-
tion rates without compromising diagnostic yield. Reliable RoSE results may 
also allow therapeutic interventions to be undertaken at the time of diagnostic 
bronchoscopy. Use of RoSE during sampling of peripheral pulmonary lesions 
(PPLs) has not previously been examined 
Aims: To determine the ability of RoSE performed on transbronchial brush-
ings of peripheral pulmonary lesions to accurately determine ﬁnal proce-
dural diagnosis Methods: Prospective cohort of patients undergoing radial 
probe endobronchial ultrasound-guided bronchoscopy for investigation of 
PPLs. RoSE diagnosis, bronchoscopic diagnosis and ﬁnal diagnosis were all 
recorded, along with procedure time and complication rates 
Results: Data were recorded from 50 consecutive cases of bronchoscopic 
assessment of PPL. Final diagnoses included non-small cell lung cancer 
(n=45), metastatic malignancy (n=1), benign inflammatory/infective inﬁltrate 
(n=5). Sensitivity of bronchoscopy for detection of NSCLC was 80%( 36/45). 
Positive predictive value of RoSE for bronchoscopic diagnosis of NSCLC 
was 96% (26/27). The single false-positive case is discussed. Procedure times 
were signiﬁcantly shorter in those in whom RoSE specimens demonstrated 
malignancy than in those in whom the procedure was non-diagnostic (16 min-
utes v 29 minutes, respectively) 
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Conclusion: RoSE examination of brushings specimen had high positive pre-
dictive value for bronchoscopic diagnosis of cancer. Potential diagnostic pit-
falls are discussed. RoSE of brushings specimens has the potential to shorten 
bronchoscopy times, reduce complications and is likely to be cost-effective.
074-P12  
BRONCHOSCOPIC DYE MARKING OF PERIPHERAL 
PULMONARY LESIONS TO AID VATS RESECTION
Steinfort D1, Larobina M2, Russell P3, Tsui A4, Irving L1 1Dept Respiratory 
Medicine, Royal Melbourne Hosp. Parkville, Victoria/AUSTRALIA; 2Dept 
Cardiothoracic Surgery, Royal Melbourne Hosp. Parkville, Victoria/
AUSTRALIA; 3Dept Pathology, St Vincent’s Hospital. Fitzroy, Victoria/
AUSTRALIA; 4Dept Pathology, Royal Melbourne Hosp. Parkville, Victoria/
AUSTRALIA
Background: Limited (wedge) resection of pulmonary lesions is frequently 
performed as a diagnostic/therapeutic procedure. Some lesions may be dif-
ﬁcult to locate thoracoscopically and conversion to open thoracotomy or 
incomplete resection are potential limitations to this approach. Multiple 
methods have been described to aid Video-assisted thoracoscopic surgical 
(VATS) wedge resection of pulmonary nodules including hookwire local-
ization, percutaneous tattoo or intra-operative ultrasound. We report on our 
experience using bronchoscopic dye marking of small subpleural lesions to 
assist wedge resection. 
Methods: patients planned for VATS underwent pre-operative bronchoscopy. 
Electromagnetic navigation was utilized to accurately guide a 25-gauge nee-
dle to within/adjacent to the lesion for resection and 1mL of methylene blue 
or indigo carmine was injected under fluoroscopic vision. 
Results: Six patients underwent bronchoscopic marking of peripheral pulmo-
nary lesions. Navigation to lesions was successful in all six patients. Surgery 
was performed within 24 hours of bronchoscopic marking. Pleural staining 
by dye was visible thoracoscopically in all six lesions either adjacent to or 
overlying the lesion. All lesions were fully excised with wedge resection. 
Pathologic examination conﬁrmed accuracy of dye staining. 
Conclusion: bronchoscopic dye marking of peripheral lesions is feasible, and 
is not compromised by complications associated with percutaneous mark-
ing procedures. Further experience is required but early ﬁndings suggest this 
method may have utility in aiding minimally invasive resection of small sub-
pleural lesions.
106-P12  
QUALITY IN LUNG CANCER CARE: THE 
DEVELOPMENT OF A POPULATION BASED LUNG 
CANCER REGISTRY
Stirling RG1,2, McLaughlin P1, Senthuren M1, McLaughlin-Barrett S2, 
Robertson M2, Evans S1, Watkins DN3, and McNeil JJ1 1Centre of Research 
Excellence in Patient Safety, Department of Epidemiology and Preventive 
Medicine, Monash University, Victoria/AUSTRALIA; 2Epworth Healthcare, 
Richmond: 3Monash Institute of Medical Research, Monash University, 
Victoria/AUSTRALIA
Rationale: Lung cancer is the fourth most common cancer in Victoria and the 
leading cause of cancer mortality. Little local knowledge exists of the factors 
which influence outcome in lung cancer. A pressing need exists to describe 
regional structure, process and outcome in lung cancer care to improve qual-
ity of care and to inform translational research and health care planning. We 
aim to develop and pilot a population-based lung cancer clinical quality regis-
try to describe clinical assessment, diagnosis, staging, management and out-
comes in lung cancer in Victoria.
Methods: The establishment of the Victorian Lung Cancer Registry Pilot 
Project commenced with the appointment of a Steering Committee to provide 
project governance. Review of current literature and evidence-based national 
and international clinical practice guidelines was undertaken by an expert 
working group. Included data items were epidemiologically sound, reproduc-
ible and valid. The data set enables the capture of identiﬁed quality indicators 
and to describe nominated structural, process and outcome indicators. Case 
ascertainment is derived from institutional ICD-10 coding of small and non-
small cell lung cancer. Consent to recruitment to the registry occurs via an 
“opt-off ” system. Follow up and outcome measures are to be captured 3 and 
12 months after initial diagnosis capturing survival, treatment and quality of 
life assessments. 
Results: Epworth Healthcare ethics approval was received January 2012 and 
data collection commences 2012. A mechanism for rapid case ascertainment 
has been established and tested. Further institutional sites have been identiﬁed 
and ethics applications are underway. A web enabled data collection tool is in 
development and data linkage options are being explored. 
Conclusion: Lung cancer registries have proven capacity for improving out-
comes in lung cancer. The development of rapid case ascertainment and “opt 
off ” recruitment strategies appear viable and should ensure broad recruitment 
from eligible patients diagnosed with lung cancer in Victoria.
083-O12  
FIVE YEAR SURGICAL EXPERIENCE WITH LUNG 
CANCER RESECTIONS AT THE GOLD COAST
Strahan A1 MBBS, Cole P2 FRACS FRCS(EdCTh) 1Principle House Officer, 
Gold Coast Hospital, Queensland/AUSTRALIA; 2Director of Thoracic 
Surgery, Gold Coast Hospital, Queensland/AUSTRALIA
Prior to August 2007 there was no Thoracic surgical service at the Gold Coast 
Hospital, and all patients had to be referred to Brisbane. However with the 
arrival of a Thoracic surgeon, patients were treated locally – only requiring to 
go to Brisbane for PET scanning and Radiation oncology. Multidisciplinary 
Cancer meetings were begun to manage patients referred. This presentation 
details lung resection for primary lung cancers performed at the Gold Coast 
Hospital over the last ﬁve years, from July 2007 to June 2012. It is a retrospec-
tive review of all cases of lung resection for Primary Lung Cancer detailing 
clinical presentation and workup, the resection performed, and the post-oper-
ative complication rate and thirty day mortality rate. No survival ﬁgures are 
given because of the short time period reviewed. 
Disclosure: The authors have no dualities or conflicts of interest to disclose.
116-S12 
A PATIENT’S PERSPECTIVE
Stubbin I, New South Wales/AUSTRALIA 
Anti-smoking campaigns and health warnings may stigmatise lung cancer 
patients. What happens to quality of care? Reflections and experience of one 
patient consider survival and funding.
002-P12  
A 10 YEARS SURVEY OF LUNG CANCER IN SHAHID 
RAJAI RADIOTHERAPY CENTER IN NORTH OF IRAN
Tayebi M1*, Moslemi D2, Sum S3, Monfared AS4 1Student, Student Research 
committee, Babol University of Medical Sciences, Babol/IRAN; 2Assistant 
Professor of Radiotherapy Oncology, Babol University of Medical Sciences, 
Babol/IRAN; 3Assistant Professor of Social Medicine, Babol University 
of Medical Sciences, Babol/IRAN; 4Professor of Medical Physics, Babol 
University of Medical Sciences, Babol/IRAN
Introduction: Lung cancer is not in the list of most common cancers in Iran. 
According to a last study it was ranked ﬁfth and eleventh among males and 
females, respectively. This study is performed to obtain more recent data on 
lung cancer among patients who referred to Shahid Rajai radiotherapy center 
during 2000-2009. 
Material & methods: Study was a historical cohort research. Data were 
obtained by the review of patients’ documents during 2000-2009. This center 
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is the only radiotherapy center in this area. Data included demographic vari-
ables, histopathological malignancy and metastasis history. 
Results: 317patients with lung cancer were referred to this center (3.8% of 
all). 83% were male. The mean age of the men and women was 63.85 ± 12.56 
and 59.94 ± 13.59, respectively. Most frequency (33.8%) was among men 
70-79 years of age at the time of diagnosis and women (25.9%) 50-59 age 
groups. Mean age for men was signiﬁcantly higher than women (P=0.03) 
and among women it considerably dropped from 73 in 2000 to 55 years in 
2009, but for men it decreased slightly from 63 to 61.A more detailed survey 
between 2008 and 2009 showed that squamous cell carcinoma (37.5%), small 
cell carcinoma (28.1%) and adenocarcinoma (18.8%) were the most common 
subtypes of the lung cancer. About half of patients (43.7%) were metastasized 
and most common sites of metastasis were brain (27%) and bone (17.6%) 
Conclusion: Results showed most age group was 70-79. According to a sharp 
decrease in mean age among women during these years, we can suggest expo-
sure to carcinogens like cigarette has increased among young women.
036-P12  
ASPIRATION CYTOLOGY OF NON-SMALL CELL 
LUNG CARCINOMA: A CYTOLOGIC-HISTOLOGIC 
CORRELATION REVIEW AT A REFERRAL CENTER
Templo FS Jr 1 Philippine Heart Center, Quezon City/PHILIPPINES
Introduction: Aspiration cytology through CT-guided procedure has become 
the favored modality in the diagnosis of lung carcinoma. Classiﬁcation 
into small cell lung carcinoma (SCLC) and non-small cell lung carcinoma 
(NSCLC) is possible in most cases. This study reviews the extent of diag-
nostic correlation between the cytologic aspirates of NSCLC and lobectomy/
wedge specimens.
Materials and Methods: We reviewed 53 cases (2004-2011) of NSCLC 
with histologic diagnoses rendered on lobectomy/wedge resection. Their 
corresponding aspiration cytologic studies are then reviewed and analyzed 
the cytologic-histologic correlation. on histology, cases include 30 (56.6%) 
Adenocarcinoma/subtypes, 21(39.6%) Squamous cell carcinoma and 2 
(3.7%) Large cell neuroendocrine carcinoma
Results: of the 53 cytologic aspirates, 20 (38%) were given speciﬁc subtypes 
while 33 (62%) were given the diagnosis of ‘non-small lung cell carcinoma 
not otherwise speciﬁed’. of the cases with speciﬁc subtype diagnoses, 16 
(30%) yielded the correct diagnoses based on tissue specimens (8 squamous 
cell carcinoma, 7 adenocarcinoma/subtypes and 1 large cell type). of the 
remaining 4 cases (7.5%), 3 turned out as adenocarcinoma while 1 turned 
as squamous cell carcinoma. of the 33 cases with ‘non-small cell carcinoma 
not otherwise speciﬁed’ diagnosis, 20 (37.7%) turned out as adenocarcinoma, 
12 as squamous cell carcinoma (22.6%) and 1 (1.8%) as large cell type. The 
extent of our cytologic-histologic correlation approached statistical signiﬁ-
cance (P=.004)
Conclusion: The results provided evidence that aspiration cytology diagnoses 
of non-small cell lung carcinoma correlates with the histology and correct 
subtyping can be achieved in at least 30% of cases. The cytologic diagnosis 
of adenocarcinoma and its subtypes however seems to be more of a challenge 
and imply that further familiarization to its cytomorphologic features will 
improve diagnostic interpretation.
108-O12  
SUICIDE IN LUNG CANCER PATIENTS: WHO IS AT 
RISK?
Urban D*, Rao A, Mileshkin L, Solomon B Department of Medical Oncology, 
Peter MacCallum Cancer Centre, Melbourne/AUSTRALIA
Background: Lung cancer patients have a 5-times higher rate of suicide than 
the general population. This study aims to further identify patient and dis-
ease characteristics associated with higher suicide rates in patients with lung 
cancer. 
Methods: We performed a Surveillance, Epidemiology and End Results 
(SEER) based analysis of subjects with primary lung cancer diagnosed 
between 1973 - 2008. Demographic, tumour characteristics and treatment 
variables were assessed and correlated to suicide rates. 
Results:of 779,229 patients diagnosed with primary lung cancer, 1055 
(0.14%) committed suicide. The median time to suicide was 7 months, with 
25% of suicides occurring within 2 months of diagnosis (range 0-312). on 
univariate analysis patient characteristics associated with a higher risk of sui-
cide included: older age, male gender, white race, married and live in areas of 
low income (all p<0.05). The only tumour factor associated with a higher risk 
was locoregional compared to metastatic disease (RR 1.6 p <0.001). Refusal 
of local treatment (surgery and/or radiotherapy) was not associated with sui-
cide. When considering patients who committed suicide within 6 months of 
diagnosis, small cell lung cancer and neuroendocrine cancers (including car-
cinoid) had a higher risk compared to non-small cell lung cancer (p<0.05). 
Conclusion: The risk of suicide in lung cancer patients is particularly high 
in unexpected subsets of patients, such as those suitable for curative treat-
ment. Given the majority of suicides occur soon after diagnosis, strategies are 
needed to facilitate early identiﬁcation of and support for patients at risk of 
suicide following a diagnosis of lung cancer. 
Disclosure: The authors indicated no potential conflicts of interest.
004-O12  
SEX AND SUVMAX: SEX DEPENDENT 
PROGNOSTICATION IN EARLY NON-SMALL CELL 
LUNG CANCER
Wainer Z*1,2, Daniels M2, Callahan J3, Binns D3, Hicks RJ3, 4, Antippa P5, 6, 
Russell P7, Alam NZ1, 2, Conron M8, Solomon B4, 9, Wright GM1, 2, 6 1University 
of Melbourne; Department of Surgery; St Vincent’s Hospital, Melbourne, 
Victoria/AUSTRALIA; 2Department of Cardiothoracic Surgery; St Vincent’s 
Hospital, Melbourne, Victoria/AUSTRALIA; 3Centre for Cancer Imaging, 
Peter MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA; 
4University of Melbourne; Department of Medicine, Melbourne, Victoria/
AUSTRALIA; 5Department of Cardiothoracic Surgery, The Royal 
Melbourne Hospital, Melbourne, Victoria/AUSTRALIA; 6Division of 
Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria/
AUSTRALIA; 7Department of Anatomical Pathology, St Vincent’s Hospital, 
Melbourne, Victoria/AUSTRALIA; 8Department of Respiratory Medicine 
and Sleep Medicine, St Vincent’s Hospital Melbourne, Melbourne, Victoria/
AUSTRALIA; 9Department of Haematology and Medical Oncology, Peter 
MacCallum Cancer Centre, Melbourne, Victoria/AUSTRALIA
Background: The identiﬁcation of sensitive prognostic factors for patients 
with early-stage non-small cell lung cancer (NSCLC) is clinically important. 
The International Association for the Study of Lung Cancer has identiﬁed the 
maximum standardized uptake value (SUVmax) of 2-[F-18]-fluoro-2-deoxy-
D-glucose in the primary tumor as measured by positron emission tomog-
raphy (PET) as a potential prognostic variable. We examined the prognostic 
value of SUVmax in a surgical cohort of patients with NSCLC and disaggre-
gated the ﬁndings by sex. 
Methods: Patients with NSCLC, who had undergone a pre-operative PET 
scan and surgical resection with curative intent from 2001-2009, were iden-
tiﬁed from a prospective database. A SUVmax cutoff was calculated using 
receiver operator characteristic curves. overall survival was correlated with 
SUVmax for the whole cohort and disaggregated by sex. 
Results: Inclusion criteria were met by 201 patients, 134(67%) men and 
67(33%) women. Five-year survival was 54·2% for the whole cohort, 48·3% 
for men and 66·4% for women. Using 8 as a cutoff, SUVmax correlated 
with survival in univariate analysis for the whole cohort (HR=2·21; 95%CI 
1·53-3·50, p=0·001) and men (HR=3·31; 95%CI 1.92-5·69; p<0·000) but 
not women (HR=0·89; 95%CI 0·34-2·15, p=0·99). In multivariate analysis, 
SUVmax correlated with overall survival for the whole cohort (HR=1·78; 
95%CI 1·08-2·93, p=0·023) and men (HR=2·69; 95%CI 1·44-5·01; p=0·002) 
but not for women (HR=0·74; 95%CI 0·29-1·89, p=0·53). 
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Conclusion: SUVmax independently predicted overall survival for men, but 
not women in this surgical cohort. our results suggest that SUVmax is an 
independent prognostic variable in men with surgically treated early NSCLC. 
Conflicts of Interest: We have no conflicts of interest to declare. 
Ethics: We have adhered strictly to the ethics obtained for this research from 
the Peter MacCallum Cancer Centre Ethics Committee.
Dr Zoe Wainer was the recipient of the Royal Australasian College of Surgeons 
Raelene Boyle Scholarship. No other funding sources were obtained for this 
research.
104-P12 
REAL WORLD USE OF MAINTENANCE 
CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL 
LUNG CANCER IN AN AUSTRALIAN CANCER CENTRE
Wann A1, Newnham G2 1 2 St Vincent’s Hospital, Melbourne, Victoria/
AUSTRALIA
The usual treatment for advanced non-small cell lung cancer (NSCLC) is 
ﬁrst line chemotherapy, observation and second line when there is disease 
progression with recent research suggesting maintenance therapy during the 
observation phase. We aim to explore the rate of use of maintenance therapy 
in advanced NSCLC in our Cancer Centre.
The study was approved by the ethics board. Data was extracted from our 
cancer database in correlation with patient’s notes, pharmacy records and 
correspondence for 123 patients from 2005-2011 with advanced NSCLC. 
Demographics, the proportion of patients going onto second line chemother-
apy, the reasons why they didn’t receive it and overall survival (oS) data in 
various subgroups were analysed.
Results show that of the 105 patients for analysis, 44 achieved stable disease 
or partial response after their ﬁrst line chemotherapy. of the 42 eligible for 
maintenance therapy; only 7 received it. of the 35 observed patients; 12 didn’t 
receive any treatment at disease progression (the reasons why were explored) 
and 23 received second line chemotherapy and reflected the subgroup with 
the best mean oS.
We concluded that a signiﬁcant proportion of patients that didn’t receive 
second line chemotherapy at disease progression were due to ill health and 
postulated that the use of maintenance therapy may improve their progres-
sion free survival as highlighted in recent studies. With this information, we 
hope to incorporate maintenance therapy into the guidelines for treatment of 
advanced NSCLC at our Cancer Centre. 
Disclosure: No conflict of interest.
045-P12  
HEDGEHOG SIGNALING, INNATE CHEMORESISTANCE 
AND TUMOR REGENERATION IN SMALL CELL LUNG 
CANCER
Watkins DN1 1Monash Institute for Medical Research, Monash University, 
Clayton, Victoria/AUSTRALIA
Evidence suggest that innately chemoresistant cells possess and/or acquire 
a phenotype resembling somatic stem cells, and are therefore dependent on 
speciﬁc embryonic signaling pathways for survival and regeneration. These 
pathways are evolutionarily conserved, and are derived from cell fate and pat-
terning genes in Drosophila, including the Hedgehog (Hh), Wingless, Notch 
or Decapentaplegic families of morphogens. The Hedgehog (Hh) pathway 
is an attractive therapeutic target in cancer, since inhibitors of Smoothened 
(Smo), a molecule required for all known components of the pathway, can 
potently and speciﬁcally shut down Hh signalling. To explore this idea, we 
focused on small cell lung cancer (SCLC) as a model of cancer cell regen-
eration in a highly chemosensitive, common adult solid tumor. In a primary 
xenograft model, we showed that depletion of bulk tumour with cis-plati-
num chemotherapy resulted in a small population of residual tumour cells 
that demonstrated markedly enhanced Hh pathway activation. Moreover, it 
was this residual population, but not the bulk tumour, that was responsive 
to manipulation of Hh signalling in vivo and in vitro. The Smo antagonist 
LDE225 (Novartis) was able to block or delay regeneration of SCLC cells 
following chemotherapy, but had no effect on the growth of the chemonaïve 
tumour. These data suggest that in chemosensitive carcinomas such as SCLC, 
Hh inhibitors may be useful in blocking or delaying the regeneration of mini-
mal residual disease.
Disclosure: Dr Watkins receives an honorarium from Novartis for participat-
ing in their Hedgehog Scientiﬁc Advisory Board.
081-P12  
EXTRACTING HIGH QUALITY RNA FROM FFPE 
SAMPLES FOR GENE EXPRESSION STUDIES
Weiss J.*1, Do H. 1, Wright G. 2, Russell P. 3, Dobrovic A. 1 1Department 
of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria/
AUSTRALIA; 2University of Melbourne Department of Surgery, St Vincent’s 
Hospital, Melbourne, Victoria/AUSTRALIA; 3Department of Anatomical 
Pathology, St Vincent’s Hospital, Melbourne, Victoria/AUSTRALIA
The use of targeted therapies in the treatment of non-small cell lung can-
cer is still limited to a relatively small fraction of patients. Chemotherapy 
remains the mainstay of treatment for most patients today. So far, the best pre-
dictors for chemotherapeutic success are based on the expression of certain 
nucleotide metabolism or DNA damage response and repair related genes. 
However, the samples available for study most commonly comprise FFPE 
samples, which are characterised by a high degree of RNA fragmentation or 
degradation.
To address this problem, we have developed a protocol to reliably extract large 
amounts of high-quality RNA from FFPE samples. The protocol includes 
pathology review of the FFPE block to identify tumour rich areas, removal of 
a 2mm core, followed by RNA extraction from this core. Next, the total RNA 
amount is quantiﬁed and a small proportion is tested for fragment length by 
a multiplex RT-PCR.
We extracted total RNA from 9 core punches and 3 sections for a total of 12 
different samples. All extracted samples contained RNA (100ng to 1ug/ul elu-
tion). The total amount of RNA extracted from sections was generally lower 
compared to the amount extracted from 2mm cores. Ten samples contained 
fragments of sufﬁcient length for RNA-Seq as assessed by our established 
multiplex RT-PCR.
In conclusion, our extraction protocol enables us to reliably extract total RNA 
from FFPE samples. These RNAs can be used to study the expression of che-
motherapy-response related genes like BRCA1, ERCC1 and RRM1 as well as 
whole transcriptome analysis by RNA-seq.
006-O12  
FEASIBILITY OF MEASUREMENT OF FUNCTION IN 
ADVANCED CANCER: COMPARISON OF THE 6-MINUTE 
WALK TEST, 2-MINUTE WALK TEST, ISOMETRIC ARM 
EXERCISES AND READING NUMBERS ALOUD
White K 1,2, Agar M2,3, Currow D2 1Prince of Wales Hospital, Randwick, New 
South Wales/AUSTRALIA; 2Department of Palliative and Supportive Services, 
Flinders University, South Australia/AUSTRALIA; 3Braeside Hospital, 
Department of Palliative Care, Prairiewood, New South Wales/AUSTRALIA
Introduction: The pattern in which functional decline in people living with 
advanced cancer occurs has been described as an initial period of reason-
ably stable function, followed by more rapid functional deterioration with 
a deﬁned terminal phase. However little is known about the more subtle 
changes in function in the more advanced stages of cancer, and the role 
that breathlessness plays in functional changes. Objective: The aim of this 
pilot study was to compare the feasibility of conducting a range of stan-
dardised assessments at different levels of performance status in people with 
advanced cancer. 
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Methods: A consecutive cohort was recruited to a cross sectional study from 
2 large palliative care units in metropolitan Sydney. Assessments were com-
pleted by an occupational therapist including: Australian Modiﬁed Karnofsky 
Performance Scale, Eastern Cooperative oncology Group Performance Scale, 
Life-Space Assessment, Charlson Comorbidity Index, Six-minute Walk Test 
(6MWT), Two-minute Walk Test (2MWT), Isometric Upper limb Exercises, 
Reading Numbers Aloud, Medical Research Council Dyspnoea Scale (MRC), 
Intensity and Unpleasantness of Breathlessness Visual Analogue Scales and 
Numerical Rating Scale for Breathlessness. 
Results: 42% (n=5) of pilot participants were able to complete the 6MWT, 
67% (n=8) completed the 2MWT, 84% (n=10) completed the isometric arm 
exercises and 100% (n=12) completed reading numbers aloud. Ten partici-
pants had baseline breathlessness at rest using the MRC. Findings from the 
pilot study suggest that at AKPS<60 this predicts an inability to do the 6MWT.
Conclusion: These measures of function are feasible in the palliative popula-
tion and have potential to contribute to clinical assessment.
This oral presentation will highlight the pilot study results and the feasibility of 
using these assessments in clinical practice to improve the assessment of func-
tional capacity and breathlessness in people living with advanced cancer. There 
is currently limited evidence into how function can be assessed in advanced 
cancer when breathlessness is present. This pilot study adds to the evidence and 
knowledge base around the assessment of function in this population.
018-P12  
MULTIDISCIPLINARY CARE IN LUNG CANCER: 
COLLABORATIVE PRACTICE IN ACTION
White K, Ivimey B Prince of Wales Hospital, Randwick, New South Wales/
AUSTRALIA
Prince of Wales Hospital provides a specialist service to people living with 
lung cancer in the eastern and south-eastern suburbs of Sydney. The lung can-
cer team consists of medical oncology, radiation oncology, respiratory, cardio-
thoracic surgery and palliative care doctors. The patients are linked in with a 
specialist lung cancer nurse coordinator to ensure their needs are being met 
and they are receiving the right service at the right time. How is this specialist 
nurse supported and what makes the service at Prince of Wales Hospital work?
Collaborative practice between the specialist oncology occupational therapist 
and lung cancer nurse coordinator has developed over the past 6 years. Working 
together to provide the best possible outcome for the patient ensures patients are 
offered a whole person and true multidisciplinary approach to their care. Many 
specialist nurses and allied health professionals work in isolation, which can 
lead to professional deskilling, burnout and decreased referrals to other team 
members. Through this collaborative approach we have achieved an immediacy 
of nursing and allied health intervention for patients, which in turn leads to 
decreased hospital admission, enabling patients to remain at home for longer 
and facilitating the achievement of patient goals towards the end of their life.
This paper will present case vignettes of joint intervention between nurs-
ing and occupational therapy for lung cancer patients at PoWH. The eco-
nomic, physical and psychosocial impact of this collaborative practice will 
be discussed.
078-P12  
LUNG CANCER REFERRALS IN NEW ZEALAND – THE 
EXPERIENCE OF ONE REGIONAL CANCER SERVICE
Winter H1, Harrington J 1, Batten L 2, *Hardie C 1 1 Regional Cancer Treatment 
Service, MidCentral Health, Private Bag 11036, Palmerston North/NEW 
ZEALAND; 2Research Centre for Maori Health and Development, Massey 
University, Palmerston North/NEW ZEALAND
Background: The overall 5 year survival rates for lung cancer in New Zealand 
are 10%, and only 5% in Maori patients. In other countries, guidelines have 
been set up to facilitate referrals for suspected lung cancer, and ultimately to 
improve survival with earlier diagnosis. 
Method: We undertook a retrospective audit and review of case notes of 168 
patients diagnosed with lung cancer and referred into a regional cancer ser-
vice. The UK guidelines were used to examine duration of symptoms and 
diagnostic pathways. Management and outcomes were investigated. Data was 
collected manually and analysed using Microsoft Excel. 
Results: This population consisted of 102 male (61%) and 66 female patients 
(40%). of these, 39 (23%) were Maori. 79% had a histological diagnosis 
of lung cancer (87% NSCLC). 64% of patients were referred from outpa-
tients, 31% from hospital inpatient services and 5% from the community. 
Histological diagnoses were made using bronchoscopy (48), ﬁne needle aspi-
ration (36) and biopsy of metastases (28). Signiﬁcant delays from onset of 
symptoms to diagnosis were identiﬁed. In the majority, the intent of treatment 
was palliative by the time of ﬁrst oncology consultation. 
Conclusions: Varied pathways, routes to diagnosis and delays from onset of 
symptoms to diagnosis persist. Earlier detection and access to trials and new 
therapies are urgently required. We have now established a lung cancer MDT 
and prioritised engagement with Maori cancer coordinators. We have under-
taken a feasibility research project on EGFR testing for Maori. A re-audit will 
examine the impact of such initiatives.
019-012  
A NOVEL APPROACH TO RESTORATION OF TUMOUR 
SUPPRESSION BY P16INK4A IN LUNG CANCER
Wolyniec K1,2, Levav-Cohen Y3, Young R1,2, Russell P4, Haupt S1.2,Wright G1,2,4, 
Dobrovic A1,2, Solomon B1,2, Haupt Y1,2,5,6 1 Peter MacCallum Cancer Centre, 
Victoria/AUSTRALIA; 2Sir Peter MacCallum Department of Oncology, The 
University of Melbourne, Victoria/AUSTRALIA; 3The Hebrew University 
Hadassah Medical School, Jerusalem/ISRAEL; 4St.Vincent Hospital, 
Melbourne, Victoria/AUSTRALIA; 5Department of Pathology, University of 
Melbourne, Melbourne, Victoria/AUSTRALIA; 6Department of Biochemistry 
and Molecular Biology, Monash University, Victoria/AUSTRALIA
The tumour suppressor p16INK4a is downregulated, or lost in the vast majority 
of lung cancer patients (~70%). This has been linked to poor survival and 
therapeutic resistance. In half of the cases loss of p16INK4a expression cannot 
be explained by promoter methylation, deletions or mutations. Restoration 
of p16INK4a provides one of the most attractive therapeutic targets for tumour 
suppression through cellular senescence.
E6-Associated Protein (E6AP) has been extensively studied in HPV-induced 
cervical carcinoma but its role in other cancers remains elusive. We have 
recently linked E6AP to the regulation of cellular stress response. Here we 
report that cells lacking E6AP show attenuation of p16INK4a resulting in the 
bypass of RAS-induced senescence and acquisition of tumourigenic potential. 
We found that E6AP positively regulates p16INK4a at the transcriptional level via 
CDC6 (Cell Cycle Division 6), a well-deﬁned repressor of INK4a/ARF locus. 
E6AP forms complex with E2F1 and suppresses transactivation of CDC6.
overexpression of CDC6 was previously associated with aggressive disease 
and poor clinical outcome in NSCLC patients. Interestingly, we found that 
low levels of E6AP and p16INK4a inversely correlate with elevated CDC6 in a 
subset NSCLC cell lines and resected patient samples. Importantly, expres-
sion of E6AP in NSCLC cells using lentiviral inducible system resulted in the 
reduction of CDC6 accompanied by induction of p16INK4a-mediated senes-
cence. Furthermore, restoration of E6AP in a xenograft model signiﬁcantly 
delayed tumour development supporting the role of E6AP-CDC6-p16INK4a 
axis in lung carcinogenesis. our study provides a rational for a novel thera-
peutic approach by targeting E6AP/CDC6. 
Disclosure: The authors declare no possible dualities or conflicts of interest.
088-P12  
THE EXPRESSION OF LONG NONCODING RNAS IN 
MALIGNANT PLEURAL MESOTHELIOMA
Wright CM1, Kirschner MB1, Cheng YY1, Relan V2, van Zandwijk N1, Reid 
G1 1Asbestos Diseases Research Institute, University of Sydney, New South 
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Wales/AUSTRALIA; 2Thoracic Research Centre, The Prince Charles Hospital, 
University of Queensland, Queensland/AUSTRALIA
Background: Long noncoding RNAs (lncRNA) are a class of RNAs >200 
nucleotides in length, that do not code for protein but make up >90% of 
the human genome. Recent studies have investigated the potential role of 
lncRNAs in cancer. As malignant pleural mesothelioma (MPM) is an aggres-
sive disease and lncRNAs have not been previously investigated, our aims 
were to characterize the expression of lncRNAs potentially involved in MPM 
biology. 
Methods: Microarray proﬁling was performed on ﬁve cell lines - MeT-5A and 
four MPM lines (H28, H226, MM05 and MSTo) using Invitrogen’s NCode 
lncRNA microarrays. Data was analysed using Gene Spring V12.0. High pri-
ority candidate lncRNAs were selected on the basis of statistical (P<0.05) and 
biological signiﬁcance (>3-fold difference). Expression levels of candidate 
mRNA and lncRNAs were validated using Taqman Gene Expression assays 
on 7 MPM cell lines and 5 cancer cell lines (HCT115, HCT116, A549, PC-3, 
MDA-MB-231, MCF-7). 
Results: Microarray proﬁling of MeT-5A versus MPM cell lines identiﬁed 
350 probes (310 mRNA, 40 lncRNA) differentially expressed between meso-
thelioma and normal cell lines at >3-fold and P<0.05. These probes included 
known cancer genes including EGFR, CDKN2A, MYC and MET. The major-
ity of candidates were found to be up-regulated in tumor cell lines. Validation 
of microarray data by RT-qPCR is underway and will be presented at the 
conference. 
Conclusions: Microarray proﬁling has identiﬁed novel lncRNAs and mRNAs 
with a putative role in MPM biology. Independent validation of MALAT1 
using RT-qPCR identiﬁed over-expression in MPM cell lines compared to 
a normal mesothelial cell line MeT-5A. Further biological and functional 
validation is required to conﬁrm the role of novel lncRNAs in the biology 
of MPM. 
Disclosures: No conflicts of interest
076-P12  
REVIEW OF SUBCLASSIFICATION OF NON SMALL 
CELL LUNG CANCER (NSCLC) REPORTING AND 
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) 
TESTING AT THE ROYAL HOBART HOSPITAL
Wuttke M, Jessup P, Harle R, Hunter C, Wong SW, Nott L The Royal Hobart 
Hospital, Tasmania/AUSTRALIA
Background: Clinical decisions regarding the management of NSCLC 
require the accurate distinction between adenocarcinoma and squamous 
cell carcinoma as studies have demonstrated differences in therapeutic efﬁ-
cacy and toxicity based on this information. Similarly, identifying subsets of 
NSCLCs harbouring EGFR mutations is of clinical importance. 
Aim: To analyse our institution’s rates of histological subtyping in NSCLC 
cases and rates of molecular testing. 
Methods: Retrospective analysis of data on 178 patients with NSCLC 
recorded at the Royal Hobart Hospital Lung Cancer Multidisciplinary 
Meetings between February 2010 -February 2012 
Results: The median age of patients was 71 years and 70% were advanced 
stage at diagnosis. 96% of patients had a diagnosis of NSCLC that included a 
speciﬁc histological subtype; 99 (55%) adenocarcinoma, 50 (28%) squamous, 
13 (7%) NSCLC not otherwise speciﬁed (NoS), 5 (3%) large cell neuro-
endocrine and 4 (2%) adenosquamous. 2 patients had synchronous tumours 
of differing pathological subtypes. 8(5%) patients were given a diagnosis of 
NSCLC but had either inadequate tissue available or incomplete immuno-
histochemical proﬁle performed to allow further subclassiﬁcation. 16 (9%) 
patients had EGFR testing (13 with adenocarcinoma, 3 NSCLC NoS). 2 
patients with adenocarcinoma had activating mutations. 
Conclusion:The reporting of speciﬁc histology subcategories of NSCLC 
appears high at our institution but EGFR mutation testing rates are low 
suggesting we miss patients who may beneﬁt from EGFR Tyrosine kinase 
inhibitors. EGFR mutation testing can be expected to increase with recent 
addition of testing on the Medicare Beneﬁts Schedule.
Disclosures: There are no dualities or conflicts of interests to be declared by 
the authors of this abstract.
077-O12  
UTILISATION OF INVESTIGATORY PROCEDURES TO 
OBTAIN A HISTOLOGICAL DIAGNOSIS OF NON SMALL 
CELL LUNG CANCER (NSCLC)
Wuttke M, Hunter C, Jessup P, Harle R, Wong SW, Nott L The Royal Hobart 
Hospital, Tasmania/AUSTRALIA
Background: The increased variety of diagnostic tools and advent of targeted 
therapies necessitating greater sample quantity potentially require patients to 
undergo multiple diagnostic procedures prior to starting deﬁnitive treatment. 
This is not only unpleasant for patients but will increase time taken to com-
mence treatment and health care costs.
Aim: To review the utilisation of different modalities in obtaining a histologi-
cal diagnosis of NSCLC at the Royal Hobart Hospital (RHH).
Method: We analysed all diagnostic procedures performed on all patients 
with a histological diagnosis of NSCLC between February 2010 and February 
2012 at the RHH.
Results: 178 patients (median age 71) had a histological diagnosis of NSCLC. 
231 procedures were performed with 180 histologically positive. 46 (26%) 
patients had more than 1 procedure. Main procedures performed (% posi-
tive histology) were bronchoscopy 102 (62,7%), computed tomography (CT) 
guided biopsy 72 (95.8%), lymph node biopsy 9 (88.9%), surgery 8 (100%), 
pleural aspirate 16 (60%), sputum 7 (71.4%). of those who had a failed 
bronchoscopy, positive histology was then obtained by CT guided biopsy 22, 
surgery 5, sputum 4, repeat bronchoscopy 5 and other biopsy 2. Signiﬁcant 
complication for CT biopsy was 2% and bronchoscopy 1%.
Conclusion: our positive bronchoscopy rate is low which may reflect a reli-
ance on bronchoscopy as initial diagnostic strategy when CT guided biopsy 
may be more appropriate. It is important that an investigatory protocol in 
line with current evidence is established (especially prior to introduction of 
additional techniques) to avoid patients undergoing multiple investigations 
and suffering delays in treatment.
Disclosures: There are no dualities or conflicts of interests to be declared by 
the authors of this abstract.
070-O12  
MUTATIONS IN RESECTED NODE-NEGATIVE LUNG 
ADENOCARCINOMA
Yip, PY*1,7, Yu, B3,7, Cooper, WA2,3,8, Kench, JG2,4, Boyer, M1,7, Kohonen-
Corish, MJ4,8,9, Trent, R3,7, McCaughan, B5, Kennedy, C5, O’Toole, SA2,3,4,7, 
Horvath, L1,4,7 1Department of Medical Oncology, Sydney Cancer Centre, 
Royal Prince Alfred Hospital, Camperdown, New South Wales/AUSTRALIA; 
2Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, 
Camperdown, New South Wales/AUSTRALIA; 3Department of Molecular 
and Clinical Genetics, Royal Prince Alfred Hospital, Camperdown, New 
South Wales/AUSTRALIA; 4Kinghorn Cancer Centre and Garvan Institute 
of Medical Research, Darlinghurst, Sydney, New South Wales/AUSTRALIA; 
5Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, 
Camperdown, New South Wales/AUSTRALIA; 7Sydney Medical School, 
University of Sydney, New South Wales/AUSTRALIA; 8School of Medicine, 
University of Western Sydney, New South Wales/AUSTRALIA; 9St Vincents 
Clinical School, University of Western Sydney, New South Wales/AUSTRALIA
Aim: To examine the diversity of mutations in resected node-negative lung 
adenocarcinoma 
Methods: We analysed the clinicopathologic characteristics and outcomes 
data for 204 patients who underwent resection at our institution for stage 
IB lung adenocarcinoma. No patient received adjuvant treatment. Tumours 
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were genotyped using the oncoCarta v1.0 kit (ABL1, AKT1, AKT2, BRAF, 
CDK4, EGFR, ERBB2, FGFR1, FGFR3, FLT3, JAK-2, KIT, MET, HRAS, 
KRAS, NRAS, PDGFR, PIK3CA and RET) and processed on the Sequenom 
compact MassARRAY platform. 
Results: The median age was 69 (40-87). 84 (41%) were female. Majority 
of patients (80.4%) underwent lobectomy, 6.4% underwent pneumonectomy 
and the remainder had lesser resections. Median survival was 6.5 years and 
5-year survival rate was 55%. Patients with KRAS and PIK3CA mutations 
tended to have poorly differentiated tumour (p=0.06), while patients with 
EGFR mutations had well differentiated tumour (p=0.02). 116 (57%) cases 
harbored at least one somatic mutation. KRAS, EGFR, PIK3CA, MET, ALK 
and less common mutations (AKT1, BRAF, FGFR1, HRAS and PDGFR) 
were detected in tumours from 77 (37.7%), 29 (14.2%), 9 (4.4%), 7 (3.4%), 
2 (1%) and 6 (3%) patients respectively. Synchronous mutations (eg PIK3CA 
+ KRAS) were detected in 9.3% of patients. Two cases of T790M, mutation 
related to resistance were identiﬁed. 
Conclusion: Mutations are common in resected node-negative lung adeno-
carcinoma. Pattern of mutations may play an important role in identifying 
high risk patients who may beneﬁt from adjuvant treatment. 
Source of funding: Postgraduate Grant-in-aid of Australian Lung Foundation 
and The Chris o’Brien Lifehouse at RPA Grant. 
Disclosure statement: Authors have no dualities or conflicts of interest to 
declare.
027-O12  
AUSTRALIAN MESOTHELIOMA REGISTRY
van Zandwijk N1*, Sim MR2, Armstrong B3, Musk W4, Hill J5, Anderson 
A5, Raftery A6, Laws P6 1Asbestos Diseases Research Institute, New South 
Wales/AUSTRALIA; 2Monash University Centre for Occupational and 
Environmental Health, Victoria/AUSTRALIA; 3Cancer Epidemiology and 
Health Services Research Group, University of Sydney, New South Wales/
AUSTRALIA; 4Western Australian Mesothelioma Registry, Western Australia/
AUSTRALIA; 5Safe Work Australia, New South Wales/AUSTRALIA; 6Cancer 
Institute NSW, New South Wales/AUSTRALIA.
Aims: The Australian Mesothelioma Registry (AMR) was established to col-
lect information on all new cases of mesothelioma in Australia, including 
detailed information on asbestos exposure. 
Methods: The AMR is funded by Safe Work Australia and managed by the 
Cancer Institute NSW, which coordinates notiﬁcations from state/territory 
cancer registries. Participants complete a job and residential history postal 
questionnaire and are assessed for their past asbestos exposure by telephone 
interview using occIDEAS, an online exposure assessment tool. Clinicians 
are required to advise if their patient is suitable for recruitment to the asbestos 
exposure component. Detailed information on occupational and environmen-
tal asbestos exposure can only be obtained if clinicians promptly review and 
respond to AMR requests. 
Results: The AMR became operational in 2011. More than 600 cases of 
mesothelioma were notiﬁed to the Registry in the ﬁrst year. This number will 
further increase when supplementary notiﬁcation processes, including from 
clinicians, are implemented.
The long latency between ﬁrst exposure to asbestos and onset of mesothe-
lioma is a major reason why incidence is expected to peak over the coming 
decade. Exposure assessments collected within the AMR framework will pro-
vide information not previously available. Data will be presented for 2011, 
the ﬁrst calendar year of data collection. 
Conclusions: AMR information will aid federal and state governments to 
more accurately deﬁne the relationship between work and environmental 
asbestos exposure sources and the development of mesothelioma. It provides 
a national resource for researchers to identify preventable risk factors and will 
assist in preventing mesothelioma in the future. 
Disclosure: No conflict of interests
107-P12  
THE ONCOLOGY ANALYSIS SYSTEM (OASYS): 
APPLICATIONS IN LUNG CANCER SERVICE 
IMPROVEMENT AND BENCHMARKING
Zarate D*, Harden H, Colquist S Queensland Cancer Control Analysis Team 
(QCCAT), Queensland Health, Brisbane, Queensland/AUSTRALIA
The oncology Analysis System (oASys) is the single most comprehensive 
source of Queensland cancer data online and is now available both locally 
and internationally to lung cancer clinicians and researchers worldwide. 
Built using online analytical processing technologies and accessible over 
the internet using any regular browser, oASys makes available a range of 
lung cancer measures such as age-standardised incidence and mortality and 
Kaplan-Meier survival curves and rates, all of which can be aggregated and 
stratiﬁed by clinical and demographic factors such as primary site, morpho-
logical subtype, residence geography and remoteness, and indigenous and 
socioeconomic status. Clinicians and lung cancer service providers can use 
oASys to:
• Evaluate the potential scope and impact of proposed interventions or 
changes to a lung cancer practice or service
• Estimate the potential pool of patients available for cross-institutional clini-
cal trials
• Identify disparities in lung cancer outcomes that may warrant further study
• Examine data on lung cancer patients with rare histological subtypes
• Monitor trends for speciﬁc patient cohorts at population level
• Analyse hospital catchment distribution and outcomes
• Formulate benchmark and baseline measures of lung cancer incidence and 
survival
A hands-on demonstration and tutorial on oASys with examples of these 
applications will be provided.
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